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1GENERAL INTRODUCTION AND OUTLINE 
1.1 An introduction to hemangioma
1.1.1 Classification
In ancient medical literature the word ‘hemangioma’ was used to describe a wide range 
of vascular tumors and malformations, resulting in indistinctness concerning diagnosis 
and prognosis. In current literature, as well as in this thesis, the term ‘infantile hemangioma’ 
(IH) is used to make a distinction with other vascular anomalies.
 According to the classification of the International Society for the Study of Vascular 
Anomalies (ISSVA), vascular anomalies may be mainly classified as vascular tumors and 
vascular malformations, based on differences in biologic and cellular characteristics as 
well as the natural course of the lesion.1 Infantile hemangioma belongs to the group of 
vascular tumors and is a true neoplastic proliferation of endothelial cells with characteristic 
early natural history of growth, followed by spontaneous involution over years. Vascular 
malformations on the other hand are structurally abnormal vessels arising from errors in 
embryogenesis, have normal endothelial cell turnover and do not involute spontaneously. 
Unlike other vascular anomalies, IH cells express a unique immunohistochemical 
phenotype that includes glucose transporter protein type 1 (GLUT1) at all stages of 
development.2
1.1.2 Epidemiology and genetics
Although the exact prevalence is difficult to determine,3 IH is estimated to occur in about 
3-10% of the Caucasian infants and is therefore the most common benign tumor of 
childhood.4,5 Low birth weight (less than 1500 gram) appears to be the most significant 
risk factor for IH development according to multivariate analysis. Other risk factors for the 
development of IH are female sex, with a sex ratio ranging from 3:1 to 5:1, Caucasian race, 
prematurity, family history of IH and newborns from multiple gestations. Perinatal 
associations include older maternal age, placenta previa and pre-eclampsia. Infants from 
women who have undergone transcervical chorionic villus sampling (CVS) also seem to 
have an increased risk for developing IHs as opposed to other prenatal diagnostics like 
transabdominal CVS and amniotic fluid puncture.6,7
 The vast majority of IH occurs sporadically; in less than 10% of the IH patients there is 
a marked family history of IH.8 In a small number of these families, IH segregates as a highly 
penetrant autosomal trait.9 Gene linkage studies of familial IH show evidence of linkage to 
chromosome 5q31-33.10 On the other hand, it could be concluded in twin studies, that 
hereditary factors were not principal causes of IH.11
1.1.3 Clinical phenotypes  
During the growth phase, IHs are in general firm and elastic tumors, irrespective of the 
clinical subtype. They are slightly warm but not pulsatile on palpation and painless, except 
in case of ulceration.12 The clinical appearance of the IH is variable, depending on the 
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infiltration depth of the tumor within the skin. The most common superficial IHs (50-60%), 
located in the superficial dermis, are bright red and lobulated. Deep IHs comprising 15% 
of all IHs, on the other hand, arise in the reticular dermis or subcutis and emerge as raised 
soft masses, often with a bluish shine. Not uncommonly, IHs have both superficial and 
deep features (25-35%) and are called mixed IHs.13 
Besides, each IH can be subclassified according to the size, the anatomic localization and 
the morphologic subtype:
•	 The	size	of	the	IH	may	vary	significantly,	ranging	from	pinhead	large	to	the	involvement	
of an entire limb. In most cases (80%) however, IHs are less than 3 cm in diameter.14
•	 For	 unknown	 reasons,	 the	 anatomic	 localization	mainly	 includes	 the	 face	 (40%)	 and	
neck (20%).14 On the other hand, IHs can appear anywhere on the body and may even 
affect internal organs, in most cases the liver.15
•	 In	addition,	four	different	morphologic	subtypes	can	be	recognized.	The	first	and	most	
common are localized IHs with a focal tumor-like aspect. The second are segmental IHs 
with a more plaque-like distribution involving a region of skin and are more often 
associated with complications. Undeterminated IHs are the third type and not always 
distinguished as a separate subgroup in literature, but correspond to IHs with a 
segmental distribution but without clear circumscription. The last subtype; multifocal 
IHs, are sometimes associated with visceral involvement.12 
1.1.4 Natural history
Infantile hemangiomas are unique and distinctive with respect to their natural growth 
characteristics. Because of the enormously variable spectrum of severity, from tiny, banal 
to large and risky lesions, the prediction of natural behavior and prognosis of the IH in the 
Figure 1
Superficial, localized IH
Age of the patient: 3.5 months
Figure 2
Superficial, segmental IH 
Age of the patient: 1 month
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individual patient is difficult. Nevertheless, a pattern of the growth characteristics of IH in 
phases is discernible. The distinct growth phases are: nascent, proliferating, involuting and 
involuted.16 In approximately 50% of the neonates in whom an IH develops, a precursor 
lesion is present at birth.17 These nascent lesions appear most frequently as a telangiectatic 
macule with a pale halo or as a pale or an erythematous macule.18 In the first days or weeks 
after birth, the IH appears and grows disproportionally whereby the growth phase 
comprises the first 3-6 months,14 but may extend until the 9th to 12th month in IHs with a 
subcutaneous component.12 In exceptional cases, this growth phase may continue until 
24 months.19 The growth of the IH in general implicates no significant increase of the 
primarily affected surface area, but merely a thickening and thereby an increase in volume 
of the tumor. Following this growth phase, most IHs stabilize spontaneously, and regress 
over several months or years.12 The median age at the end of the involution phase is about 
4 years.20
 After involution, residual lesions such as telangiectasias, skin atrophy, skin surplus, 
scarring and/or fibrofatty tissue may remain. It seems that epidermal invasion is a predictor 
for these residual lesions.20
1.1.5 Pathology
Histologically, proliferating IHs are composed of masses of compact capillaries lined by 
plump endothelial cells with increased mitotic rates.21 In addition to endothelial cells, IHs 
are also composed of stromal components, including fibroblasts, pericytes and mast 
cells.22,23 As the lesion involutes, mitosis gradually decreases with increased apoptosis of 
endothelial cells and gradual replacement of vascular tissue by fibrofatty tissue.
Figure 3
Deep IH
Age of the patient: 8 months
Figure 4
Mixed IH
Age of the patient: 4.5 months
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1.1.6 Pathogenesis
Despite their frequency, the etiology of IH has only just started to be elucidated. At this 
time, there are three partially competing, but in some way complimentary, hypotheses of 
underlying developmental mechanisms.
a) Embolization of placental endothelial cells 
A great similarity between immunohistochemical markers of IH and human placental 
microvessels is demonstrated (GLUT1, Lewis Y antigen, merosin, chemokine receptor 6 
(CCR-6), CD15, indoleamine 2,3-dioxygenase (IDO)).2 This immunohistochemical profile 
differentiates IH from other vascular tumors. Infantile hemangioma endothelial cells have 
also been found to express other types of molecules normally found in placenta, including 
type-3 iodothyronine deiodinase (D3) and insulin-like growth factor 2 (IGF-2).24-26 In line 
with these findings is the high level of genetic similarity between placenta and IH.27 With 
this knowledge, it was hypothesized that embolization of placental endothelial cells to the 
fetus could play a role in the pathogenesis of IH. In favor of this hypothesis is the finding 
that chorionic villus sampling is associated with an increased incidence of IH.28 But 
subsequent molecular genetic investigation could not reveal evidence for maternal-fetal 
microchimerism in children with a solitary IH. This however does not rule out the possibility 
of placental origin of IH tissue, because the placenta is predominantly fetal in origin.29,30 
It also remains to be explored whether or not this applies to diffuse neonatal hemangio-
matosis as well, which is characterized by numerous cutaneous and visceral IHs, and 
associated with placental hemangiomas (chorangiomas).6
b) Increased angiogenic and vasculogenic activity 
Angiogenic peptides, like vascular endothelial growth factor (VEGF) and basic fibroblast 
growth factor (bFGF) and their receptors, are largely involved in endothelial cell regulation 
and the growth of IH. Mutations in key growth regulatory pathways might play a role in 
the clonal expansion of endothelial cells in IH. Somatically acquired mutations in the VEGF 
receptors have been found in histological specimens of some IH patients and this point 
may lead to abnormal endothelial cell proliferation as a result of dysregulated VEGF 
signaling. Expression of vascular endothelial growth factor receptor 1 (VEGFR1) is reduced 
in IH endothelial cells, resulting in VEGF-induced activation of VEGFR2 and downstream 
signaling pathways, leading to stimulation of angiogenesis.31 
 As opposed to the previous thoughts, vasculogenesis, in addition to stimulated 
angiogenesis, is relevant in the pathogenesis of IH as well. Endothelial progenitor cells 
(EPCs) are vascular stem cells with the potential to contribute to postnatal vascular 
development. At the present time, there is compelling evidence that IH arises from bone 
marrow-derived EPCs, capable of inducing postnatal formation of vascular tissue.32,33 A 
subset of progenitor cells possessing the surface markers CD34+ and CD133+ could be 
isolated from IH tissues. These EPCs have been shown to differentiate into endothelial cells 
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in vitro34 and are increased 15-fold in IH compared to controls.35 Several mediators of EPC 
trafficking and vasculogenesis, such as VEGF-A and hypoxia inducible factor-1α (HIF-1α), 
were found to be elevated in blood and IH specimens taken from IH patients.36 A major 
breakthrough was the development of an IH animal model by injecting immune-deficient 
mice with CD133+ EPCs. The development of GLUT1+ vascular tumors in these mice 
highlighted the importance of CD133+ EPCs in the pathophysiology of IH and was an 
important impulse for the study of mechanisms of action of drugs used in IH.37,38 
c) Tissue hypoxia 
Tissue hypoxia seems to be the most influential inducer of angiogenesis (and 
vasculogenesis). In literature an association between placental hypoxia and IH has been 
described.39,40 The inverse relationship between birth weight and IH incidence41 and the 
association of IH with retinopathy of prematurity are indications in the same direction.42 
Hypoxic environment triggers the production of the transcription factor HIF-1α, regulating 
genes enhancing angiogenesis such as VEGF-A, IGF-2 and GLUT1.43-45 Hypoxia can also 
trigger angiogenesis by stimulating the secretion of pro-angiogenetic molecules from 
myeloid cells in IH.46 
Given the giant variability in IHs, it is likely that the pathogenesis of IH will not be restricted 
to one, but to a combination of genetic and environmental factors.47 
1.1.7 IH associated with structural anomalies
The two main clinical variants in which the IH can give an indication of an underlying 
anomaly are: large, flat, facial IHs with a segmental distribution (typically 5 cm in diameter 
or larger) and medium to large sized IHs involving the lumbosacral or perineal region. 
 The first one is associated with PHACES syndrome (posterior fossa malformations, 
hemangioma, arterial anomalies, cardiac anomalies, eye abnormalities and sternal defects), 
an uncommon but not rare cutaneous neurovascular syndrome. The exact incidence of 
PHACES among patients with large IH in the head and neck region is unknown but has 
previously been estimated at 20-30%, with cerebrovascular and cardiac anomalies being the 
most common extra-cutaneous associations.48,49 Particularly the IH in the fronto temporal 
and frontonasal segments of the face correlate with an increased risk of this association.48 
For these patients, cerebral magnetic resonance imaging (MRI)/magnetic resonance 
angiography (MRA) and careful cardiac and ophthalmological examination is indicated.49
 Infantile hemangiomas overlying the lumbosacral skin or perineum can also be 
associated with underlying structural anomalies like tethered spinal cord. The structural 
anomalies in this region have been referred to by different acronyms, highlighting similar 
associations: LUMBAR50 (lower body hemangioma and other cutaneous defects, urogenital 
abnormalities, ulceration, myelopathy, bony deformities, anorectal malformations, arterial 
anomalies and renal anomalies), SACRAL51 and PELVIS.52 Screening MRI of the spine is 
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recommended for children with these lesions. For children younger than three months, 
MRI may not be sensitive enough and in asymptomatic cases, this imaging study may best 
be postponed till approximately three to six months of age. Before this age, ultrasonogra-
phy of the spine, abdomen and pelvis with color Doppler is in the first instance 
recommended.50,53
1.1.8 Differential Diagnosis
The diagnosis of IH is usually easily made on clinical findings. Nevertheless IHs share many 
characteristics with other benign and malignant vascular anomalies.54,55 Incorrect 
diagnosis may lead to significant errors in management as well as in prognostic information 
given to patients and/or their parents. In some atypical cases, duplex ultrasonography or 
a biopsy should therefore be performed to exclude other soft tissue tumors or vascular 
anomalies.12 The differential diagnosis of IH is very extensive, associated with the variability 
in clinical aspect (Table 1). A selection of the most important differential diagnoses, 
relevant for this thesis, is described below.
•	 Congenital hemangioma
 These vascular tumors are fully-grown at birth in contrast to IHs. Congenital hemangiomas 
can be divided into rapidly involuting (RICH) and non-involuting (NICH) subsets, on the 
basis of their clinical behavior. The lack of GLUT1 staining may be helpful to distinguish 
these tumors from IHs, but the clinical aspect and ultrasound aspect is often so 
distinctive that a biopsy is not required.54,56
•	 Tufted angioma and Kaposiform hemangioendothelioma
 Tufted angioma (TA) is an uncommon, benign vascular tumor of the skin with a variable 
clinical presentation. The etiology and pathogenesis has not been fully elucidated. Most 
TA are acquired early in infancy but are typically not noted at time of birth. Three 
distinguishing features can be helpful: the firm aspect of the tumor, the presence of 
localized pain and increased hair growth.57
 Kaposiform hemangioendothelioma (KHE) is a vascular tumor that is present at birth or 
may develop in early childhood. Lesions of KHE may be more deeply infiltrated than IH 
or TA. Because of the clinical and histological overlap of KHE and TA, a spectrum of 
disease is suggested. Both TA and KHE can be associated with Kasabach-Merritt 
phenomenon (KMP), characterized by clinically significant and life-threatening throm-
bocytopenia in the presence of a TA or more often a KHE. The primary process behind 
the KMP is platelet-trapping within the tumor.58
1.1.9 Imaging
More than 90% of vascular anomalies can be classified as IHs or vascular malformations by 
only taking history and performing physical examination.16 Imaging studies are rarely 
17
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necessary, except for cases in which the diagnosis is unclear or in which the extent of the 
lesion is difficult to assess. Further investigation may also be required to rule out 
concomitant lesions and other associated abnormalities.59 
 Duplex ultrasonography is the least invasive and most cost-effective imaging 
modality for IH and recommended as the initial test of choice to differentiate between 
Table 1  Main differential diagnosis of IH
Congenital Anomaly
Vascular tumor or malformation
Congenital hemangioma RICH type
Congenital hemangioma NICH type
Kaposiform hemangioendothelioma
Tufted angioma
Port-wine stain
Macrocystic lymphatic malformation
Venous malformation
Others
Myofibromatosis
Dermoid cyst
Teratoma
Sarcoma (fibrosarcoma)
Neuroblastoma
Leukemia (blue berry muffin baby)
Tumor or anomaly developed after birth
Vascular tumor or malformation
Pyogenic granuloma (especially on the face)
Macrocystic lymphatic malformation
Glomuvenous and venous malformation
Hemangioendothelioma
Others
Hematoma
Benign tumors (pilomatrixoma, Spitz naevus, 
myofibromatosis, neurofibroma, eosinophilic granuloma, myxoma, lipoblastoma….)
Malignant tumors (sarcoma, lymphoma, cutaneous localization of neuroblastoma or leukemia)
Modified from Léauté-Labrèze C, Prey S, Ezzedine K. Infantile haemangioma: Part I
Pathophysiology, epidemiology, clinical features, life cycle and associated structural abnormalities
J Eur Acad Dermatol Venereol 2011; 25: 1245-1253.12
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vascular tumors and malformations.60,61 It is useful for distinguishing deep IHs from other 
entities like venous malformations, because it typically shows combined high and low flow. 
Duplex ultrasonography is however highly operator dependent and it fails sometimes in 
assessing the extent of the lesion and presence of other anomalies.62 
Computed tomography (CT) or MRI are superior in delineating the extent of the lesion.62 
For volume measurement of IH in daily practice, these imaging studies are only moderately 
suitable because they are not immediately available, costly and require sedation or general 
anesthesia in young infants.60 
 Besides, several bedside techniques have been described for estimating IH volume, 
assuming that IHs are perfectly dome shaped.63-65 These methods are not suitable for 
irregular shaped IHs and have an inevitable inter-observer variation. Until now, in most 
studies, two-dimensional photographs have been used to follow up the evolution of the 
IH. This method is however not appropriate for objective assessment of growth and 
involution, in the first place because IH proliferation generally implicates thickening of the 
IH without increase of the affected surface area, and in the second place because of a 
great inter-observer variation. Objective ways, like three-dimensional (3D) imaging, to 
measure growth and involution of IH are important, for monitoring patients in routine 
clinical practice and evaluating treatment efficacy in clinical studies.65 
1.2 Complications and treatment indications for IH
In relation to their natural history, characterized by spontaneous involution, most IHs do 
not require therapeutic intervention and the policy of active non-intervention is 
legitimized. However, 10-15% of the IHs potentially result in serious complications which 
should be anticipated, because treatment options do exist.66 The IHs requiring special 
attention will be described in the following four sections.
1.2.1 Vital risk
Infantile hemangiomas associated with potentially life-threatening complications are rare. 
But particularly IHs affecting the airway or liver, as well as extensive IHs, may lead to life-
threatening emergencies.
•	 Airway	IHs	are	notorious	for	their	morbidity	and	mortality	in	young	infants.	A	cutaneous	
IH in a mandibular distribution (‘beard’ region) is a marker for a high risk of airway IH.62 In 
clinical practice however, skin lesions may be absent and airway IHs may be 
unpredictable and unexpectedly revealed during ‘routine’ bronchoscopy for evaluating 
respiratory distress. Although subglottic IHs are more emphasized in literature, IH may 
occur anywhere throughout the airway. Clinicians should be alert of signs and symptoms 
that could indicate an airway IH, especially hoarse cry, stridor or noisy breathing. Prompt 
referral to pediatric otolaryngology is imperative to directly evaluate the airway and 
19
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start treatment as early as possible if necessary, perhaps even before laryngoscopy has 
been performed.67
•	 The	liver	is	the	most	common	extra-cutaneous	site	of	IH	involvement.	Hepatic	heman-
giomatosis is usually associated with multifocal IHs, especially more than 5 IHs on the 
skin, particularly of pinhead size and called diffuse neonatal hemangiomatosis or 
multifocal IHs with extra-cutaneous disease. The innocuous variant, benign cutaneous 
hemangiomatosis or multifocal IHs without extra-cutaneous disease, is characterized 
by identical cutaneous IHs but without visceral involvement.68 Liver ultrasonography 
with Doppler flow assessment of the hepatic blood flow is useful in diagnosing hepatic 
involvement. If liver IHs are present, small and asymptomatic, serial ultrasonography is 
adequate for follow-up.69 Much less frequently, liver IHs can cause severe liver 
enlargement and/or high-output cardiac failure with possibly consumptive 
hypothyroidism.70 The last is probably associated with the high level of type-3 
iodothyronine deiodinase-activity found in IH tissue, normally expressed in the brain 
and placenta and involved in the inactivation of thyroxine. It is therefore postulated that 
in a large growing IH, increased inactivation of thyroxine exceeds the normal production 
capacity of the thyroid, clinically resulting in hypothyroidism.24 
•	 Large,	 voluminous	 cutaneous	 IH	 can	be	 complicated	by	high-output	 cardiac	 failure,	
resulting from increased vascular flow.66
1.2.2 Painful or extensive ulceration
Ulceration is the most common complication of IH, occurring in about 15-25% of the IH in 
referral centers.67,71 It is the most common reason for IH referral to specialists, since it causes 
pain, resulting in parental concern. Besides pain, ulceration can cause some other 
significant complications including infection, bleeding and more commonly eventual 
scarring and disfigurement. Ulceration most commonly occurs during the peak of IH 
proliferation. The pathogenesis of ulceration is not completely clarified, however three 
main factors may play a role. In the first place sites of trauma (maceration, friction or both), 
in the second place local factors like bacteria (infection or colonization) and in the last 
place tissue hypoxia, such that ulceration occurs when an IH outgrows its own blood 
supply.62
1.2.3 Functional risk
Infantile hemangiomas can lead to functional impairment in many different ways; location 
in periorificial areas constitutes the largest group. Most common are the periorbital IHs, 
possibly threatening vision development. Amblyopia is the most common complication 
associated with periorbital IHs and in general, three major causes can be differentiated. 
Anisometropia is the first and most common cause of amblyopia. In IH patients, this 
anisometropia generally results from induced astigmatism or myopia due to direct 
pressure of the tumor on the eye. The second way amblyopia can be induced is by visual 
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deprivation secondary to occlusion of the visual axis duo the mass effect of the IH itself or 
induced ptosis from the IH. Strabismus is the third cause of amblyopia, resulting from a 
mass effect of the IH or due to direct involvement of the extra-ocular muscles.72
 Other potential complications of periorbital IHs include myopia, tear duct obstruction, 
proptosis and ptosis. To prevent loss of vision, any infant with a periorbital IH should be 
referred early to an ophthalmologist, familiar with these issues, for evaluation.16 
 Other examples of worrying functional impairment include oral IHs, with lip 
involvement, in which an indurated swelling may interfere with the suction ring and 
adversely affect feeding, in particular in case of painful ulceration. Nasal IHs can cover the 
nostrils and threaten underlying cartilage tissue in case of necrosis or extensive growth. 
Infantile hemangiomas of the ear can result in ear infection, closure of the ear canal and 
subsequent conductive hearing loss. In addition, large IHs located on the head and neck, 
may lead to positional torticollis and/or plagiocephaly.66,67
1.2.4 Aesthetic risk/psychosocial risk
The perception that IH may lead to permanent disfigurement has increased significantly 
in the past decades and is becoming an increasingly important reason for initiation of 
treatment. There are numerous IHs that may lead to significant aesthetic problems as a 
result of their location, size or shape. Large facial IHs, occupying a significant region of skin 
may cause significant cosmetic concern, both in the growth and involution phase but also 
after involution, in case of significant residual lesions. Also smaller facial IHs, particularly on 
the central face or involving contoured surfaces, for example the nasal tip or lip, can result 
in significant cosmetic sequelae. When poor aesthetic outcome is anticipated, intervention 
Figure 5
Superficial, localized ulcerating IH
Age of the patient: 3 months
Figure 6
Superficial, localized ulcerating IH
Age of the patient: 3 months
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should be considered as soon as possible, with the physician weighing risks and benefits 
of the specific treatments.
 On the other hand, in present times, physicians have become increasingly concerned 
about the impact of IH on patients and their family life. During consultation, parents often 
express their concern about the visible lesion of their child. In some cases several 
psychosocial problems may occur for the patients and their children, particularly above 
the age of 4-5 years, when the child goes to school. From this age, IH patients start to 
experience themselves as being different.73 These facts play also an increasingly important 
role in both the attitude of physicians treating children with an IH and their decision 
whether or not, and when to start treatment.
1.3 Management and treatment 
In 2008, a Dutch treatment guideline, initiated by parents and patient support group 
Hevas has been published and an update will appear in the immediate future, with the 
addition of beta-blockers as therapeutic modality. Despite the relatively high frequency of 
IH and the potential severity of complications, there are however no international uniform 
guidelines for treatment. Nevertheless, in the last decades, several modalities in the 
treatment of IH have been described. Some of them are rarely or no longer used (radiation 
therapy, cryotherapy, imiquimod and bleomycin) related to disappointing efficacy and/or 
side effects. Prospective data concerning the efficacy and safety of treatment modalities 
for IH have not yet been generated. Available data are confounded by the lack of consensus 
on treatment criteria and objective outcome measurements. The most common 
management and treatment modalities for cutaneous IHs will be described in the 
paragraphs below.
1.3.1 ‘Active non-intervention’
In a vast majority of IH patients, the best approach is choosing not to treat. This is a 
valuable choice for children with small innocuous IHs where parental concern may be 
much greater than the actual threat of the condition. A proactive approach of the 
physician and attention for the coping of the parents is of great importance in these cases. 
At the initial visit there should be a clear explanation of the natural history and the general 
prognosis, for example illustrated with photographs. Also the advantages and 
disadvantages of the various treatment options should be discussed. Parents should be 
provided with reputable sites/resources that can help in supporting families with an IH 
patient. Regular visits particularly during the proliferation phase, with assessments and 
serial photographs to document growth velocity are also recommended. This strategy 
called ‘active non-intervention’ is the most optimal approach for the majority of patients.
22
Chapter 1
1.3.2 Corticosteroids: topical, intralesional and systemic
There are reports on the beneficial effect of potent topical steroids (particular clobetasol 
propionate) on small superficial IHs, particularly early in the proliferation phase. However, 
randomized controlled trials, to support the use of topical corticosteroids in the treatment 
of IH are lacking in literature. Potential side effects of topical corticosteroids include: 
systemic absorption, cutaneous atrophy and striae, making close follow-up necessary. 
 Intralesional corticosteroids were initially used for periorbital IHs by ophthalmologists, 
but the risk of retinal artery damage and blindness has ensured that intralesional 
corticosteroid treatment for these IHs is no longer applied.74,75 Intralesional steroids for IH 
on other sites (e.g. nasal tip, lip) can be effective in stabilizing growth or decreasing the 
size of the IH, particularly in the proliferation phase. Intralesional application may be 
effective in small tumors, where the medication is likely to be distributed equally. Mostly, 
triamcinolon 10 mg/ml is used and doses do not exceed 1-2 mg/kg per injection. The 
injections can be repeated at six-week intervals and usually one to three injections are 
required and anesthesia is not obligatory. Possible side effects include bleeding, skin 
atrophy, infection and adrenal suppression.67
 Systemic corticosteroids (prednisolone, prednisone) were first described in 1960 in the 
treatment of IH and were until recently, the mainstay of therapy.76 Prednisolone, administered at 
2-3 mg/kg/day, in a single daily dose, is reported in several studies as an effective therapy for the 
majority of the IH patients, predominantly in the proliferation phase, as defined by cessation of 
growth or involution.77-79 Several side effects are however reported, particularly in case of 
long-term treatment: gastro-intestinal upset and irritability, weight gain, Cushingoid appearance, 
hypertrophic cardiomyopathy (HCM), hypertension, delayed growth, adrenal suppression and 
immunosuppression.80 Catch-up growth occurs in most cases, nevertheless numerous courses 
of corticosteroid therapy, can lead to serious long-term side effects.81 The careful monitoring 
of patients treated with oral corticosteroids is therefore emphasized in literature.
1.3.3 Laser-therapy
Pulsed dye laser (PDL) is the most commonly applied modality for superficial IHs, ulcerated 
IHs and residual lesions, with minimal requirements for anesthesia. Because PDL has only 
a limited penetration depth, it is not used for IHs with a deep compartment. The risks of 
scarring and induction of ulceration are actually limited because of the current use of 
epidermal cooling systems and longer pulse duration.82,83 As opposed to the layman’s 
ideas, it is important to realize that laser treatment of the tiny initial IH, never prevents the 
development of any bulky IH.84 
 Lasers with longer wavelength like Nd:YAG may be used in difficult, recalcitrant cases, 
but implicate a greater risk of scarring.85 
 Fractionate CO2 laser is reserved for the resurfacing of involuted lesions, to diminish 
textural changes.86 Sometimes laser treatment is used successfully, in combination with 
other particularly systemic therapies.46,87
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1.3.4 Interferon
Since 1989, several studies reported the use of subcutaneous interferon alpha-2a and -2b 
in the treatment of IH. Interferon has anti-angiogenetic properties, it stops the growth of 
IH slowly and may result in a higher rate of actual shrinkage than seen with corticosteroids. 
Subsequently, reports appeared of serious side effects including spastic diplegia in up to 
20% of patients.88 Given the severity of this potential complication, the use of interferon in 
the treatment of complicated IH is limited.
1.3.5 Vincristine
Vincristine is a vinca alkaloid widely used in cancer chemotherapy and successful in 
treating IH, most commonly in conjunction with other therapies.89 It is administered 
intravenously at a dose of 1.0-1.5 mg/m2 weekly. This modality also has limited use due to 
the need for central line access for chronic administration as well as the potential severe 
side effect of peripheral mixed sensory-motor neurotoxicity.46 It is only indicated for 
severely threatening IHs, resistant to other therapies. 
1.3.6 Surgery
In some cases, surgical excision may be the best therapeutic choice. Particularly in case of 
large pedunculated IHs that are located where a surgical scar will be less noticeable. The 
expected cosmetically aspect of the scar needs to be weighed against the expected 
residual lesion after involution of the IH. In some instances, eventual surgical involvement 
is inevitable because of permanent fibrofatty tissue. Besides, the timing of surgical 
intervention is often a difficult decision. The clinician should consider whether postponing 
the operation, allowing further natural involution, may eventually result in a smaller size of 
the operated lesion with finally a smaller scar.16,46 On the other hand, choosing to operate 
before the school-going age in a lesion that eventually may need surgery after all, may 
also be an option as the IH is (significantly) decreased and the intervention ‘forgotten’ by 
the young child.
1.3.7 Propranolol
1.3.7.1  Propranolol and IH
The effectiveness of propranolol in the treatment of IH was serendipitously discovered by 
Léauté-Labrèze et al. in 2008. In two children their IH showed very rapid involution when 
treated with propranolol, which was given for other indications. The first child received 
propranolol for obstructive HCM, secondary to corticosteroids given for a nasal IH. The 
second child was initiated on propranolol for increased cardiac output due to a large, 
bulky IH in the head and neck region.90 Since this initial report, there has been an outbreak 
of case reports and case series in medical literature describing efficacy and potential side 
effects of propranolol for IH. From the current clinical experience, propranolol has shown 
to be rapidly effective for IH and well tolerated. It seems that propranolol stops the growth 
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and induces regression of IH much better than previous therapies. These observations 
have led to rapid and worldwide implementation of this new therapeutic modality for 
IH.91 
1.3.7.2  Mechanisms of action
Propranolol is a synthetic, highly lipophilic, beta-adrenergic receptor-blocking agent that 
is classified as non-selective because is blocks both beta-1 and beta-2 adrenergic 
receptors. This beta-blocker is a pure antagonist without partial agonistic effects. 
Propranolol has been used for decades in pediatric patients, primarily for the prevention 
and treatment of cardiac arrhythmias, HCM, hypertension and to prevent cyanotic spells 
in Tetralogy of Fallot. The standard dosing is 0.5-4.0 mg/kg/day, however much higher 
dosages are given to reduce the risk of sudden cardiac death in HCM.92 Its antihyperten-
sive effects result from decreased heart rate, decreased cardiac contractility, inhibition of 
renin release by the kidneys and decreased sympathetic tonus. Control of IH-growth by 
propranolol is hypothesized to work via different mechanisms with distinct early, 
intermediate and long-term effects, which can be attributed to different pharmacological 
targets.
a. Vasoconstriction - early effect
Propranolol inhibits epinephrine-mediated vasodilatation, leading to vasoconstriction of 
the microvessels of the IH, resulting in rapid color change and tissue softening. These 
effects can be observed within 1-3 days after the onset of therapy.90,93
b. Inhibition of angiogenesis - intermediate effect
Beta-adrenergic receptors are G-protein-coupled receptors, which, when activated by 
adrenergic catecholamines, can promote a series of intracellular signal transduction 
pathways including that of angiogenetic factors such as VEGF or bFGF and some matrix 
metalloproteinases (MMP) such as MMP-2 and MMP-9, involved in degradation and 
transformation of extracellular matrix proteins. These signal transduction pathways are 
inhibited by beta-blockers, resulting in a reduction of angiogenesis.93 
c. Apoptosis - long-term effect
Blockade of beta-adrenergic receptors by propranolol can induce apoptosis of different 
cell types in vitro, e.g. endothelial cells or pancreas carcinoma cells. It is hypothesized that 
beta-adrenergic antagonists are capable of disengaging the inhibition of apoptosis 
caused by beta-adrenergic agonists, resulting in an increased apoptosis rate.93
d. Renin-angiotensin system
More recently a fourth mechanism has been suggested after the discovery of the presence 
of both angiotensin-converting enzyme (ACE) and angiotensin II-receptor on the CD34+ 
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endothelial progenitor cells of the microvessels of proliferating IHs. This, together with the 
observation of increased renin levels in premature, female and Caucasian infants, the 
prototypical IH patient characteristics, has resulted in the investigation of the position of 
the renin-angiotensin system (RAS) in the pathogenesis of IH. Propranolol reduces renin 
activity in the periphery by reducing plasma renin activity, resulting in reduced angiotensin 
I (AT I) and eventually AT II levels. A reduction in AT II levels causes a reduction in proliferation 
of the hemogenic endothelium of proliferating IHs combined with an increased rate of 
cellular apoptosis through the tumor necrosis factor (TNF)-related apoptosis ligand 
pathway. The natural history of IH is consistent with the reduction in renin levels that occur 
physiologically after the first year of life. Also the effect of beta-blockade on IH is in line 
with the interfered mechanism of action of propranolol through the RAS.94,95
1.3.7.3  Adverse events
Beta-blockers have a well-documented safety and side effect profile. A review of literature 
of the 40 years of clinical use at therapeutic doses in children younger than 7 years of age, 
revealed no cases of mortality or serious cardiovascular events, except for one girl, in 
relation to an overdose.96,97 The most frequently reported serious complications after use 
for IH are hypotension, pulmonary symptoms, related to direct blockade of adrenergic 
bronchodilatation, hypoglycemia, asymptomatic bradycardia and hyperkalemia. The 
most commonly reported, non-potentially life-threatening complications were sleep 
disturbances including nightmares, somnolence, cold extremities and gastro-esophageal 
complaints.91 
 Hypoglycemia is considered the most serious side effect of propranolol. Propranolol 
may cause hypoglycemia as a result of decreased glycogenolysis, gluconeogenesis and 
lipolysis. Young children are more susceptible to hypoglycemia for two reasons. Firstly, 
their lower glycogen stores lead to reduced fasting ability and secondly their glucose 
utilization rates are higher when fasting. Children previously or actually treated with oral 
corticosteroids, are more at risk due to adrenal suppression.98 Another concern is the 
masking of early sympathetic signs of hypoglycemia such as tachycardia, sweating and 
palpitations by propranolol. It is therefore advised that propranolol should be temporarily 
discontinued in case of (preoperative) fasting or intercurrent illness, associated with 
diarrhea and vomiting.99 
1.4 Aims and outline of the thesis
1.4.1 Aims of the thesis 
The studies carried out in this thesis are designed to investigate the implications of the 
changing landscape of treatment of complicated IHs since the discovery of propranolol as 
treatment modality. Secondary, we intend to achieve more insight in complicated IHs.
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The following aims are formulated:
Aim 1:  To explore the indication area and treatment regimen of propranolol in infantile 
hemangioma. 
Aim 2:  To get more insight in the role of propranolol in the treatment of ulceration, the 
most common complication of infantile hemangioma.
Aim 3:  To enlarge knowledge about quality of life aspects in patients with infantile hemangioma 
and their families, especially with respect to different treatment modalities.
Aim 4:  To explore the future role of quantitative imaging analysis, in particular 3D stereo-
photogrammetry in the follow-up of infantile hemangioma growth and regression.
Aim 5:  To investigate and describe the broader applicability of propranolol in vascular 
tumors.
1.4.2 Outline of the thesis
In Chapter 2, a prospective study is described of the first 174 patients treated with 
propranolol for complicated IHs. The experiences of the Hecovan-working group are 
delineated with the focus on the indications area and treatment regimen.
 The first part of Chapter 3, comprises a retrospective analysis, investigating the 
differences between ulcerated and non-ulcerated IHs. These characteristics could be 
important in the consideration of whether or not to start treatment. In the second part of 
chapter 3, the results of a retrospective study are reported, in which twenty patients with 
an ulcerated IH treated with propranolol were compared with a historical control group. 
In this study the role of propranolol for patients with ulcerated IH is explored. 
 Chapter 4 presents a retrospective study exploring the impact of treatment and 
contentment with treatment-outcome for propranolol-treated IH patients and their 
parents compared with a matched patient group treated with oral corticosteroids. 
 In Chapter 5, a pilot study is described, in which the role of two methods in 3D 
 stereophotogrammetry for the measurement of volume changes in facial IH is explored.
 In the first part of Chapter 6, the role of propranolol for airway IHs is described based 
on a case series of five patients and a review of the experiences in literature. In the second 
part of chapter 6, a patient with Kaposiform hemangioendothelioma (KHE) and Kasabach-
Merritt phenomenon (KMP) is described, treated with propranolol and only a total of 4 
weekly doses vincristine.
 In Chapter 7, the aims of this thesis are discussed in the view of our findings described 
in chapter 2-6. Moreover, recommendations for additional clinical research are outlined 
and viewpoints for future developments are revealed.
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Summary
Background Infantile hemangioma (IH) is a benign, common and self-limiting tumor of 
infancy; only a minority of cases need active treatment. Currently, propranolol appears 
superior to classic treatments.
Objectives To document in a prospective study indications and side effects of propranolol 
for complicated IH in a large patient group.
Methods Analysis of prospectively collected data was performed on 174 patients with IH 
treated with propranolol in a tertiary referral centre from September 2008 to January 2012.
Results The group consisted of children with a potentially threatening and/or complicated 
IH; the girl/boy ratio was 123/51, and the mean age at the start of treatment was 4.8 
months. In 173 cases (99.4%), treatment was successful, as assessed non-quantitatively by 
clinical observation. This striking effect was characterized by immediate cessation of 
growth, softening, fading of the erythema and rapid induction of regression. The mean 
duration of treatment was 10.7 months. The most important adverse effects were 
hypotension (3.4%), wheezing (9.2%), nocturnal restlessness (22.4%) and cold extremities 
(36.2%). In one patient, propranolol was stopped. In 15 patients it was necessary to reduce 
the dose, although the lower dose was still effective.
Conclusions In this study, propranolol was effective and safe in almost all patients with 
complex IH. Administration of systemic medication to an infant with a benign condition 
requires careful consideration, as only a minority of patients with IH require an active 
medical intervention. A shift of the indication of propranolol for IH is evident, expanding 
its application for life-threatening situations or severe functional impairment to early 
prevention of disfigurement or cosmetically permanent sequelae. However, the indication 
for such an active approach should be determined by experienced physicians.
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Infantile hemangioma (IH) is the most common tumor of childhood, with an estimated 
prevalence of 10–12% in populations of European descent. IH is characterized by an 
inconspicuous appearance at birth, a proliferative phase throughout the first year of life 
with disproportionate growth, followed by a slow involution phase that lasts on average 
until the age of 7–10 years. Residual lesions are frequent and depend on the degree of 
epidermal involvement.1 This benign course of IH in general justifies a conservative 
approach during the growth phase of the tumor. Nevertheless, 10% of all cases of IH cause 
substantial morbidity, which is an indication for an active approach in the proliferation 
phase.2 Until recently, the first-choice treatment in this patient group consisted of 
administration of high-dose oral corticosteroids.3 In June 2008, Léauté-Labrèze et al.2,4 ser-
endipitously observed the extraordinary and fast effect of the adrenergic beta-antagonist 
propranolol on IH. This observation has caused a worldwide shift in the therapeutic 
approach for complicated IH. Our tertiary referral centre also started with propranolol 
treatment in patients with a complicated IH.
 The experience with 174 children is presented as ‘real clinical practice’ data in the 
current report and is the largest group in the literature to date.
Materials and methods
Treatment protocol
After the treatment indication for propranolol was established by a multidisciplinary team, 
the pediatric cardiologist monitored (initiation of) propranolol treatment in all the 
patients. Prior to treatment, a medical history was taken and patients were examined 
physically. An echocardiogram (ECG) was performed in all patients and echocardiography 
was performed in our first 75 propranolol patients. However, with our growing experience, 
echocardiography was performed only in a subset of patients. These included children 
with signs of a syndromal IH associated with cardiac pathology, such as PHACES (posterior 
fossa malformations–hemangiomas–arterial anomalies–cardiac defects–eye abnormalities– 
sternal cleft and supraumbilical raphe syndrome),5 cardiac murmur, ECG abnormalities, or 
signs of cardiac failure and in children with a large bulky IH.
 Propranolol was administered orally; the starting dosage was 0.7–1.0 mg kg-1 daily in 
three divided doses. The dose was gradually increased to the total target dosage of 2.0–2.5 
mg kg-1 daily. Initially, treatment was started clinically for all infants. However, in a later 
stage, with our increasing experience, treatment was started at home in patients without 
contraindications. The initial low dosage was given at home, followed by monitoring in a 
day care setting while increasing the dosage to 2.0–2.5 mg kg-1 daily.
 Heart rate and blood pressure were measured three times a day during the first 3 days 
if treatment was started in a clinical setting. If treatment was given in day care, heart rate 
and blood pressure were measured after dose increment, three times in about 8 h. In the 
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case of young premature infants and neonates with a higher risk for hypoglycemia, renal 
dysfunction, cardiac morbidity and hypotension, a lower dosage of 1–1.5 mg kg-1 daily was 
given, which was gradually increased to the target dosage. For infants aged < 3 months, a 
fasting glucose level was determined. In addition, the parents of all patients were informed 
extensively about the increased risk and characteristics of hypoglycemia. In cases of a 
threatening IH resulting in, for example, compromised airway function, the target dosage 
was adjusted upwards to a maximum of 3.0 mg kg-1 daily. All patients with a periorbital IH 
were also monitored by an ophthalmologist and orthoptist during treatment.
 The follow-up interval was every 6 weeks in the first 6 months of treatment; 
subsequently this interval was extended to 3 months. The propranolol dose was adjusted 
to the target dosage of 2–3 mg kg-1 daily, guided by body weight, until the age of 9 
months, after which the dose was no longer increased. For patients in whom an additional 
effect was necessary, dose adjustments were made above the age of 9 months. The 
degree of improvement (fading and softening) was recorded by two observers during 
each visit (D.J.J.H., C.J.M.v.d.V.). Possible adverse events were recorded.
 Treatment was continued during the proliferation phase and gradually tapered in 2–3 
weeks. In general, the reduction schedule was as follows: 2 weeks of two divided daily 
doses, 1 week of one daily dose. Treatment was stopped at the age of 12–18 months, 
depending on the localization of the IH and ⁄or primary treatment indication.
Analysis
Data obtained from patient files of all the 174 patients with IH treated with propranolol 
between September 2008 and January 2012 were analyzed to define the characteristics of 
the study group. The numeric data are reported as mean (SEM).
Results
General characteristics
In total 174 patients were treated with propranolol; 123 were girls (70.7%). Thirty-nine 
patients (22.4%) were born prematurely; 10 were extremely premature (gestation < 32 
weeks). The patients had on average 2.4 IHs (SEM 0.3). Further characteristics of the treated 
IHs are listed in Table 1.
 Treatment was indicated in potentially threatening and/or complicated IHs. The 
primary treatment indications of the IHs are shown in Table 2.
 For 168 of the 174 patients (96.6%), treatment with propranolol was successful within 
72 h. In five patients (2.9%) the effect was visible within 2–3 weeks. Improvement was 
characterized by fading and softening of the IH. The effect of propranolol is illustrated in 
three infants with a complicated IH, all with different treatment indications (Figures 1–3). 
The five patients with airway obstruction involving the upper respiratory tract due to an 
IH improved within hours, thereby reducing or preventing an intensive care stay.
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 Besides treatment with propranolol, in two out of five patients with an airway IH oral 
corticosteroids were administered because of initial unclear diagnosis. After the diagnosis 
of IH was established, propranolol was started successfully and corticosteroids were 
reduced. For ulcerated IHs, in some patients, propranolol was initiated right away. In other 
patients, treatment was started with oral antibiotics combined with non-adhesive silicone 
or foam dressings and low-threshold pain medication. Propranolol was started when the 
above treatment regimen had insufficient effect. In 27 of the patients (45%) with an 
ulcerated IH, oral antibiotic treatment had been started before treatment with propranolol 
was initiated.
 In patients with a periorbital IH, no major ophthalmological complications, such as 
amblyopia, have been seen to date, except for two patients who started propranolol 
relatively late, at the ages of 7.1 and 14.0 months.
Table 1  Characteristics of infantile hemangioma (IH) (n = 174)
Characteristic na %
Growth pattern
Superficial macular 14 8.0
Superficial nodular 73 42.0
Deep 30 17.2
Mixed 57 32.8
Localization
Head ⁄neck 141 81.0
Eyelids ⁄ periorbital 65
Nose ⁄perinasal 19
Lips ⁄perioral 18
Subglottic 3
Ear ⁄periauricular 7
Cheek 8
Beard area 2
Neck 4
Scalp 9
Forehead 6
Trunk 4 2.3
Extremities 11 6.3
Diaper area 18 10.3
Total number of ulcerated IH 60 34.5
a Number of IHs with the primary treatment indication.
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Treatment regimen
At the time of analysis, 113 patients (64.9%) had completed their treatment. The mean age 
at the start of the treatment was 4.8 months (SEM 0.2, range 0.9–29.0 months). Mean 
duration of treatment was 10.7 months (SEM 0.4).
Table 2  Treatment indications
Indication n %
(Impending) visual impairment 69 39.7
(Impending) nasal obstruction 11 6.3
(Impending) hearing impairment 5 2.9
Cosmetic risk ⁄ face deformitya 14 8.0
Ulceration (primary treatment indication) 49 28.2
Ulceration risk in near future 7 4.0
Bleeding 3 1.7
Airway obstruction ⁄stridor 5 2.9
Nutritional problems 7 4.0
Mechanical impairmentb 4 2.3
Total 174 100
a Cosmetic risk ⁄facial deformity: (facial) infantile hemangioma (IH) with very high ⁄ great risk of psychosocial 
implications now and in the future. b Mechanical impairment: when size or location of the IH created a restriction 
in daily functioning.
Figure 1
(a) A 3-month-old girl with hemangioma of the nose with painful ulceration and 
obstruction of nostrils at the start of treatment with propranolol; (b) the same girl at the 
age of 8 months after propranolol treatment.
(a) (b)
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 After discontinuation of propranolol treatment, 14 of 113 patients (12.4%) had 
reappearance of some swelling, in 11 patients (9.7%) an increase in erythema appeared, 
and in nine patients (8.0%) both changes were seen. In one patient there was a slight 
increase in blue color and in one patient mild ulceration appeared after cessation of 
treatment, characterized by rapid improvement. The rebound swelling of the IH was 
significant enough to merit a second course of propranolol in four patients: two patients 
with eyelid IHs, one patient with a large facial IH with respiratory implications and one 
patient with a nasal IH. The second course of propranolol lasted on average 7.9 months 
(range 2.0–12.0 months) and was successful in all patients. In these four patients, the first 
course of propranolol had been stopped beyond the proliferation phase. For three 
patients rebound swelling during the reduction phase was the reason to slow down the 
tapering of propranolol, with good results.
Figure 2
(a) A 3.5-month-old boy with an ulcerated hemangioma of the buttock; (b) the same boy 
at the age of 6.5 months after propranolol treatment.
Figure 3
(a) A 4.5-month-old boy with hemangioma affecting the upper eyelid; (b) the same boy 
at the age of 11.5 months after propranolol treatment.
(a)
(a)
(b)
(b)
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 In general, a target dosage of 2–2.5 mg kg-1 daily was adequate. For 16 of the 174 
patients (9.2%) a lower starting dosage of propranolol was chosen than the median target 
dosage of 2–2.5 mg kg-1 daily, ranging from 0.75 to 1.9 mg kg-1 daily (mean 1.5 mg kg-1 daily) 
because of (extreme) prematurity, young age, comorbidity or low blood pressure at the 
starting dose. For 15 patients (8.6%), the dose was adjusted downwards during treatment 
due to adverse events, in particular respiratory symptoms, effects on blood pressure and 
nocturnal restlessness. The lesions continued to respond well, without adverse effects, 
despite dose reduction. In three patients with the indication of airway obstruction (n = 2) 
and repeated severe bleeding (n = 1), a higher target dosage of 3 mg kg-1 daily was chosen. 
For two patients the dosage was successfully adjusted upwards to 3 mg kg-1 daily during 
treatment because of the need for an additional effect given the relatively slow initial 
effect of the propranolol. In one patient with extreme nocturnal restlessness, a switch was 
made to the selective adrenergic beta-antagonist atenolol 1 mg kg-1 daily in two divided 
doses, resulting in comparable clinical efficacy and improvement of the sleep pattern.
Safety
During follow-up visits, all possible side effects were recorded as shown in Table 3. Possible 
side effects during treatment were recorded for 108 patients (62.1%). Despite this relatively 
large number, the adverse reactions were in general not serious and were reversible and 
dose dependent. Lowered blood pressure was noted in six patients. In five of these 
patients, blood pressure effects were observed in the first 3 days of clinical treatment. For 
the sixth patient, possible anamnestic hypotension at home was reported but could not 
Table 3  Possible side-effects during treatment in 62.1% (108) of the 174 patients
n %
Effects on blood pressure 6 3.4
Nocturnal restlessness 39 22.4
Cold extremities 63 36.2
Respiratory symptoms 16 9.2
Medication necessary 9
No medication necessary 7
Less active during the day ⁄sleepy ⁄drowsy 28 16.1
More active ⁄restless in the daytime 9 5.2
Gastrointestinal complaints 12 6.9
Feeding difficulty 3 1.7
Onset of ⁄worsening of ulceration 4 2.3
Breath-holding spells 2 1.1
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be verified with certainty. This did not require further follow-up. Sixteen patients 
developed respiratory problems during treatment, characterized by wheezing during 
upper respiratory tract infections. In nine of these patients, treatment was started with 
inhaled corticosteroids, inhaled sympathomimetics or both. In one of the first patients 
treated in our centre, an extremely premature infant (30 weeks’ gestation) with a periorbital 
IH, the therapy had to be discontinued early due to hypotension, drowsiness and cold 
extremities at a dosage of 1.0 mg kg-1 daily. Treatment was continued with corticosteroids. 
This case was one of the first children treated with propranolol in our centre. In retrospect, 
further reduction of the dosage might have been tolerated and effective. In all other 
patients with decreased blood pressure due to propranolol, treatment was successfully 
continued after a dosage reduction.
 For 15 of 113 patients (13.3%), the parents reported that their child became more 
active after discontinuation of treatment.
Discussion
Based on the currently available data, propranolol appears to be more successful for the 
treatment of IH than any other treatment modality, with a possible exception of surgery in 
selected cases.6 It is anticipated that this will be progressively demonstrated in emerging 
randomized controlled trials, one of which has been published with promising outcomes.7
 Propranolol is a highly lipophilic nonselective beta-adrenergic antagonist with an 
inhibitory effect on both b1- and b2-adrenoceptors with similar affinity. Its main effect in 
IH can be explained by different mechanisms: vasoconstriction; inhibition of angiogenesis 
by downregulation of angiogenic factors, vascular endothelial growth factor and basic 
fibroblast growth factor; and induction of apoptosis of capillary endothelial cells. These 
mechanisms correspond, respectively, with the following clinical observations: softening 
and fading, cessation of growth, and long-term regression.8
 As IHs have variable localization, size and type, it is almost impossible to describe the 
treatment effect in a standardized manner. Therefore, in this study a treatment was 
considered successful if obvious improvement was seen in color and size, as evaluated 
subjectively by two observers. In 173 of the cases (99.4%) propranolol treatment was 
successful; fading and softening of the IH was seen, usually starting within 72 h after the 
start of treatment. Growth of the IH stopped in all cases and regression was judged as 
significant at the end of treatment (9–18 months).
 Like many drugs used in children, there are no pharmacokinetic data and no 
prospective controlled studies that can be used to make an adequate treatment regimen 
and follow-up scheme for this patient group. At the current time, a target dosage of 2–3 
mg kg-1 daily, with regular adaption to the body weight, is considered a safe and effective 
dosage for the healthy infant.2,9,10 However, in the recent literature a minimal dosage 
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required to induce involution of 1.5–2.0 mg kg-1 daily has been described.11 This was also 
the case for several patients in this study. The target dosage could be adjusted downwards 
successfully during initiation or during the course of the treatment, which appears to 
indicate that for certain patients lower dosages may also be effective. Large-scale studies 
are required to establish the optimal dosage. In some cases, especially in patients with IH 
with airway involvement, higher dosages (3 mg kg-1 daily) and strict dose adjustments 
were necessary, because the effect of propranolol on stridor diminished at the moment 
that the relative dose decreased due to the weight gain of the child.
 Treatment duration was adjusted for the type of IH and the specific treatment 
indication. In deep and mixed IHs the proliferation phase starts and stops later, treatment 
was therefore continued until the age of 12–16 months. In cases of ulceration, for example, 
treatment was continued to 9–12 months of age, because of the marginal risk of recurrence 
of ulceration after this phase. Deep periorbital IHs and airway IHs, on the other hand, 
required treatment up to 15–18 months of age, because of the potential life-threatening 
implications of swelling after cessation of treatment.
 Rebound swelling in this study was generally not interpreted as regrowth but as 
swelling that occurred due to decreased vasoconstriction after stopping propranolol. This 
refill seems to occur particularly in more bulky IHs, which exhibit a sponge-like residual 
lesion.
 At the end of the treatment period, a slow reduction of the dose in 2 or 3 weeks 
is indicated, as abrupt discontinuation of beta-blockers bears the risk of cardiac hyper- 
reactivity due to upregulation of beta-receptors.12
 Propranolol has been used for more than 40 years in young children aged < 7 years, 
particularly for cardiological indications, without severe cardiovascular events or lethal 
outcome.13 Adrenergic beta-antagonists have a well-documented safety and side-effect 
profile. The main side effects of propranolol are bradycardia, hypotension and hypoglycemia. 
In addition, bronchospasm, rash, gastrointestinal symptoms, fatigue, behavioral changes, 
peripheral vasoconstriction and sleep disturbances have also been described. The most 
serious side effect of propranolol is hypoglycemia, also reported following its use for IHs, 
either aggravated or not by the fact that propranolol can mask early clinical symptoms of 
hypoglycaemia.14–16 The patient groups with higher risks for hypoglycemia are patients aged 
< 3 months with decreased food intake or concomitant treatment with oral corticosteroids, 
in particular in a reduction schedule. In these patient categories, intensive and frequent 
monitoring is therefore recommended as well as good instructions for parents.12,17 In our 
patient group, the measured fasting glucose levels were normal and fortunately no 
hypoglycemic side effects were seen. Additionally, propranolol diminishes cardiac 
performance and can mask the clinical signs of cardiac failure. This means that special care 
must be taken in patients with cardiac comorbidity, particularly in patients with cardiac 
failure, due to a large, bulky IH.
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 With our increasing experience with propranolol, in selected cases we chose to start 
the lowest dose at home and to increase to the target dosage during day care. This 
protocol was followed in patients born at term, with normal birth weight and no 
abnormalities on physical examination or ECG. In all other cases, treatment was started in 
hospital. Complication rates were similar for in- and outpatients. Important advantages of 
the outpatient start are the quick and easy application of the treatment without any time 
delay due to limited clinical capacity, and the fact that it is more cost-effective and patient
friendly. The main disadvantage of outpatient initiation of propranolol treatment is the 
absence of monitoring of blood pressure and heart rate during the first doses. This is why 
this protocol was applied only to a minority of children; initiation of propranolol in a 
clinical setting is still our preference.
 Following the observation of Léauté-Labrèze et al.,4 several case series have been described 
in which a large variety of clinically different IHs were treated successfully with propranolol.
 Initially, predominantly complicated IHs were treated. The indications are gradually 
broadening and are starting to include cosmetically disturbing cases such as large facial 
IHs. For both indications (functional and cosmetic), early initiation of treatment is probably 
the best, before rapid expansion of the tumor. If the IH is located mainly in important 
cosmetic areas, an early start with propranolol treatment may reduce the residual lesions 
after involution, making cosmetic correction less complicated or even unnecessary.1,18 To 
date, there is no evidence that early propranolol treatment leads to less disturbing residual 
lesions. However, for ulcerated IHs an early start appeared to result in shorter ulceration 
time; an analogy with less severe residual lesions due to an early start seems likely. Future 
research will determine the appropriate cosmetic indications. This shift in indications 
makes timely assessment by an experienced physician necessary.19–21
 In accordance with recent literature, we also noted a positive effect on the rate of 
involution in the few cases where propranolol was started at the end of the growth phase 
or thereafter.22,23 However, the residual lesions (e.g. fibrofatty tissue, skin surplus) are expected 
to be comparable with the situation in which treatment was not administered.
 Besides treatment modifications pertaining to initiation and/or duration, future 
developments may include the use of more selective beta-blockers. Reports on selective 
beta-blockers, such as atenolol or acebutolol, have already been published, but further 
investigation is required as to whether this selectivity is accompanied by a more favorable 
safety–efficacy profile.24,25
 Alternative approaches, such as the possible beneficial effect of angiotensin-converting 
enzyme (ACE)-inhibitors, will be further explored in the future. The renin–angiotensin 
system has recently been determined as a factor in the pathogenesis of IH. Expression of 
ACE and angiotensin II receptor-2 on immature capillaries of a proliferating IH has been 
observed and it has been proposed that beta-blockers decrease renin activity, resulting in 
decreased angiotensin II in IH tissue, leading to accelerated involution.26 The ACE-inhibitor 
captopril was recently reported to be effective.27,28
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 There is currently limited experience with the application of topical beta-blockers 
such as timolol. A beneficial effect can be seen, especially in superficial IHs, but the topical 
approach seems insufficient for the expansive growth of bulky deep IHs. On the other 
hand, application of topical beta-blockers in very young children (aged < 4 weeks) with a 
still flat IH appears to be a therapeutic option.29 However, topical beta-blockers must be 
prescribed with caution, especially in larger lesions, because of the risk of systemic 
absorption and subsequent side effects.30
 In conclusion, propranolol is definitively a valuable and promising therapeutic option 
for IH. In our patient group it was effective and safe in almost all patients. However, for 
some patients dose adjustments were necessary because of side effects. Future research 
is required on the treatment regimen and long-term follow-up. From the extensive 
experience of our tertiary referral centre and data from the literature, we expect that in the 
near future propranolol will become the first-choice treatment in complicated and 
disfiguring IHs, and very likely with further expanding areas of indication. On the other 
hand, it is important to emphasize that giving beta-blockers to young infants has to be 
justified for each individual patient as IHs are common, benign, self-limiting tumors that 
usually do not need an active approach. Only a small minority of IHs are life- or function-
threatening, and require therapy. Large, facial IHs with serious cosmetic outcomes may 
also be eligible for an active approach. Therefore, patients with life-threatening lesions or 
lesions with a severe psychosocial impact should be assessed individually and early by an 
experienced physician or a dedicated multidisciplinary team. The characteristics of the IH 
and the patient and the potential risk of propranolol treatment need to be taken into 
account.
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Summary
Our purpose was to get better insight into the ulceration of hemangiomas, by comparing 
patient characteristics of non-ulcerated hemangiomas with hemangiomas with active or 
past ulceration. A retrospective analysis was performed of files of patients who visited the 
Radboud University Medical Centre Nijmegen (UMCN), the Netherlands, between 1997 
and 2007 for one or more infantile hemangiomas. The medical records of 465 patients 
were reviewed. Twenty three percent of the patients were diagnosed with ulceration. The 
size of ulcerated hemangiomas was significantly larger (28.6 cm2 vs. 6.0 cm2, p < 0.05). 
Predilection areas for ulceration were the head and neck region and the anogenital region. 
Ulceration was significantly most frequently seen in hemangiomas with a superficial 
(epidermal) component (98.5%, p < 0.05) and a segmental distribution (29.3%, p < 0.05). 
Ulceration most frequently took place during the proliferation phase of the hemangioma 
(83.1%). In the whole study population the male to female ratio was 1:2 compared to a 
tendency to more girls (1:3) for the group with ulcerated hemangiomas (p = 0.08). We 
conclude that larger, more superficial hemangiomas in areas more susceptible to trauma 
and contamination were more likely to ulcerate. This study contributes to the possibility of 
assessing the likelihood of ulceration in an individual patient.
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Although infantile hemangiomas (IH) occur in 10-12% of children younger than 1 year of 
age, this benign tumor is not well understood. One of these unknown areas is ulceration.1 
Although ulceration is the most common and distressing complication of IH, possibly 
affecting between 5% and 13% of the IH, little is known about its pathogenesis.1,2 In the 
literature three factors were found that may play a role: localization with a high risk of 
trauma, local factors such as bacteria (either infection or colonization) (Figure 1) and tissue 
hypoxia caused by a fast growing IH that outreaches its blood supply (Figure 2).2,3 In the 
past, few studies were carried out that investigated ulcerating IH. The purpose of the 
present study was to get a better insight into the clinical characteristics of ulcerated IH and 
non-ulcerated IH in a retrospective analysis of hemangioma patients, who visited our mul-
tidisciplinary hemangioma-study group over the past 10 years. For this extensive patient 
group, the known differences between ulcerated and non-ulcerated IH from earlier 
studies were investigated again and supplemented with other characteristics that were 
also considered important. Better knowledge of the differences between ulcerated and 
non-ulcerated IH will hopefully deliver better insight into the pathogenesis and treatment 
of this distressing problem in young children.
Patients and methods
Patients
A retrospective analysis was performed of all IH at the Radboud University Medical Centre 
Nijmegen (UMCN), the Netherlands, from 1997 to 2007. The medical records and photo 
documentation of 465 patients with a hemangioma were reviewed. The following information 
Figure 1
Ulcerated hemangioma involving  
the scrotal skin.
Figure 2
Large segmental hemangioma on the arm 
with multiple localizations of ulceration.
56
CHAPTER 3.1
was obtained from each patient file: Hemangioma: ulceration or not (1), number of IH per 
patient (2), size (3), anatomic localization (4), type (5), age at time of discovery (6). Ulceration: 
phase of growth at time of ulceration (7), duration (8). Other: sex (9), prematurity/gestational 
age (10), birth weight (11), multiple gestation (12), (transcervical) chorionic villus sampling (13), 
atopic constitution/dermatitis (14).
Analysis
Data from the patient files were transported into a database and analyzed to define the 
characteristics of the study group and subsequently the differences between the 
ulcerated and non-ulcerated IH. The numeric data were reported as mean ± SEM. For 
statistical analysis the t-test for unpaired values was used. The other non-numeric data 
were analyzed with the Fisher exact test. The two tailed hypothesis was employed to 
interpret data. A p-value ≤ 0.05 was regarded as statistically significant.
Results
After registration of data mentioned above, the files were divided in two groups: IH with active 
or past ulceration versus IH which never ulcerated. Comparison between the two groups was 
carried out. In the description below, the results of all examined characteristics are reported.
Ulcerated vs. non-ulcerated IH
A total of 465 records of patients were investigated. Of these 107 (23%) were diagnosed 
with an ulcerated IH versus 358 (77%) patients with one or more non-ulcerated IH. The 
patients with an ulcerated IH had a total of 235 IH, 108 ulcerated and 127 non-ulcerated. 
The 358 patients with only non-ulcerated IH had a total of 815 IH.
Number of IH
The average number of IH in the group of patients with an ulcerated IH was 2.2 (SEM ± 0.5). 
For the patient-group with only non-ulcerated IH this mean number was 2.3 (SEM ± 0.3). 
This difference is not statistically significant (p = 0.9).
Size of IH
The surface of the IH was measured with a tape-measure in 2 perpendicular directions, 
using the maximum diameter in each to calculate the final surface. The mean length and 
width of the ulcerated IH were respectively 5.1 cm. (SEM 0.4) and 4.3 cm. (SEM 0.3). For the 
non-ulcerated IH this was 2.1 cm. (SEM 0.1), and 1.8 cm. (SEM 0.1). This shows that the 
ulcerating IH had a significantly larger surface than the non-ulcerated IH (28.6 cm2 vs. 6.0 
cm2, p < 0.05). Data concerning the size were only known from 51.6% of the ulcerated IH 
and 62.0% of the non-ulcerated IH.
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Anatomical localization
The IH were classified in 7 different region categories: (1) extremities, (2) head and neck, (3) 
perineum, (4) groin, (5) trunk, (6) buttock and (7) sacral region. In general, most IH were 
located on the head and neck region, the extremities and trunk. The predilection area for 
ulceration was the head and neck region, but also IH in the perineal and buttock area 
often turned out to be ulcerating. Ulcerated IH were significantly more often localized in 
the diaper area (p < 0.05) (Table 1). The localization of the IH was not uniformly documented. 
29.5% of the non-ulcerated IH had an unknown localization.
Subtype of IH
IH were divided in 3 clinical subtypes; (1) superficial, (2) deep and (3) mixed IH with 
involvement of both epidermis and subcutis. When both ulcerated and non-ulcerated IH 
were compared, ulceration was more frequently seen in the IH with a superficial 
component. 78.2% of the ulcerated IH had a superficial component compared to 61.1% of 
the non-ulcerated IH. This was a significant difference (p < 0.05). The deep IH ulcerated 
significantly less frequently (p < 0.05) (Table 2). It was known whether they were superficial, 
deep or mixed for 65.0% of the ulcerated IH and 64.9% of the non-ulcerated IH.
 Added to this, IH can be divided in morphological subtypes; localized and segmental 
IH can be distinguished. Localized IH are focal tumor like lesions. The less commonly 
occurring segmental IH tend to be more plaque-like and involve a region or segment of 
skin. Ulcerated IH had a segmental distribution significantly more often (29.3%) compared 
to 2.1% of the non-ulcerated IH (p < 0.05) (Table 2). Data concerning the distribution were 
available for 85.2% of ulcerated IH and 95.5% of non-ulcerated IH.
Phase of ulceration
The growth characteristics of IH can be divided in phases: proliferation phase (0-9 months), 
a short plateau phase and involution phase (until the age of 10-12 years). Growth 
Table 1  Localization
Localization Ulcerated
(%)
Non-ulcerated
(%)
Extremities 21.3 20.8
Head and neck 47.2 52.9
Torso 12.0 22.4
Perineum 12.0 1.5
Buttock                            diaper area 6.5 1.4
Groin 0.9 0.6
Sacral region 0 0.5
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 characteristics of IH in an individual infant may vary. In this study the phase in which the 
ulceration occurred was investigated. Most frequently, ulceration took place in the 
proliferation phase (83.1%), but also in the involution phase (15.3%) and the plateau phase 
(1.7%). It was known in which phase the ulceration had taken place for 54.6% of the IH.
Duration of ulceration
In 20.4% of cases the duration of ulceration was well documented and varied between 
4 days and 7 months, with a mean of 8.1 weeks (SEM 1.6). 
Sex
For the patients examined the sex distribution was 67.3% girls and 33.7% boys, which 
makes a ratio of 1:2. For the group of patients with an ulcerated IH the number of male and 
female patients was respectively 27 (25.2%) and 80 (74.8%), a ratio of 1:3. This means a 
tendency to significantly more females with an ulcerated IH compared to female patients 
with just non-ulcerated IH (p = 0.08) (Figure 3).
Prematurity/gestational age
The mean gestational age in the group with an ulcerated IH was 35.0 weeks (SEM 0.6). For 
the group with just non-ulcerated IH the mean gestational age was 36.7 weeks (SEM 0.47). 
This was significantly different (p = 0.04).
 Prematurity in this study was defined as birth before 37 weeks of gestation. Analysis 
of the number of prematures in both patient groups, resulted in 61.1% prematures in the 
patient group with ulcerated IH compared to 26.5% of the children in the patient group 
with only non-ulcerated IH. This was a significant difference (p < 0.05) (Figure 3). It was 
known whether or not they were premature for 33.6% of the patients with an ulcerated IH 
and 27.4% of the children with non-ulcerated IH.
 Subsequently the degree of the prematurity for both groups was compared. For the 
premature children with ulcerated IH the mean gestational age was 33.1 weeks (SEM 0.6). 
Table 2  Subtypes
Clinical type Ulcerated
(%)
Non-ulcerated
(%)
Superficial total 78.2 61.1
Deep 1.5 25.3
Mixed 20.3 13.6
Morphological type
Segmental 29.3 2.1
Localized 70.7 97.9
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For the patients with just non-ulcerated IH this mean age was 32.7 weeks (SEM 0.6). This 
was not significantly different (p = 0.7). For 30.8% of the children with an ulcerated IH, the 
exact gestational age was known, compared to 20.1% of the children with no ulcerated IH.
Birth weight
The mean birth weight found for the patient group with an ulcerated IH was 2649 grams 
(SEM 140.7) and 3022 grams (SEM 189.3) for the other patient group with only non-ulcerated 
IH. These indicates a tendency to a significantly lower birth weight for children with 
ulcerated IH (p = 0.06).
 Birth weight was documented for 18.7% of the patients with an ulcerated IH and for 
20.1% of the patients with just non-ulcerated IH.
Multiple gestation
For both patient groups it was registered whether or not they were part of twins. In the 
total study group 5.6% of the patients were part of twins. For the patient group with an 
ulcerated IH this was 6.5%, for the patient group with non-ulcerated IH this was 5.3%. This 
is not a significant difference (p = 0.4) (Figure 3).
Chorionic villus sampling
In this study no chorionic villus sampling was performed in either patient group.
Atopic dermatitis
In the patient group diagnosed with an ulcerated IH, 54.2% of the children were also 
diagnosed with atopic dermatitis, in the patient group with only non-ulcerated IH this was 
Figure 3  Other
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46.5% (Figure 3). This is not a significant difference (p = 0.62). Overall, not all patient files 
gave clear information about the presence of atopic dermatitis in the patient. Only for 
22.4% of the patients with an ulcerated IH versus 12.0% of the patients with non-ulcerated 
IH was it noted.
Discussion
In this study, ulceration was found in 23% of the IH patients compared to 5-13% described 
in literature.1,2 This can be explained by the fact this study was carried out in an academic 
centre with a specialized multidisciplinary hemangioma team that serves as a tertiary 
centre for patients with difficult (ulcerating) IH.
 When overviewing the characteristics described, there were no differences concerning 
the number of IH per patient between the patient group with one or more ulcerated IH 
versus the group with just non-ulcerated IH. With respect to size, localization and type of 
IH, some differences could be recognized, comparable to the recently published results of 
the American cohort studied by Chamlin et al. in 2007.4
 Ulcerated IH were significantly larger than non-ulcerated IH. In line with this result, 
segmental IH, which in general cover a substantial skin surface, ulcerated more frequently. 
Probably, larger IH run a greater risk of becoming mechanically damaged by friction 
resulting in ulceration. With respect to localization, ulcerated IH were mostly localized in 
the head and neck region, but the diaper area was also a localization with an enlarged risk 
for ulceration. It seems that traumas like friction and contamination/maceration are more 
common in these areas. With respect to clinical types, IH with a superficial component 
were frequently ulcerated as opposed to deeper IH that seldom ulcerated.
 Taken together, epidermal involvement and susceptibility to trauma and maceration 
seem to play a role in pathogenesis of ulceration in IH. These characteristics are connected 
with the barrier function of the skin. If this is impaired, there seems to be a greater risk of 
ulceration.2 In view of this, it was interesting to compare the incidence of atopic dermatitis, 
in which the barrier function is also impaired, between the patient groups with and 
without ulcerated IH, but no significant difference could be found. Additional prospective 
studies need to be done to confirm or reject this assumed interesting relationship.
 The phase in which ulceration mostly took place was obviously the proliferation 
phase. This is also known from the literature.2,4,5 The possible reason given in literature is 
the outgrowth of the blood supply in the fast growing IH, resulting in central necrosis.6, 7 
The mean duration of ulceration turned out to be about 8 weeks. It must be stated that, 
because our centre is a referral centre for complicated IH, this might be overestimated in 
this study. Besides this, the exact duration is often unknown because of the difficulty of 
exact registration. Patients who do better are often lost to follow-up and/or return to the 
general practitioner. Therefore a prospective study should be carried out as well.
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 In addition, demographic characteristics were studied. From the literature it is known 
that the female to male rate for IH patients is 2.5-4 to 1.2 In our study it was found that the 
group with ulcerated IH comprised a higher percentage of female patients compared to 
the patients with non-ulcerated IH. In former studies, hemangioma patients were more 
likely to be premature. Which could be in relation with the fact that a greater percentage 
of premature children are female.8-11 In our study it was observed that the patients with 
ulcerated IH were more often premature. The mean gestational age of the children with 
ulcerated IH was also lower. Besides this, the mean birth weight of patients with ulcerated 
IH also seemed lower although with only a tendency to significance. This last result is also 
known from the literature.12 This could mean that prematurity and low birth weight 
increase the risk of ulceration.
 It was striking that in all twin cases, the other twin was unaffected. The number of 
twins in the studied cohort (5.6%) was higher than the 1.6% twins in the general 
population, which is in line with a higher incidence of prematurity and lower birth weights 
in this group. Although ulceration was not more frequent in twins with an IH.
Conclusion
Ulceration is a frequent complication affecting 23% of our studied patients. This high 
incidence of ulceration makes this Dutch cohort, containing high rates of complicated IH, 
very appropriate for evaluating the characteristics of ulcerated IH. In summary, larger IH 
with a superficial component in areas more predisposed for contamination are more at 
risk for ulceration. We found a high incidence of ulceration in the large group of IH in the 
head and neck region but also a statistical significantly higher percentage of ulcerated IH 
in the perineum and buttock area. These results will, however, give us more insight into 
the unknown and multifactorially determinated pathogenesis of ulceration in IH. Besides 
this, it will probably make it possible to predict whether or not an IH might ulcerate.
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Summary
Background Ulceration is a common but poorly understood complication of infantile 
hemangiomas (IH) that is difficult to control.
Objective To investigate the possible role of monotherapy with propranolol for ulcerating IH.
Methods Propranolol was given to 20 patients with IH, who suffered from ulceration at 
the start of treatment (mean age at onset of treatment, 3.5 months; standard error of the 
mean: 0.4). After cardiac screening, propranolol was administered in a progressive 
schedule to 2 to 2.5 mg/kg per day, divided in 3 doses. Blood pressure, heart rate, and 
fasting glucose levels were monitored during the first 3 days in hospital and, in the absence 
of complications, treatment was continued at home until the age of approximately 1 year. 
The 20 propranolol-treated patients were matched to patients from a historical control 
group, seen before the ‘propranolol era’. These matches were randomly made by using 
clinical pictures based on type, location and size of the IH, extent of ulceration, and age at 
the start of ulceration.
Results The time to complete healing from the onset of ulceration was significantly 
shorter for the propranolol-treated patients, compared with the control group (8.7 vs. 22.4 
weeks; t-test: p < 0.015). In the propranolol group, a tendency to shorter ulceration 
duration was seen in patients starting propranolol at an earlier stage of disease.
Limitations The study was limited by the partially retrospective design and the small 
number of patients.
Conclusion Propranolol reduces the duration of ulceration in IH and seems to be more 
effective when started in an early phase. We propose propranolol as the treatment of first 
choice for ulcerating IH. 
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Introduction
Infantile hemangiomas (IH) occur in approximately 10% to 12% of children younger than 
1 year of age. The most common complication is ulceration, possibly affecting 5% to 13% 
of children with IH.1,2 Ulceration is nearly always painful, and this leads to problems with 
eating and sleeping. There may also be bleeding and infection requiring treatment with 
oral antibiotics. Finally, ulceration heals with scarring, leading to functional problems and 
cosmetic disfigurement.3-6 There is no uniform approach to treatment in the literature. In 
addition to all kinds of wound dressings, topical or oral antibiotics and pain management, 
treatment with oral corticosteroids, vincristine, interferon, flashlamp pulsed dye laser 
therapy, and surgical options have been described, often with disappointing results.1,5,7
 Propranolol was recently introduced as a promising treatment for complicated IH.8 
There have been several case reports of propranolol therapy for ulcerating IH, but no 
comparative studies have been published.8-10 In our study, the role of this nonselective 
beta-blocker was explored by treating 20 patients with an ulcerating IH in the proliferation 
phase and comparing this patient group with similar historical controls.
Patients and methods
Patients
An observational analysis was performed of IH patients treated with propranolol at the 
Radboud University Medical Centre Nijmegen (UMCN), the Netherlands, from October 
2008 to March 2010. The medical records and photo-documentation of 56 infants were 
reviewed and all patients with ulceration were selected. Twenty patients suffered from 
ulceration at the start of the treatment (mean age at onset of treatment: 3.5 months, 
standard error of the mean [SEM] 0.4). Ulceration was not always the main indication for 
propranolol treatment.
 Ulceration was defined as a break in the continuity of the surface epithelium with or 
without infection.
 The ‘total ulceration time’ was defined as the time from the first sign of ulceration 
until complete healing, without complete healing in the intervening period. ‘Long-lasting 
ulceration’ was ulceration with a longer duration than the mean ulceration time. ‘Early 
starters’ were patients started on propranolol before the mean age at onset of treatment.
At inclusion, a clinical evaluation including physical examination, renal function tests, an 
electrocardiogram, and echocardiography was performed to exclude contraindications 
to propranolol treatment. Propranolol was administered in the hospital with a starting 
dose of 0.7 to 1.0 mg/kg per day, divided in 3 daily doses, increasing over a 3-day period to 
2.0 to 2.5 mg/kg per day. Blood pressure, heart rate, and fasting glucose levels were 
monitored during the first 3 days. In the absence of complications, treatment was 
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continued at home until about the age of 1 year. The patients were evaluated every 6 
weeks after starting treatment with propranolol, and more often if necessary. In the final 
phase of treatment, clinic visits were extended to every 3 months. During the study 
period, no other systemic treatment modalities, apart from oral antibiotics or analgesia, 
were administered.
 Historical data of IH patients from our center during the period 1997 to 2007 were 
analyzed retrospectively and used to establish controls.11
 Ulceration was present in 107 of these 465 IH cases. Using clinical pictures and 
medical records, two investigators, who were blinded as to the clinical outcomes, made a 
random selection of 20 patients with a comparable ulcerating IH. The comparisons were 
based on age at onset of ulceration, type, location and size of the IH, and extent of 
ulceration. Follow-up evaluations in this patient group were similar to those of the propranolol-
treated group.
Analysis
In the event of missing data in the control group, an interview with the parents by 
telephone was performed. The maximum age of the patient at the time of the interview 
was 5 years. Data from the patient-files were transported into a database and analyzed to 
define the characteristics of the study group. The numeric data were reported as mean 
plus or minus SEM.
 For statistical analysis the t-test for unpaired values was used. The other non-numeric 
data were analyzed with the chi-square test. A two-tailed hypothesis was employed to 
interpret data. A p-value less than or equal to 0.05 was regarded as statistically significant.
Results
Propranolol group
Patient characteristics. The 20 patients (Table 1) with an ulcerating IH had a total of 78 IH, 
with an average number of 3.9 IH per patient (SEM 1.7).
 Of this group, 16 (80%) were girls. The mean gestational age was 36.8 weeks (SEM 0.7). 
The mean birth weight was 3017 grams (SEM 195). Nine patients (45%) were born 
prematurely (before 37 weeks’ gestation), one with extreme prematurity (gestational age 
30.7 weeks).
 The anatomic location of the ulcerating IH was as follows: 14 (70%) in the head and neck 
region, 1 on the shoulder, 1 on the arm, and 4 (20%) in the diaper region. The following 
clinical IH subtypes were recorded: 14 (70%) superficial nodular, 4 (20%) superficial macular 
and 2 (10%) mixed; no IH had an exclusively deep growth pattern. Morphological subtypes 
included 14 (70%) with a localized and 6 (30%) with a segmental distribution. The mean age 
at which the IH was first noted by the parents was 6.4 days (SEM 2.4).
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Propranolol. Ulceration was the main indication for treatment with propranolol in 18 
cases (90%).
 In these patients, painful ulceration resulted in problems with drinking, sleeping, 
defecation or restriction of movement. In the two other infants, tachypnea and inspiratory 
stridor due to airway obstruction were the primary indications for treatment.
 The mean age of starting propranolol was 3.5 months (SEM 0.3). At the time of data 
analysis, 19 patients had discontinued propranolol and the remaining infant was in the 
final phase of treatment. The average treatment duration for the 19 patients was 9.1 
months (SEM 0.6).
 Within the first 3 days of starting treatment in the hospital, a decrease in redness and 
tenseness of the IH was observed in all cases. This effect was sustained over the remaining 
treatment period. Four (21.1%) of the 19 patients who completed treatment showed some 
regrowth and slightly increased redness after stopping propranolol, but there was no 
recurrence of ulceration. In one patient propranolol was restarted because of the mass 
effect of the IH.
 Nine patients (45%) experienced no adverse effects at all. The parents of 11 patients 
reported temporary drowsiness/tiredness (n = 6), restless sleeping (n = 2), cold extremities 
(n = 6), poor feeding (n = 2) and gastrointestinal complaints (diarrhea, vomiting) (n = 1).
Six patients (30%) were treated with an oral pain medication (acetaminophen) and 7 
patients (35%) were treated with oral antibiotics. Eleven patients (55%) were additionally 
treated with topical ointments and wound dressings either before or during propranolol 
treatment. No other systemic treatment modalities for the IH (such as systemic corticosteroids) 
were necessary.
Ulceration
All patients had an ulcerating IH at the time of starting propranolol. The mean age of the 
patients at the start of ulceration was 2.3 months (SEM 0.3). Complete healing was 
obtained after an average total ulceration time of 8.7 weeks (SEM 8.5). 
 In the propranolol-treated group, a tendency to a shorter ulceration time was seen in 
patients starting propranolol at an early age. Seven of the 10 ‘late starters’ (70%) (started 
propranolol at >3.5 months of age) had a ‘long lasting ulceration’ (>8.7 weeks) compared 
with only 2 (20%) of the 10 ‘early starters’ (2 = 5.051, df = 1, p = 0.025).
 Most parents reported a decrease in pain within a few days after initiation of propranolol.
Historical control group
The historical control group consisted of 20 comparable cases from a historical group 
treated before the propranolol era (see Table 1).
 These control patients had similar complications from an ulcerating IH, including 
problems with eating, sleeping, defecation, and restriction in movement due to pain. Five 
patients (25%) in the control group were treated with oral corticosteroids, 1 (5%) with 
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pulsed dye laser therapy, 12 (60%) with one or more oral antibiotics, and all 20 with a 
variety of local wound dressings and ointments. The mean age of the patients at the start 
of ulceration was 2.7 months (SEM 0.3), not dissimilar to the propranolol-treated group (p 
= 0.49). The mean ulceration time for the control group was 22.4 weeks (SEM 5.2). The 
outliers in both the propranolol and control groups were patients with ulceration in skin 
folds and locations with extensive exposure to friction, maceration, and external factors 
(e.g. feces, urine, food), which delayed the healing process.
Table 1  Clinical characteristics of 40 patients with ulcerated hemangioma
Propranolol
group
Gender Location Clinical 
subtype
Morphological 
subtype
Oral 
AB
Other 
systemic 
tx
Duration 
of ulceration
(wk)
Control
group
Gender Location Clinical
subtype
Morphological 
subtype
Oral 
AB
Other 
systemic 
therapy
Duration 
of ulceration
(wk)
1a F Face/cheek/mouth Sup/Nod Loc + - 3* 1b F Face (cheek/mouth) Sup/Nod Loc - Prednison 6*
2a F Diaper area  
(labium majus)
Sup/Nod Loc - - 13† 2b F Diaper area (buttocks) Sup/Nod Loc + - 30†
3a F Diaper area (buttocks) Sup/Nod Loc + - 2 3b F Diaper area (buttocks) Sup/Nod Loc + - 96
4a M Scalp Sup/Nod Loc + - 13 4b F Scalp Sup/Nod Loc + - 16
5a F Lip Sup/Nod Loc - - 11 5b F Lip Sup/Nod Loc - - 24
6a M Shoulder Sup/Nod Loc - - 4 6b F Shoulder Sup/Nod Loc + - 4
7a M Face Mixed Segm - - 5 7b M Face Mixed Segm + - 20
8a F Face 
(nose/cheek)
Mixed Segm - - 7 8b F Face  (cheek/ear) Sup/Nod Segm + - 36
9a F Ear Sup/Nod Loc - - 19 9b M Neck Sup/Nod Loc - - 4
10a F Face Sup/Mac Segm + - 5 10b F Face Sup/Mac Segm + - 20
11a F Leg/buttocks Sup/Mac Segm - - 6 11b M Buttocks Sup/Mac Segm + - 4
12a F Face (lip/mouth) Sup/Mac Loc - - 15 12b F Face (ear/nek) Sup/Mac Loc + Prednison
PDL
56
13a F Buttocks Sup/Mac Loc - - 8 13b M Buttocks Sup/Nod Loc - Prednison 24
14a M Scalp Sup/Nod Loc - - 10 14b F Neck Sup/Nod Loc + - 10
15a F Scalp Sup/Nod Loc + - 12 15b F Scalp Sup/Nod Loc - - 2
16a F Lip Sup/Nod Loc - - 4 16b F Lip Sup/Nod Loc - Prednison 44
17a F Arm Sup/Nod Loc - - 4 17b F Arm Sup/Nod Loc - - 6
18a F Scalp Sup/Nod Loc + - 19 18b F Scalp Sup/Nod Loc + - 10
19a F Lip Sup/Nod Segm - - 1 19b F Beard area/lip Sup/Nod Segm + Prednison 12
20a F Face (neck) Sup/Nod Segm + - 13 20b M Face (neck) Sup/Noc Segm - - 24
+, Prescribed; -, not prescribed; AB, antibiotics; Loc, localized; PDL, pulsed dye laser; Sup/Mac, superficial/
macular; Sup/Nod, superficial/nodular; tx, therapy.
* Patients shown in Fig 1.
† Patients shown in Fig 2. 
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Comparison IH groups: Ulceration time
The t-test for unpaired values showed a significant difference in mean ulceration duration 
between the 20 patients treated with propranolol and the 20 cases in the control group, 
including both patients treated with supportive care only and with systemic therapy (8.7 
vs. 22.4 weeks; t = 2.6, df = 38, p = 0.012, 95% confidence interval, 3.2-24.2).
 An additional analysis was performed to compare the 20 patients in the propranolol 
group with the 5 patients in the historical group treated with oral corticosteroids. This 
comparison showed a significant difference in mean ulceration time (8.7 vs. 28.4, t = 3.88, 
df = 23, p = 0.001, 95% confidence interval 9.2-30.2).
Table 1  Clinical characteristics of 40 patients with ulcerated hemangioma
Propranolol
group
Gender Location Clinical 
subtype
Morphological 
subtype
Oral 
AB
Other 
systemic 
tx
Duration 
of ulceration
(wk)
Control
group
Gender Location Clinical
subtype
Morphological 
subtype
Oral 
AB
Other 
systemic 
therapy
Duration 
of ulceration
(wk)
1a F Face/cheek/mouth Sup/Nod Loc + - 3* 1b F Face (cheek/mouth) Sup/Nod Loc - Prednison 6*
2a F Diaper area  
(labium majus)
Sup/Nod Loc - - 13† 2b F Diaper area (buttocks) Sup/Nod Loc + - 30†
3a F Diaper area (buttocks) Sup/Nod Loc + - 2 3b F Diaper area (buttocks) Sup/Nod Loc + - 96
4a M Scalp Sup/Nod Loc + - 13 4b F Scalp Sup/Nod Loc + - 16
5a F Lip Sup/Nod Loc - - 11 5b F Lip Sup/Nod Loc - - 24
6a M Shoulder Sup/Nod Loc - - 4 6b F Shoulder Sup/Nod Loc + - 4
7a M Face Mixed Segm - - 5 7b M Face Mixed Segm + - 20
8a F Face 
(nose/cheek)
Mixed Segm - - 7 8b F Face  (cheek/ear) Sup/Nod Segm + - 36
9a F Ear Sup/Nod Loc - - 19 9b M Neck Sup/Nod Loc - - 4
10a F Face Sup/Mac Segm + - 5 10b F Face Sup/Mac Segm + - 20
11a F Leg/buttocks Sup/Mac Segm - - 6 11b M Buttocks Sup/Mac Segm + - 4
12a F Face (lip/mouth) Sup/Mac Loc - - 15 12b F Face (ear/nek) Sup/Mac Loc + Prednison
PDL
56
13a F Buttocks Sup/Mac Loc - - 8 13b M Buttocks Sup/Nod Loc - Prednison 24
14a M Scalp Sup/Nod Loc - - 10 14b F Neck Sup/Nod Loc + - 10
15a F Scalp Sup/Nod Loc + - 12 15b F Scalp Sup/Nod Loc - - 2
16a F Lip Sup/Nod Loc - - 4 16b F Lip Sup/Nod Loc - Prednison 44
17a F Arm Sup/Nod Loc - - 4 17b F Arm Sup/Nod Loc - - 6
18a F Scalp Sup/Nod Loc + - 19 18b F Scalp Sup/Nod Loc + - 10
19a F Lip Sup/Nod Segm - - 1 19b F Beard area/lip Sup/Nod Segm + Prednison 12
20a F Face (neck) Sup/Nod Segm + - 13 20b M Face (neck) Sup/Noc Segm - - 24
+, Prescribed; -, not prescribed; AB, antibiotics; Loc, localized; PDL, pulsed dye laser; Sup/Mac, superficial/
macular; Sup/Nod, superficial/nodular; tx, therapy.
* Patients shown in Fig 1.
† Patients shown in Fig 2. 
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 Finally, a comparison was made between the 20 patients treated with propranolol 
and the 15 patients in the control group treated with supportive care only (oral antibiotics 
and wound dressings). This also showed a significant difference (8.7 vs. 20.4, t = 2.17, df = 
33, p = 0.037, 95% confidence interval 0.7-22.7).
 An illustration of the duration of ulceration in patients treated with propranolol 
compared with historical controls is given in Figure 1 and 2.
Figure 1
(a) Ulcerating IH on left cheek, before treatment with propranolol: total ulceration time 3 
weeks (patient 1a in Table 1). (b) Ulcerating IH on right cheek, before treatment with oral 
corticosteroids, not treated with propranolol:.Total ulceration time 6 weeks (patient 1b in 
Table 1).
Figure 2
(a) Ulcerating IH on left labium majus, before treatment with propranolol: total ulceration 
time 13 weeks (patient 2a in Table 1). (b) Ulcerating IH on left buttock, not treated with 
propranolol or oral corticosteroids: total ulceration time 30 weeks (patient 2b in Table 1).
(a)
(a)
(b)
(b)
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Discussion
A review of the literature reveals no evidence-based or uniformly accepted treatment plan 
for ulcerating IH. This is in part because of the unclear pathogenesis of the ulceration but 
also to the variable course of ulceration and involution of IH.6 The generally accepted triad 
for treatment of ulcerating IH is (1) wound care, (2) topical or oral antibiotics, and (3) adequate 
pain management. In addition, various therapeutic agents aimed at promoting involution of 
the IH have been used (e.g., corticosteroids, vincristine, interferon, flashlamp pulsed dye laser 
and surgical intervention), often with unsatisfactory results.1,5,7,12,13 There is a need for a new 
treatment modality to control this challenging complication more effectively.
 The extraordinary response of infantile IH to propranolol, first reported in the New 
England Journal of Medicine by Léauté-Labrèze et al, introduced a new therapeutic 
option.8 Our multidisciplinary hemangioma treatment group subsequently initiated 
propranolol treatment for complicated IH, including ulcerated lesions. There was almost 
immediate cessation of proliferation in every patient, leading to considerable shortening 
of the natural course of IH. This termination of proliferation had a direct effect on the 
duration of ulceration. Recently, a few case series of patients with ulcerating IH successfully 
treated with propranolol have been described.8-10
 As a great number of patients with complicated IH are treated at our tertiary referral 
center, it was possible to select a similar control patient from our historical database for 
each of the propranolol-treated cases. After the two groups were compared, it was found 
that the mean ulceration time was significantly shorter for the patients treated with 
propranolol compared with the historical matched control group (8.7 vs. 22.4 weeks). 
When the propranolol-treated patients were compared with patients in the control group 
treated with systemic corticosteroids or with supportive management only, a significantly 
shorter ulceration time for the propranolol group was still found. The relatively long 
ulceration time for both the propranolol group (8.7 weeks) and the control group (22.4 
weeks) may be explained by the fact that, as a tertiary referral center, we treat more 
complicated IH with larger ulcerations. Ulceration is a dynamic process and new adjacent 
ulceration may develop before healing of the first area of ulceration. These consecutive 
lesions mean that some ulcerations take a long time to heal completely. 
 The effect of propranolol on ulceration in IH also seemed to be related to the time of 
onset of treatment. Initiation earlier in the proliferation phase nearly always resulted in a 
tendency to faster healing. Only 2 (20%) of the early starters had a prolonged ulceration 
compared with 70% of the late starters. From earlier studies it is known that larger, more 
superficial IH in areas susceptible to trauma and contamination are more likely to 
ulcerate.11,14 Possibly, the best way to treat these potentially complicated IH is to start 
propranolol early in the proliferation phase to prevent ulceration.
 The observation that propranolol is very effective in the treatment of ulcerating IH 
compared with historical controls should be discussed in light of the limitations of this 
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study. The data were obtained retrospectively for the control group, but were recorded by 
physicians unaware of the specific hypothesis of the study. The risk of confounding is a 
threat to the validity of observational studies. The strongest evidence that propranolol is 
an effective treatment for ulcerating IH would be provided by a randomized placebo-
controlled trial. However, the undoubted clinical efficacy of propranolol in treating IH now 
makes this type of study almost unethical.
 In our opinion, clinically useful conclusions can be drawn despite the limitations of 
this study design. We propose that propranolol should be the treatment of first choice for 
seriously ulcerating IH.
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Abstract
Background Infantile hemangiomas (IHs) are common and mostly emerge in the head 
and neck area. Recently, propranolol has been replacing oral corticosteroids (OCS) as the 
main treatment modality. 
Objectives The target of this study was to explore the impact of treatment, contentment 
with treatment outcome and quality of life for families and patients with cervicofacial IHs, 
treated with propranolol versus OCS. 
Materials and Methods This case control study was performed using questionnaires 
administered by a phone interview. Parents of 16 patients with a cervicofacial IH treated 
by OCS and 16 patients with an IH of similar localization and overall severity treated with 
propranolol were interviewed. The questions concerned the impact of treatment at 
different time periods and the contentment with treatment results. Parents were also 
asked to give a quality of life (QoL)-score (1 to 10) for different time-points.
Results Parents from the OCS group seemed to feel significantly more worried during 
treatment. Moreover, parents from the propranolol group perceived less negative impact 
on normal life issues, including work and vaccination of their child. During and after 
treatment, the parents of propranolol treated IH patients gave significantly higher 
Qol-scores.
Conclusion Propranolol seems to change the impact of IHs, their treatment and the 
quality of life. Propranolol treatment interferes less with normal issues in daily life, compared 
to OCS. These findings underline propranolol as the first-choice treatment for life- or 
 function-threatening IHs. 
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Introduction
Infantile hemangiomas (IHs) are the most common vascular tumors of infancy and 
childhood with an incidence ranging from 2-10%.1 About sixty per cent of these benign 
tumors emerge in the cervicofacial area.2 
IHs go through different phases with most notably, initial rapid and massive growth 
followed by slow involution. After involution, normal or cosmetically satisfactory skin is 
restored in nearly 50% of untreated patients.3,4 In the other 50% the skin shows atrophy, 
laxity, telangiectasia, pigmentation changes, scarring or alopecia.3 
 Although the majority of IHs implicate no immediate or long-term threat, a significant 
minority can cause serious morbidity. Possible complications are painful ulceration, 
amblyopia in periorbital localization, feeding difficulties in perioral localization, breathing 
problems in airway IH, hearing problems in periauricular localization and disfigurement.5 
Deformities of the face may result in psychosocial distress in children and their parents.6 It 
is believed that disfigurements can lead to negative reactions from strangers, social 
stigmatization, sadness, stress and low self-esteem.7 Parents may start to isolate their 
children from social interaction to protect them(selves) from hurtful comments.6
 Intervening in the natural course of an IH may be indicated in case of (potential) 
complications or expected very poor aesthetic outcome.5 Until 2008, different therapies 
for IH existed, each with their own potentially dangerous side effects. Among these, oral 
corticosteroids (OCS) have long been the mainstay of treatment, with gastro-intestinal 
upset, Cushingoid appearance, hypertension and temporary growth retardation as part of 
the side effect profile.8-10 
 A novel approach in IH treatment is propranolol, an adrenergic beta-antagonist that 
has been widely used in (pediatric) cardiology, which was serendipitously discovered in 
2008, like OCS were in 1963.11,12 Case series and a recent randomized controlled trial of 
propranolol report spectacular responses with fewer side effects than previous treatments. 
The most important side effects reported in literature are hypotension, pulmonary 
symptoms and hypoglycemia.13-15 In every day practice, a careful indication shift can be 
seen for an active approach (with propranolol) of IHs: from function-threatening IHs 
towards severely cosmetically disturbing (large facial) IHs.
 Despite the current widespread use of propranolol, so far, no study has explored the 
impact of propranolol treatment on daily family life of IH-children and the quality of life 
(QoL), during and after this period, in comparison to the former approach with OCS. The 
contentment of the parents with the treatment outcome after propranolol or OCS was 
studied as well. These data are also important for further implementation of propranolol 
in daily practice. 
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Materials and methods
Patients
Our tertiary referral centre started treating IH patients with propranolol in 2008. From our 
former cohort of more than 100 propranolol treated IH patients, the children with a 
cervicofacial IH were selected by reviewing photo-documentation and medical records. 
On the basis of these propranolol-treated patients, OCS-treated IH patients from our 
cohort from before the propranolol era with a comparable IH were selected. Only patients 
that had completed treatment were included. The best possible clinical matching 
between both groups was sought based on: localization, subtype, size, ulceration and 
overall severity. All IH in both groups were in the proliferation phase at the start of 
treatment. Two patients with PHACES were included and matched. Sixteen good matches 
could be made. This method of case control study has been used previously.16 For both 
patient groups the clinical endpoints were stop of growth and start of involution of the IH, 
volume reduction and improvement of functionality (e.g. in case of earlier visual impairment). 
These endpoints were subjectively assessed by the treating physician at that time and 
were reached for all patients in both patient groups at the end of treatment.
Treatment
Prior to both treatments, the parents were extensively informed about the possible side 
effects of treatment.
 OCS: A mean dosage of 2-4 mg/kg/day Prednisolone oral suspension, in 2 doses was 
given in a course of 6-8 weeks (range 4-12 weeks) that was repeated 1-2 times in case of 
insufficient efficacy. In Table 1 the total period from the start of the treatment till the end 
of the (last) treatment is represented.14,17    
 Propranolol: After cardiologic screening the starting dosage was propranolol oral 
suspension 0.7-1.0 mg /kg /day, in three divided doses. The dose was gradually increased 
to the total target dosage of 2.0-2.5 mg/kg /day, divided in three doses. Guided by body 
weight, propranolol was adjusted to the target dosage until the age of 9 months after 
which the dose was no longer increased. Treatment was continued during the proliferation 
phase (age 12-18 months) and gradually tapered in 2-3 weeks.18 Detailed information on 
the treatment protocol can be found in a previous report.19 
 The median time span between start of treatment and time of study is 7.0 years 
(range 4.3-12.6) for the OCS group and 2.1 years (range 1.2-2.5) for the propranolol group. 
Study design with questionnaires
Data in this study were obtained from patient files and an interview by telephone. According 
to the Dutch law (WMO; Wet medisch-wetenschappelijk onderzoek met mensen; Medical 
Research Involving Human Subjects Act), review of the study by the Ethics Committee of 
Radboud University Nijmegen Medical Centre was not needed. This was confirmed after 
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consultation of the committee and informed consent from all parents was considered 
sufficient.
 An information letter was sent to all parents explaining the purpose of this study and 
asking their participation in an interview by telephone. Informed consent was obtained 
from all parents.
 Interviews of 32 parents were all carried out by the same investigator (JZ); not blinded. 
The interview consisted of a medical information form and a questionnaire on impact of 
IH treatment and contentment with treatment outcome. In a second questionnaire, 
parents were asked to indicate a score for their quality of life during different treatment 
periods. The interview took about twenty minutes per patient.
Medical information form
This form included questions about the size, localization and complications of the IH and 
treatment duration. Besides demographic data, information about pregnancy, delivery 
and birth weight were asked.
Questionnaires
Questionnaires were developed by the researchers in collaboration with the Radboud 
Expert Centre for Psychology & Medicine. The first questionnaire addressed the impact of 
IH treatment and contentment with treatment outcome and consisted of 32 questions 
with a 5 point Likert scale (totally disagree – disagree – neutral – agree – totally agree; 
score 1 to 5). The questions are divided into five time intervals: prior to treatment, during 
treatment, after treatment (directly and after three months) and expectations for the 
future. The second questionnaire was used to obtain a quality of life (QoL)-score (1 to 10) 
from the parents for the periods prior to, during and after treatment and also for the final 
result, taking their worries and problems or results of treatment into consideration. The 
higher the score, the better the period or the result was.
Analysis
Statistical Package for the Social Sciences (SPSS) 18.0 (SPSS Inc., Chicago, IL, U.S.A.) was 
used to analyze data.
 Group characteristics were explored and numeric data stated as mean plus standard 
deviation (SD). For testing all items of the questionnaires, we used the independent 
sample t-test. Given the explorative character of the study and the multiple statistical 
analyses performed, a more stringent α-level was chosen (0.01) to analyze the impact of 
treatment and contentment with treatment outcome. For the questions concerning 
quality of life-scores the α-level was set at 0.05.
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Results
Patient and treatment characteristics
Demographic and clinical characteristics of included patients are stated in Table 1. These 
characteristics show no significant differences (p-values > 0.05) between both treatment 
groups, except for current age of children and treatment duration, inherent to these 
treatment modalities.
 IH characteristics including localization, clinical and morphological subtype of treated 
IHs, as well as their treatment duration and possible ulceration, are given for each matched 
patient-pair in Table 2.
 Adverse reactions observed during treatment in both groups were in line with the 
profile of adverse events of both treatments as reported in literature.9,20
Questionnaires
 Results from the questionnaire on the impact of IH treatment and contentment with 
treatment outcome are presented in Table 3 and the quality of life scores in Table 4.
Table 1  Group characteristics of 16 matched patients
Propranolol
(n = 16)
Oral corticosteroids
(n = 16)
Respondents/parents
Mean age (years) 35 (SD 3.4) 38 (SD 4.3)
Gender 14 F / 2 M 13 F / 3 M
Origin 15 Netherlands /  
1 Germany
16 Netherlands
Mean time of pregnancy (weeks) 38.5 (SD 1.9) 38.8 (SD 2.7)
Patients
Minimum age (months) 19 55
Maximum age (months) 34 157
Gender 10 F / 6 M 12 F / 4 M
Mean birth weight (grams) 3410 (SD 766.0) 3143 (SD 1548.9)
Mean number of IHs 1.56 (SD 1.5) 1.63 (SD 1.4)
Mean age at start treatment (months) 3.3 (SD 1.2) 2.9 (SD 0.8)
Mean age of complication* (months) 2.7 (SD 1.1) 2.1 (SD 1.4)
Mean treatment duration (months) 9.6 (SD 2.4) 5.8 (SD 3.9)
F = Female, M = Male, *Mean age at which a complication of the IH occurred, e.g. ulceration, bleeding and visual 
impairment.
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 Prior to treatment: No significant differences between treatment groups existed. Also, 
the mean QoL-score for this period did not differ between both groups (p = 1.0).
     During treatment: In comparison to the parents of propranolol treated children, more 
parents from the OCS group had worries about food intake (p = 0.005), about the adverse 
effects of the oral medication (p = 0.007) and the future of their child (p = 0.001). OCS-parents 
had less confidence in treatment (p = 0.003) and felt their child was not safe with this drug 
(p = 0.003). In comparison to parents of children on propranolol, parents with a child on OCS, 
experienced a more negative influence on father’s (p = 0.005) and mother’s (p = 0.008) work. 
Treatment with OCS resulted in restrictions to participate in the national immunization 
program (p = <0.001). Besides these significant differences between both treatment groups 
there was a marked tendency to feeling more insecure during treatment and more worried 
concerning growth and development of the child for the OCS group. There also was a 
tendency about OCS-treatment being more time-consuming than propranolol treatment. 
The mean QoL-score for this period was higher for the parents of the propranolol group 
(p = 0.02).
 After treatment: The parents of propranolol group seemed more content with the 
treatment outcome directly after treatment with a tendency to significance (p = 0.019). The 
mean Qol-score for treatment outcome directly after treatment seemed to be higher for 
propranolol parents (p = 0.049).  After three months a similar trend was observed (p = 0.03). 
(Table 4)
 Expectations for the future: More parents from the OCS group stated to have become 
extra concerned about the health of their child (p = 0.004). The mean Qol-score for the 
period after treatment was higher for the parents of the propranolol group (p = 0.03).
Figure 1a
Patient I-3 in Table 2
Figure 1b
Patient II-3 in Table 2
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Table 2  IH characteristics of 16 matched patients
Pro 
group
Gender Location Clinical 
subtype
Morphological 
subtype
Age at start 
treatment
(months)
Duration of 
treatment 
(months)
Ulceration OCS 
group
Gender Location Clinical 
subtype
Morphological 
subtype
Age at start 
treatment
(months)
Duration of 
treatment 
(months)
Ulceration
I-1 F Periocular Deep Loc 3.03 7 - II-1 F Periocular Mixed Loc 3.30 12 -
I-2 F Lip Sup/Nod Loc 3.53 11 + II-2 F Lip Sup/Nod Loc 3.23 2.5 +
I-3 F Periocular Mixed Loc 3.47 6† - II-3 M Periocular Mixed Loc 3.70 3.5† -
I-4 F Periocular Deep Loc 4.40 11 - II-4 F Periocular Deep Loc 3.17 6 -
I-5 M Periocular Deep Loc 5.20 8 - II-5 F Periocular Mixed Loc 2.40 1 -
I-6 F Periocular Sup/Nod Loc 5.37 14 - II-6 F Periocular Deep Loc 3.60 8 -
I-7 F Forehead Sup/Nod Loc 3.83 6 + II-7 M Forehead Sup/Nod Loc 1.97 11 +
I-8 M Periocular Deep Loc 2.67 9 - II-8 M Periocular Deep Loc 3.67 2 -
I-9 F Cheek Sup/Nod Segm 3.30 10 + II-9 F Cheek Sup/Nod Segm 2.33 4.5 -
I-10 F Face
PHACES
Sup/Mac Segm 0.67 12 + II-10 F Face
PHACES
Sup/Mac Segm 2.17 12 +
I-11 M Periocular Sup/Nod Loc 4.33 7 - II-11 F Periocular Sup/Nod Loc 2.77 9.5 -
I-12 F Ear Sup/Nod Loc 2.90 11 + II-12 F Cheek Sup/Nod Loc 1.67 8 +
I-13 M Cheek Mixed Segm 2.03 12 + II-13 M Cheek Mixed Segm 1.47 1 -
I-14 F Lip Sup/Nod Segm 2.27 11 + II-14 F Paranasal Mixed Segm 3.70 3.5 +
I-15 M Periocular Sup/Nod Loc 3.43 8 - II-15 F Periocular Deep Loc 3.93 1.5 -
I-16 M Perioral Sup/Mac Segm 3.00 10 - II-16 F Perioral Sup/Mac Segm 2.77 6 +
Pro, Propranolol; OCS, Oral corticosteroids; F, female; M, male; Sup/Nod, superficial nodular; Sup/Mac, superficial 
macular; Loc, local; Segm, segmental; +, present; -, absent
† Patients shown in Figure 1
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Table 3   Mean impact of IH treatment and contentment with treatment outcome 
scores for parents with IH children treated with propranolol or OCS
Pro
(n=16)
OCS
(n=16)
p-value
Prior to treatment: Impact of treatment
1. I am well informed about my child’s treatment  3.37  (0.81) 3.06 (1.12) 0.373
2. I knew what the adverse effects of treatment could be  2.87 (1.46) 2.56 (1.50) 0.555
3.  For a while I had doubts about starting treatment  1.44 (1.50) 1.25 (1.29) 0.708
4.  I wondered if starting treatment for my child’s IH was the 
right thing to do   
2.12 (1.31) 1.56 (1.32) 0.235
5.  I wondered how important starting treatment was when I 
heard IHs are benign  
1.00 (1.41) 0.75 (1.00) 0.568
During treatment: Impact of treatment
6.  I felt insecure not knowing what the adverse effects of 
treatment would be
1.81 (1.52) 2.69 (1.25) 0.085
7.  During treatment I felt sometimes insecure 1.94 (1.34) 2.87 (0.62) 0.019
8.  I had little confidence in treatment 0.31 (0.48) 0.87 (0.50) 0.003
9.  I had a feeling that my child would not be safe with this 
drug
0.50 (0.73) 1.44 (0.89) 0.003
10.  I had extra worries when my child was ill 1.56 (1.37) 2.56 (1.32) 0.043
11.  I had worries about the growth/development of my child 1.19 (1.17) 2.25 (1.18) 0.016
12.  I had worries about the nourishment of my child 0.87 (1.15) 2.25 (1.39) 0.005
13.  I had worries about the adverse effects of this drug 2.00 (1.21) 3.06 (0.77) 0.007
14.  I had worries about the appearance of my child 1.56 (1.26) 2.44 (1.26) 0.059
15.  I had worries about the future of my child 0.94 (1.12) 2.31 (1.01) 0.001
16.  Treatment took a lot of time (e.g. hospital visitation) 2.31 (1.25) 3.25 (0.58) 0.013
17.  Treatment had a negative influence on our daily activities 
(e.g. going to day-nursery, hobby, sport, relaxation)
1.00 (0.97) 2.06 (1.44) 0.021
18.  Treatment had a negative influence on father’s work 0.44 (0.51) 1.37 (1.09) 0.005
19.  Treatment had a negative influence on mother’s work 0.69 (1.01) 1.94 (1.44) 0.008
20.  Treatment had a negative influence on house keeping 0.81 (0.98) 1.31 (1.30) 0.229
21.  Treatment was an emotional period for me/us 1.81 (1.33) 2.81 (1.05) 0.025
22.  Treatment was a burden physically (e.g. lack of sleep, 
exhaustion)
1.31 (1.3) 2.00 (1.67) 0.205
23.  Treatment had a negative influence on the vaccination of 
our child
0.56 (0.81) 2.44 (1.50) <0.001
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Table 3   Continued
Pro
(n=16)
OCS
(n=16)
p-value
After treatment: Impact of treatment and contentment with treatment outcome
Directly after treatment
24.  I am content with treatment outcome 3.75 (0.45) 2.94 (1.18) 0.019
25.  I am content with the care program of this hospital   3.44 (0.96) 3.13 (0.89) 0.347
26.  Treatment was different from what I expected  0.87 (1.09) 1.50 (1.32) 0.154
Three months after treatment  
27.  I am content with treatment outcome   3.81 (0.40) 3.06 (1.18) 0.027
28.  I am content with the care program of this hospital    3.44 (0.96) 3.25 (0.86) 0.565
Expectations for the future   
29.  I think my child will be content with treatment outcome   3.56 (0.63) 2.56 (1.41) 0.017
30.  I am not having any worries about my child’s appearance  3.00 (1.03) 2.12 (1.41) 0.055
31.  I am having extra worries about the health of my child  0.44 (0.81) 1.62 (1.26) 0.004
32.  I would choose this treatment again  3.81 (0.40) 2.94 (1.24) 0.015
Scores stated as mean (SD). Pro: Propranolol; OCS: Oral corticosteroids
Significance level of p < 0.01
A higher score means more agreement or a higher quality of life
Table 4   Quality of life scores for parents with IH children treated with propranolol  
or OCS
QoL-score for different periods Pro (n=16) OCS (n=16) p-value
Score prior to treatment   6.00 (1.63) 6.00 (2.31) 1.000
Score during treatment   7.12 (1.93) 5.50 (1.75) 0.018
Score directly after treatment   8.50 (1.10) 7.25 (2.18) 0.049
Score three months after treatment 8.88 (0.89) 7.50 (2.22) 0.029
Score for the future 8.63 (0.81) 7.50 (1.79) 0.032
A higher score means a higher quality of life.
Scores stated as mean (SD). Pro: Propranolol; OCS: Oral corticosteroids
Significance level of p < 0.05
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Discussion
Before the serendipitous discovery of propranolol in 2008, OCS were the first choice 
treatment for complicated IHs. In the subsequent period, the adrenergic beta-antagonist 
propranolol rapidly took over this role. Meanwhile, there have been several studies 
comparing the effect of both treatment modalities for this indication.14,21-24 A study 
comparing the impact and contentment of both treatments has never been performed. 
These are however interesting aspects of both treatments, particularly for propranolol, a 
primary cardiac drug without a long reputation in the dermatological field. In the present 
study, we address impact and contentment of both treatment modalities in children with 
a cervicofacial IH treated with propranolol or OCS and their parents. Because data on the 
more favorable effect/side effect profile of propranolol are emerging, 11-13 the option of 
giving high doses OCS for IHs does not seem ethical anymore. Therefore prospective and 
blinded studies are impracticable. A case control study design seemed like an adequate 
alternative. For this study, the best possible matches were made between cervicofacial 
IH-patients from our cohort treated with propranolol (since September 2008) and OCS 
(treated before 2008). This method for case control study has been used previously to 
evaluate the effect of propranolol in ulcerated IH.16 The search for optimal matching would 
ideally be based on validated scoring systems like the recently described Hemangioma 
Severity Scale (HSS) in prospective studies.25 For this study however, matching based on 
photo-documentation and medical records was the best possible way, because of the 
retrospective character of the study design.
 Prior to treatment, the two matched treatment groups showed no major differences 
on the items of our medical information questionnaire. This similarity between both 
groups prior to treatment supplements the comparability between both groups and 
gives more value to the outcome of our questionnaire ‘during’ and ‘after’ treatment.
 During their child’s treatment, parents from the OCS group seemed to significantly 
feel overall more concerned and insecure, compared to the parents of the children treated 
with propranolol. Additionally, parents from the propranolol group perceived less negative 
influence on normal life issues, including parents’ work and the vaccination of their child, 
and gave a higher Qol-score for this period. The reason for the greater influence on 
everyday life (and parents’ work) experienced in the OCS group, has not been specifically 
investigated in this study, but could be explained by more outpatient controls due to the 
treatment schedule of OCS and the advice not to bring the child to daycare. Also after 
treatment, the parents of propranolol treated IH patients gave significantly higher 
Qol-scores than OCS-parents.     
 Since this retrospective study design inevitably has limitations, conclusions from this 
study can only be drawn carefully. One limitation of this study may be the fact that 
children treated with the recently discovered treatment propranolol were younger than 
the patients in the OCS group at the moment of the interview. So, parents in the 
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propranolol group may not yet be thinking of possible necessity of subsequent treatment. 
This age difference and its associated difference in time after completion of treatment 
may also have influenced the grading of treatment outcome and impact of treatment by 
the parents by an inevitable recall bias. 
 Another limitation may be the difference in treatment duration for both groups, this 
being inextricably linked with the two treatments. Propranolol was continued until the 
age of 12-18 months; much longer than OCS therapy was given. This may also influence 
parents’ grading. 
 In addition, the questionnaires used in this study were not validated. But in literature, 
no validated questionnaires focusing on IH do exist today. To increase however the 
discriminative power of the questionnaire, the 5 point Likert scale was applied.
 Finally, testing all the different items in two comparable matched treatment groups 
brings the risk of ‘multiple testing’. Therefore in this study data were interpreted carefully 
and a significance level of α < 0.01 was used to assess the impact of treatment and 
contentment with treatment outcome.
 Despite these limitations, this is the first study to address differences in impact of 
treatment and contentment with treatment outcome between children with cervicofacial 
IHs treated with propranolol or OCS. The results of this study show that propranolol seems 
to change the impact of IH as a disease, its treatment as well as the quality of life of the 
parents by reducing additional distress in parents of cervicofacial IH patients. Furthermore, 
OCS treatment (as opposed to propranolol) also negatively influenced normal issues in 
the life of young children and families (like vaccination and going to day care while parents 
were working).
 In everyday practice, the awareness of the impact of treatment and contentment 
with treatment, underline the choice for propranolol in the treatment of function- or life 
threatening IHs. 
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Abstract
Accurate and objective measurement of volume changes in infantile hemangiomas (IH) is 
essential in routine clinical practice and clinical studies, particularly in the changing 
therapeutic landscape after the discovery of propranolol. Several bedside techniques for 
volume measurement have been described in literature, but an objective method of 
measurement of this variable, dynamic vascular tumor is lacking. Three-dimensional (3D) 
photo-technology with data analysis is an up and coming technique in the objective 
measurement of facial volume changes. In this pilot study, the usability and clinical 
relevance of two methods of 3D stereophotogrammetry in the volume measurement of 
IH were explored.
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Introduction
Infantile hemangiomas (IH) are the most common benign tumors of infancy, characterized 
by rapid growth during the proliferation phase in the first year of life followed by slow 
regression.1 The clinical appearance of IH is variable, which makes assessment of growth 
and regression difficult, especially in voluminous IHs. Therefore, no standard method for 
measuring IH dynamics during growth and involution exists. 
 Accurate objective assessment of volume changes in IH is essential in routine clinical 
practice and clinical studies. Since the discovery of the effectiveness of beta-blockers for 
IH, there is an increasing need to evaluate and compare therapeutic effects. 
 In the past few years, three-dimensional (3D) photo-technology has evolved rapidly. 
Three-dimensional cameras (3D stereophotogrammetry) in combination with specialized 
software seem useful in assessing objective and quantitative evaluation of volume 
changes in IH. A number of reproducibility and validity studies of 3D stereophoto-
grammetry have been performed.2,3 It can be concluded from earlier studies that surface-based 
registration is an accurate method of comparing 3D photographs of the same individual 
at different times.2
 To the best of our knowledge, no studies have been performed to investigate the 
relevance of 3D photographs for IHs. The usability and clinical relevance of two methods 
of 3D stereophotogrammetry for volume quantification in IH were explored in this pilot 
study.
Patients and Methods
This prospective study sample comprised 11 IH patients who visited our vascular anomalies 
clinic. Inclusion criteria were: patients with an IH in the head and neck region of the 
superficial nodular, deep or mixed type, with an indication for propranolol treatment. 
Three-dimensional photographs of the patients were taken at the start (T0) of propranolol 
treatment and at the first control visit (T1). A 3D stereophotogrammetric camera setup 
(3dMDfaceTM System, 3dMD Ltd, Atlanta, USA) was used. The camera setup consisted of 
two pods, each equipped with three digital cameras and a flash.4 During acquisition, 
patients were carefully positioned in a natural head position.5 A trained photographer 
took all 3D photographs (Figure 1).
 Two methods are described for the 3D measurement of the changes between two 
different moments in time. 
Method 1: Superimposing images
The 3D photographs taken at T0 and T1 were superimposed using the surface based 
matching tool of the Maxilim® software.2 In medical imaging, this matching procedure is 
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Figure 1   Three-dimensional (3D) camera setup and 3D photograph of patient with 
infantile hemangioma
Figure 2   Flowchart method 1: Superimposing images
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referred to as surface-based registration. After this registration procedure with volume 
subtraction, a  color map (distance map) could be calculated illustrating the volume 
diff erences between T0 and T1 as a color scale image, indicating the unchanged areas (in 
white), decreased volume (in red discoloration) and increased volume (in green 
discoloration). A higher intensity of discoloration corresponds with a larger change in 
facial volume. The lighter red areas indicate a small diff erence (decrease) between the two 
3D images, lighter green areas indicate a small increase. Areas with a more intense red or 
green color indicate a larger decrease or increase, respectively. 
Figure 3   Flowchart method 2: Mirroring images
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 From this color map, the region covering the IH (which showed a red discoloration) 
was selected and the mean difference between the photographs could be calculated 
(Figure 2).
Method 2: Mirroring images
Surface-based registration was applied in the second method as well, but in another way. 
The 3D photograph taken at T0 was mirrored and aligned with the original 3D photograph.
 The color map was subsequently computed, and the volumetric difference between 
T0 and T1 could be calculated. This mirroring procedure was validated earlier and 
described by Verhoeven and colleagues.6 The procedure was repeated with the 3D 
photograph taken at T1, resulting in two mean differences and two volumes. By subtracting 
the post-treatment volumes from the pretreatment volumes a difference could be 
computed. (Figure 3).
Results
This study included 11 patients (eight girls, mean age 4.3 months at time of first photograph; 
range 2.0-12.5 months). T0 was the time of the first photograph at the start of propranolol 
treatment and T1 was the time of the first control visit (mean 9.1 weeks after starting 
treatment, range 3.1-16.6).
Table 1   Characteristics of IH and time between photographs
Patient 
number
Sex Location 
of IH
Type of IH Crossing 
the facial 
midline
Time between 
photographs 
(wk.)
1* Male Upper eyelid Nodular No 3.1
2 Female Forehead Combined No 6.9
3 Female Orbital Deep No 16.6
4 Female Nostril Combined Yes 3.9
5 Female Cheek Deep Yes 14.6
6 Female Upper eyelid Deep No 10.6
7 Male Nose tip Nodular No 6.9
8 Female Occiput Nodular Yes 13.4
9 Female Upper eyelid Nodular No 8.0
10 Female Cheek Deep No 7.4
11 Male Upper eyelid Nodular No 8.6
* Patient in Figs. 1, 2 and 3.
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 Table 1 shows the characteristics of the IHs; including location, type and whether or 
the IH crossed the facial midline. Table 2 illustrates the volume differences measured 
between T0 and T1 for both methods. 
Discussion
Infantile hemangiomas have dynamic growth patterns and great clinical variability, 
complicating volume measurements. In most studies, 2D photographs have been taken 
to monitor the evolution of the IH, but accurate volumetric measurements cannot be 
derived from this technique, only overall evaluation and follow-up. To the best of our 
knowledge only three publications7-9 have described bedside techniques for estimating 
IH volume. In addition to the inevitable interobserver variation, these methods model IH 
as perfect spheres, half-spheres, or ellipsoids, making them moderately suitable for 
assessment of irregularly shaped IH.
 Radiologic diagnostics such as serial duplex ultrasonography may be applicable but 
are operator dependent. Other imaging techniques such as magnetic resonance imaging 
and computerized tomography are generally not practical for measuring changes in 
volume, because of costs, the need for sedation, and the involvement of invasive radiation 
in serial measurements. 
 Since 2008, propranolol has been an up and coming, successful treatment option for 
complicated IHs. After the discovery of this beta-blocker, several associated  new therapies 
Table 2   Absolute volume differences in cc after propranolol treatment between T1 
and T0 in both methods
Patient number Absolute volume difference cc)
Method 1
Absolute volume difference ( cc)
Method 2
1* -2.5 -2.3
2 -3.3 -3.3
3 -5.6 -4.4
4 -1.9 not suitable for method 2
5 -4.0 not suitable for method 2
6 -4.9 -4.8
7 -1.6 -1.5
8 -4.2 not suitable for method 2
9 -2.6 -2.6
10 -2.0 -2.8
11 -0.6 -0.6
*Patient in Figs. 1, 2 and 3
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emerged.10,11 With the advent of these novel therapies, there is an increasing need to 
evaluate or compare treatment effects and possible regrowth or relapse after cessation of 
treatment but also to evaluate the course of untreated IH in functionally important 
threatening areas (e.g. eye, nose). These findings may be important in the considering 
whether to treat.
 Three-dimensional stereophotogrammetry can be useful in daily clinical practice in 
evaluating facial volume changes, not only with subjective parameters but also with 
objective measurements. An increasing number of hospitals have acquired this 
technology. The time involved in image acquisition is limited and is a function of correct 
positioning of the patient. The time needed to capture high-quality ‘external surface’ 
photographs using this technique is < 2 milliseconds, which makes it ideal for collecting 
3D data from faces, even in children or babies. Reconstruction of the 3D image takes 30 
seconds of computational time and post-processing of the images takes approximately 15 
minutes per case. With adapted software, this technique is also applicable to IH at some 
other sides of the body, but it is most suitable for the head and neck region.
 Volumetric registration of IH with two methods of 3D photography was explored in 
this pilot study. Method 1 is more basic and calculates the difference in the region of 
interest of two photographs taken at different times. This method can be used for 
voluminous IH, even for IH crossing the midline of the body. The major drawback of this 
technique is that the effect of the growth of the child cannot be excluded, although this 
is inevitable with any technique of volume measurements of tumors occurring in infancy 
and childhood.
 Method 2 is slightly more complicated and uses mirroring of the face to calculate the 
volumetric difference at two different times. A disadvantage of this method is that it 
applicable only for unilateral IH and it is based on facial symmetry as baseline. The major 
advantage is that the effect of growth is minimized. The second method may be more 
accurate for IH not crossing the midline, especially in the case of longer time intervals 
between the measuring points. When the times between photographs are closer 
together, either method may be suitable. 
Given the small number of patients enrolled in this pilot study, no statistical calculations 
were performed to illustrate comparability of the techniques. The focus of the study was 
the applicability. A larger study with more patients will follow to determine the statistical 
difference between the techniques more accurately. 
 
Conclusion
Three-dimensional stereophotogrammetry is a promising, new, accurate, fast, noninvasive 
way to determine and compare volumetric changes in IH.
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Abstract
Objective Infantile hemangiomas (IHs) in the airway may be potentially life-threatening 
during the proliferative phase. Available treatments like oral corticosteroids (OCS) and 
chemotherapeutic agents usually showed variable responses and serious side effects. 
Propranolol is a new and promising treatment option. 
Methods A case series of five IH patients with airway involvement is presented, 
supplemented with a review of literature. Propranolol treatment (2.0-3.0 mg/kg/day) was 
initiated between 3 weeks and 6 months of age. Three cases were treated with propranolol 
monotherapy, two cases with OCS primarily and propranolol secondarily, in which 
treatment with OCS could be reduced rapidly.
Results In our case series a dramatic, fast response was observed in all cases, with a 
permanent effect after discontinuation in four cases. In one patient a relapse of airway 
problems occurred 2 months after discontinuation of propranolol at 16 months of age; 
this resolved after re-start of propranolol. Review of literature together with these five 
cases showed 81 patients with airway IHs treated with propranolol. Propranolol was 
effective in 90% of the cases and seven patients were classified as non-responders. Eight 
IHs relapsed while weaning of propranolol or after discontinuation; dose adjustment or 
restart was effective in most cases but one patient appeared resistant to therapy. 
Conclusions Propranolol seems to be a rapidly effective and safe treatment strategy for 
most IHs obstructing the airway. Because of the fast and important effects of propranolol, 
randomized controlled trials are hardly justifiable for this specific, relatively rare but, acute 
treatment indication. Despite the efficacy of propranolol, close monitoring of the patients 
with an airway IH is required, considering the risk of relapse of symptoms during or after 
treatment and the reported resistance to propranolol in at least 9% of the published cases. 
The dose and duration of treatment should be high and long enough to prevent relapse. 
Further research should focus on the optimal treatment protocol; the actual percentage 
of non-responders and also the mechanism of resistance to propranolol is unknown and 
needs to be illuminated.
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Introduction
Infantile hemangiomas (IHs) are true neoplastic proliferations of endothelial cells and the 
most common benign vascular tumors in children. An IH has the characteristic to 
proliferate rapidly in the first year of life. Most IHs proceed to resolution over a period of 
months to years without complications, not requiring any medical intervention.1 The 
clinical significance of IHs varies widely and is often linked to their location, size and type. 
The predilection area for IH is the head and neck region; external compression of the 
airway or airway localization with obstruction may lead to life-threatening situations. 
Cutaneous signs of airway IHs typically are segmental skin lesions in a mandibular 
distribution (‘beard hemangioma’) in up to 50% of the patients. Patients usually present 
with stridor, respiratory distress or feeding difficulties.1,2 Airway IHs can be evaluated by 
nasopharyngoscopy, laryngoscopy and/or magnetic resonance imaging (MRI). Multiple 
treatment modalities have been proposed in the management of airway IHs to maintain 
airway patency and to avoid tracheotomy and intensive care admission. Treatment options 
consisted of intralesional and systemic corticosteroids, chemotherapeutical agents 
(interferon or vincristine), laser therapy and/or open submucosal resection. Unfortunately, 
these treatment options have only limited therapeutic benefits with potential side effects 
and risks.3,4 Until recently, systemic corticosteroid therapy was considered the first choice 
treatment in (airway) IHs but this therapy was not successful in many cases and entailed 
serious side effects like hypertension, growth retardation, Cushing face, and an increased 
susceptibility to infection.5 
 The effect of the oral beta-blocker propranolol on IH is promising, described as a 
serendipitous finding by Léauté-Labrèze in 2008.6 Since then, several (case-) reports have 
demonstrated the effectiveness of propranolol in the treatment of IH, also in case of airway 
involvement. Potential modes of actions for propranolol in IH include vasoconstriction, a 
downregulation of angiogenetic factors like vascular endothelial growth factor (VEGF) and 
basic fibroblast growth factor (bFGF) and an upregulation of apoptosis of capillary 
endothelial cells.7 More recently there is growing evidence that the renin-angiotensin system 
(RAS) plays an important role in the mechanism of action of propranolol for IH.8,9 
 To provide definite evidence for the effect of propranolol on IH, randomized 
double-blinded controlled studies are most desirable. Nevertheless, case series are very 
useful to establish the role of new therapeutic agents. Several aspects regarding 
propranolol treatment for IH with airway involvement however remain to be illuminated: 
e.g. optimal dosage, duration and timing of therapy, effect on the natural course of IH, 
monitoring of short and long-term side effects and requirement of other treatment 
modalities.
 We present five children with an airway-compromising IH treated with propranolol 
and a review of cases with airway IH treated with propranolol published in English 
literature. Finally, important issues and recommendations for the future will be discussed. 
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Clinical observations
Case 1
A 2-weeks-old female neonate, born at term, presented a segmental IH, covering the right 
parieto-occipital skull, ear and neck. An ulceration (2 cm diameter), probably in the aplasia 
cutis spectrum was already visible at birth (Figure 1a). Further examination revealed a 
grade II-III/VI high frequent systolic murmur, left parasternal, suspected for a ventricular 
septal defect (VSD). Oral antibiotics were given for 7 days and wound care was started. In 
the fourth week of life there was rapid expansion of the IH resulting in an inspiratory 
stridor and feeding difficulties. After ultrasonography showing a massive IH in the right 
neck region (right glandula parotis and parapharyngeal), the girl was referred to the 
intensive care unit of our tertiary centre because of a threatened airway. 
 Propranolol was started in an increasing schedule to the target dosage of 3.0 mg/kg/
day (in 3 doses). The inspiratory stridor disappeared within 24 hours and discoloration of 
the skin localization of the IH was visible within a few days under stable hemodynamic 
controls and normal fasting glucose levels.
 As part of the work-up for PHACES (Posterior fossa brain malformations, Hemangiomas 
of the face, Arterial Cerebrovascular abnormalities, Eye abnormalities and Sternal defects) 
echocardiography was performed; the left ventricle (LV) showed dimension on the 95th 
percentile and revealed a small VSD. During propranolol treatment however, the LV 
dimensions normalized. Electrocardiography (ECG), MRI of the head and ophthalmologic 
evaluation showed no abnormalities. 
 The IH improved dramatically in the following months (Figure 1b). Propranolol was 
continued until 15 months of age and tapered in 3 weeks. Two months after discontinuation 
of propranolol, significant recurrence of swelling was observed with respiratory distress 
and audible breathing during a viral upper airway infection (Figure 1c). Echocardiography 
showed LV dimensions on the 95th percentile again. Because of this significant relapse of 
swelling of the IH with concomitant airway symptoms and increased LV dimensions, 
propranolol was restarted (2.0 mg/kg/day). The swelling of the lesion and audible 
breathing disappeared again in a few weeks. The treatment was continued till the end of 
the patients’ second year of life (Figure 1d). Then, the propranolol was tapered and 
discontinued successfully. The IH remained in regression and the patient is still free of 
airway symptoms at the age of 3.5 year. Residual lesions characterized by fibrofatty tissnue 
are clearly visible in the neck.
Case 2 
A 2-month-old boy, born at term, was referred to the ear nose and throat (ENT) department 
because of a progressive inspiratory stridor and threatening respiratory failure. A left-sided 
subglottic IH was diagnosed by laryngoscopy and oral dexamethason 0.5 mg/kg was 
started. After he showed some clinical improvement, the patient was sent home. Several 
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Figure 1
(a) Age 4 weeks; segmental hemangioma with swelling of parotid region. (b) Age 9 months; 
improvement of the hemangioma, 8 months after initiation of propranolol.
(c) Age 18 months; increased redness and swelling, 2 months after discontinuation of
propranolol.
(d) Age 22 months; 4 months after restart of propranolol.
(a)
(c) (c)
(d) (d)
(b)
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readmissions followed because of feeding difficulties and respiratory distress treated with 
inhalation corticosteroids. After admission to our centre, at the age of 4 months and after 
cardiac evaluation, propranolol was added at a maximum dose of 2.2 mg/kg/day in 3 
doses, resulting in disappearance of the stridor in one day. The respiratory distress resolved 
completely and the boy no longer presented symptoms of obstructive airway. After 
initiation of propranolol, the boy was observed clinically for 2 days and the tolerance of 
propranolol was good with stable blood pressure, heart rate and normal fasting glucose 
levels. Oral corticosteroids were tapered and stopped successfully in a few weeks’ time. 
Propranolol was continued until the age of 14 months without side effects and tapered 
over 4 weeks. The patient showed no symptoms of respiratory distress or side effects of 
propranolol in the 2-years follow-up. 
Case 3
A 6-weeks-old boy, born at term, was referred to the department of ENT/ maxillo-facial 
surgery, because of a left-sided nose obstruction during viral upper airway infections, due 
to an intracavitar mass, probably an IH. This diagnosis was confirmed with a biopsy 
revealing a vascular tumor with positive glucose transporter protein 1 (GLUT1)-staining. 
Because of severe respiratory distress, propranolol was started at the age of 3 months to a 
target dosage of 2.2 mg/kg/day in 3 doses. General physical examination and cardiological 
screening (ECG and echocardiogram) before the start of propranolol were normal. Within 
three days there was a considerable shrinkage of the IH, resulting in disappearance of the 
nose obstruction, an obvious improvement of the respiration, a more vigorous state and 
less feeding problems. During propranolol, a viral upper respiratory tract infection resulted 
in respiratory wheezing and a prolonged expirium. The bronchospasm was attributed to 
propranolol, the viral infection or the combination of both. Besides, there was a positive 
family history for asthma. After the propranolol dosage was lowered to 1.5 mg/kg/day and 
a corticosteroid inhaler was started, wheezing improved and the IH further decreased. At 
the age of 12 months, propranolol was tapered successfully and the respiratory wheezing 
disappeared. In the 2-year follow-up, the patient is doing well without signs of nose 
obstruction.
Case 4
A 1-month-old girl, born at 37 weeks after a twin pregnancy presented with a progressive 
segmental IH in the right-sided head and neck region. She was referred to the neonatal 
intensive care unit due to respiratory distress including stridor, tachypnea and feeding 
difficulties. Laryngoscopy revealed swelling of the arytenoids and epiglottal fold on the 
right side. As part of the PHACES work up; cardiac evaluation (ECG and echocardiography), 
ophthalmologic evaluation and cerebral ultrasonography showed no abnormalities. 
 The patient started with propranolol on an increasing schedule to 2.0 mg/kg/day in 3 
doses. The IH softened and the respiratory symptoms and feeding difficulties improved 
115
6
PROPRANOLOL AND AIRWAY HEMANGIOMAS
within days. Because of remaining mild inspiratory stridor during exercise, the dose was 
successfully increased to a target dosage of 3.0 mg/kg/day with subsequent adjustments 
of the dose to the body weight of the patient. The propranolol was well tolerated without 
any side effects. Concomitant with disappearance of the respiratory distress, there was a 
significant regression of the cutaneous part of the IH. An MRI of the brain was performed 
with no evidence of posterior fossa malformations and the psychomotor development 
was within the normal range. 
 The propranolol was given till 20 months of age and discontinued successfully 
without rebound swelling and no signs of respiratory distress in the 12 months follow-up. 
Some erythema of the skin with fibrofatty tissue remains visible.
Case 5
A 2-month-old female neonate, born at term, presented in a district hospital with 
progressive inspiratory stridor concomitant with mild hypotonia and reduced tendon 
reflexes. Direct laryngoscopy showed besides mild laryngomalacia no other abnormalities. 
MRI of the head and spine revealed compression of the myelum at C1 level due to 
narrowing of the cervical spinal canal. Therefore a dorsal laminectomy was performed to 
decompress the myelum. After detubation a severe inspiratory stridor with desaturation 
was present whereupon endotracheal swelling was hypothesized. A re-intubation was 
carried out and treatment with dexamethasone was given temporarily. Three days later, 
detubation could be performed successfully and dexamethasone was discontinued. After 
10 days (at 3 months of age), the patient was discharged without any stridor. Ten days later 
however, she was re-admitted with progressive respiratory distress owing to stridor, 
tachydyspnoea, desaturations and feeding problems. Considering the cervical myelopathy 
in the past, laryngomalacia with a viral upper airway infection was hypothesized as the 
main cause of the stridor and treatment with dexamethasone (0.8 mg/kg/day) was 
restarted. Cessation of the dexamethasone therapy failed because stridor persisted and a 
dose of 0.15 mg/kg/day of oral steroids were maintained. Nevertheless intermittent stridor 
persisted in combination with a Cushingoid appearance. At 6 months of age, re-evaluation 
with laryngobronchoscopy was performed, because of persisting respiratory distress that 
revealed a large subglottic IH. After cardiac evaluation (ECG and echocardiogram) 
propranolol was promptly initiated successfully with an increasing schedule to a maximum 
of 3.0 mg/kg/day in 3 doses. The stridor disappeared within a few days and the patient 
remained asymptomatic. The dexamethasone was tapered slowly and propranolol 
monotherapy is continued till the age of 18 months. In the 1-year follow-up the patient is 
free of respiratory symptoms.
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Review of literature
Methods
Eligible studies were identified by searching the electronic literature (PubMed database) 
for relevant published reports (using the terms: infantile hemangioma, propranolol, airway 
obstruction, subglottic, head and neck) and by hand searching reference lists of articles 
on this topic. The search included reports on this topic published since the initial report of 
propranolol use for the treatment of IH in 2008, until February 2013. Only human studies 
in the English language were included in the analysis. Articles describing the use of 
propranolol for complicated IH without further specification about airway involvement 
were excluded. Data were extracted from the original reports. Analysis was performed on 
available data. If patients were doubly reported, they were analyzed one time only, unless 
longer follow-up revealed new information. Patients were qualified as good responders to 
propranolol if the IH showed persistent regression with disappearance of symptoms. 
Treatment failure was defined as none response to treatment or recurrence of symptoms 
during propranolol at the target dosage, after initial response. Relapse was defined as 
return of airway symptoms once propranolol was stopped or the dosage was decreased.
Results
Table 1 represents characteristics of published cases with IH complicated by compromised 
airway, treated with propranolol. Data from 85 children, including our five cases, with 
airway IH who received propranolol treatment are summarized.4,10-32 Four of the 85 cases 
are doubly reported. In total, 81 patients are analyzed, in one doubly reported patient (#14) 
longer follow-up revealed new information. 
 Eighty percent (65/81) of the children were girls; the mean age at presentation was 2.2 
months (ranged from 2 weeks to 6 months). In 96% (78/81) the airway IH was located 
subglottically, as an isolated entity or as part of IHs located in the head and neck region.
 Seventy-seven percent (62/81) of patients received an alternative treatment with 
OCS, intralesional corticosteroids, vincristine, laser therapy and/or tracheotomy. These 
other treatments were given before propranolol, as dual therapy or in case of failure of 
propranolol treatment. Beta-blocker treatment was mostly initiated after full cardiovascular 
and respiratory review. Median age at start of propranolol was 3.0 months (range 3 weeks 
to 22 months). The most common propranolol dose was 2 mg/kg/day (ranged from 1 to 
3). Data about efficacy were available in all patients, 81% (66/81) of them had a good 
permanent response without relapse.  
 Within a few days after the initiation of propranolol treatment, fading and softening 
of the skin localization of the IH was noticeable. Symptoms such as dyspnea and 
hemodynamic compromise also regressed. Many patients formerly receiving OCS could 
be weaned off OCS within a few weeks. In ten percent (8/81), after good initial response, 
the IH relapsed once the propranolol was decreased or stopped. Restart of propranolol or 
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dose adjustment to bodyweight afterwards was effective in most cases but failed in 
one case. Case #36 developed snoring 3 days after stopping propranolol at the age of 
10 months and the effect of restart was not described. Cases #14 and #25 demonstrated 
clinical symptoms again with significant rebound swelling of the IH at endoscopic 
evaluation after discontinuation of the first course. Reintroduction of propranolol 
was successful in case #14, but failed in case #25, resistance to beta-blockers was 
hypothesized. This last patient required two additional endoscopic procedures and 
ultimately a laryngoplasty. 
 In case #1 rebound growth with audible breathing was seen when propranolol was 
tapered at 15 months, restart had however good effect and at the age of 2 years the 
propranolol was discontinued without symptoms of respiratory distress. Although 
propranolol was started early in life, significant residual fibrofatty tissue persisted. 
 Case #54 required a second course of propranolol due to recurrence 2 months after 
stopping the first course. It was not documented how long the second course was given. 
Case #80 developed recurrent stridor after 2 months on propranolol and prednisolone. 
These symptoms subsided after the dose was increased to 3 mg/kg/day. However at the 
age of 16 months, symptoms reoccurred on a tapering dosage of propranolol (1.5 mg/kg/
day) and bronchoscopy confirmed rebound swelling of the subglottic IH. Restart on 2.0 
mg/kg/day was however effective. Mahadevan et al. described in two of ten patients, not 
further specified, recurrence of airway symptoms after 9 months of therapy, which 
improved after dose adjustment to body weight. 
 In nine percent (7/81) of the cases, the symptoms of the airway IH remained present 
and they were considered as non-responders to propranolol therapy. In case #47, the 
cutaneous IH improved, but the subglottic component continued to proliferate over time 
on propranolol treatment. Case #55 is classified as non-responder because she did initially 
not respond to propranolol, once symptoms relapsed after OCS and open surgery she 
was restarted on propranolol with fairly response.
 Summarized, ninety percent of the cases (73/81) with an airway IH turned out to 
respond to propranolol. 
 In only seven patients (#3, #15, #54, #56, #64, #83, #85) noticeable side effects of 
propranolol were mentioned. Two cases had mild gastrointestinal symptoms. In case #15, 
severe asthmatic symptoms occurred during the first week of treatment. Propranolol 
could be replaced successfully by another, more selective beta-blocker (acebutolol) with 
a comparable clinical effect but without severe bronchoconstriction.15 In case #3, 
respiratory wheezing and a prolonged expirium developed during a viral upper respiratory 
tract infection. The propranolol dosage was lowered to 1.5 mg/kg/day and a corticosteroid 
inhaler was started. This resulted in an improvement of wheezing and nevertheless a 
steady decrease of the IH. Case #83 appeared to have a low blood pressure associated 
with impaired peripheral circulation, during a routine clinic visit. The dosage of propranolol 
was not changed. 
118
CHAPTER 6.1
Table 1  IH characteristics of 16 matched patients
Author Pt. no Gender Location of IH Age at 
presentation
(months)
Alternative 
treatment
Age at  
start of 
propr.
(months)
Propranolol 
dosage  
(mg/kg/day)
Duration 
therapy
(months)
Age at end
propranolol
(months)
Response: 
good, relapse 
or failure
Follow up after 
discontinuation
(months)
Reported 
side effects
Ref
Our cases 1 F Right glandula parotis, 
parapharyngeal
1 None 1 3 1st 14
2nd 7
1st 15
2nd 24
Relapse, restart  
good effect
18 None
2 M Subglottic 2 Corticosteroids 4 2.2 10 14 Good 24 None
3 M Nose: intracavitar 1.5 None 3 2.2 9 12 Good 24 Wheezing
4 F Beard, neck, arytenoids, 
epiglottic
1 None 1 3 19 20 Good 12 None
5 F Subglottic 2 Corticosteroids 6 3 12 18 Good 12 None
Blanchet* 6 F Subglottic 3 Corticosteroids 3 3 9 Ongoing Good None 4
Buckmiller 7 F Beard, subglottic 2 weeks Corticosteroids, laser, 
vincristine
22 2 4 Ongoing Good None 10
Canadas 8 F Subglottic 2 None, later open 
surgery
2 2-3 3 5 Failure None 11
Denoyelle 9 F PHACES, lip, parotid, chest, 
subglottic
2 Corticosteroids, 
vincristine
11 3 7 18 Good NA None 12
10 F Mucosal, subglottic 4 Corticosteroids 4 2 1 Ongoing Good None
Guye 11 M Subglottic 6 weeks None 6 weeks NA 8 9.5 Good 9 None 13
Jephson 12 F Subglottic 4 None 4 1 - 2 5 Ongoing Good None 14
Leboulanger 13=9 b F Subglottic, PHACES 1.5 Corticosteroids, 
vincristine
11 3 Mean 6 Ongoing Good None 15
14=10 b F Subglottic, cutaneous 
hemangiomas
4 Corticosteroids 4 2 1st 10
2nd NA
1st 14
2nd NA
Relapse, restart 
good effect
Mean 6 after 
last endoscopic 
evaluation
None
15 All F
except 
one M
Subglottic 3 Corticosteroids 5 2 1 week Switched 
acebutolol
Good Severe asthma
16 Subglottic, PHACES 1.5 Corticosteroids 1.5 3 Mean 6 Ongoing Good None
17 Subglottic 3 None 3 3 5 8 Good None
18 Subglottic 3 Corticosteroids, laser 16 3 Mean 6 Ongoing Good None
19 Subglottic 3 Corticosteroids, laser 7 2 Mean 6 Ongoing Good None
20 Subglottic 2 Corticosteroids, laser 5.5 2 Mean 6 Ongoing Good None
21 Subglottic 1.5 Corticosteroids 2 2 Mean 6 Ongoing Good None
22 Subglottic 3 None 3 3 Mean 6 Ongoing Good None
23 Subglottic, large facial 3 weeks None 0.75 3 Mean 6 Ongoing Good None
24 Subglottic 2 Corticosteroids, laser 8 2 5 13 Good None
25 Subglottic 1 Corticosteroids, laser 2 3 1 3 Relapse, restart 
propranolol 
resistant
None
26 Subglottic 4 Corticosteroids 4 3 Mean 6 Ongoing Good None
Maturo and 
Hartnick
27 F Supraglottic 3 Laser 3 2 6 Ongoing Good None
1628 F Subglottic 5 None 5 2 3 Ongoing Good None
Mistry 29 F Pharyngeal/subglottic 5 weeks Corticosteroids 5 weeks 2 8 Ongoing Good None 17
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Table 1  IH characteristics of 16 matched patients
Author Pt. no Gender Location of IH Age at 
presentation
(months)
Alternative 
treatment
Age at  
start of 
propr.
(months)
Propranolol 
dosage  
(mg/kg/day)
Duration 
therapy
(months)
Age at end
propranolol
(months)
Response: 
good, relapse 
or failure
Follow up after 
discontinuation
(months)
Reported 
side effects
Ref
Our cases 1 F Right glandula parotis, 
parapharyngeal
1 None 1 3 1st 14
2nd 7
1st 15
2nd 24
Relapse, restart  
good effect
18 None
2 M Subglottic 2 Corticosteroids 4 2.2 10 14 Good 24 None
3 M Nose: intracavitar 1.5 None 3 2.2 9 12 Good 24 Wheezing
4 F Beard, neck, arytenoids, 
epiglottic
1 None 1 3 19 20 Good 12 None
5 F Subglottic 2 Corticosteroids 6 3 12 18 Good 12 None
Blanchet* 6 F Subglottic 3 Corticosteroids 3 3 9 Ongoing Good None 4
Buckmiller 7 F Beard, subglottic 2 weeks Corticosteroids, laser, 
vincristine
22 2 4 Ongoing Good None 10
Canadas 8 F Subglottic 2 None, later open 
surgery
2 2-3 3 5 Failure None 11
Denoyelle 9 F PHACES, lip, parotid, chest, 
subglottic
2 Corticosteroids, 
vincristine
11 3 7 18 Good NA None 12
10 F Mucosal, subglottic 4 Corticosteroids 4 2 1 Ongoing Good None
Guye 11 M Subglottic 6 weeks None 6 weeks NA 8 9.5 Good 9 None 13
Jephson 12 F Subglottic 4 None 4 1 - 2 5 Ongoing Good None 14
Leboulanger 13=9 b F Subglottic, PHACES 1.5 Corticosteroids, 
vincristine
11 3 Mean 6 Ongoing Good None 15
14=10 b F Subglottic, cutaneous 
hemangiomas
4 Corticosteroids 4 2 1st 10
2nd NA
1st 14
2nd NA
Relapse, restart 
good effect
Mean 6 after 
last endoscopic 
evaluation
None
15 All F
except 
one M
Subglottic 3 Corticosteroids 5 2 1 week Switched 
acebutolol
Good Severe asthma
16 Subglottic, PHACES 1.5 Corticosteroids 1.5 3 Mean 6 Ongoing Good None
17 Subglottic 3 None 3 3 5 8 Good None
18 Subglottic 3 Corticosteroids, laser 16 3 Mean 6 Ongoing Good None
19 Subglottic 3 Corticosteroids, laser 7 2 Mean 6 Ongoing Good None
20 Subglottic 2 Corticosteroids, laser 5.5 2 Mean 6 Ongoing Good None
21 Subglottic 1.5 Corticosteroids 2 2 Mean 6 Ongoing Good None
22 Subglottic 3 None 3 3 Mean 6 Ongoing Good None
23 Subglottic, large facial 3 weeks None 0.75 3 Mean 6 Ongoing Good None
24 Subglottic 2 Corticosteroids, laser 8 2 5 13 Good None
25 Subglottic 1 Corticosteroids, laser 2 3 1 3 Relapse, restart 
propranolol 
resistant
None
26 Subglottic 4 Corticosteroids 4 3 Mean 6 Ongoing Good None
Maturo and 
Hartnick
27 F Supraglottic 3 Laser 3 2 6 Ongoing Good None
1628 F Subglottic 5 None 5 2 3 Ongoing Good None
Mistry 29 F Pharyngeal/subglottic 5 weeks Corticosteroids 5 weeks 2 8 Ongoing Good None 17
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Author Pt. no Gender Location of IH Age at 
presentation
(months)
Alternative 
treatment
Age at  
start of 
propr.
(months)
Propranolol 
dosage  
(mg/kg/day)
Duration 
therapy
(months)
Age at end
propranolol
(months)
Response: 
good, relapse 
or failure
Follow up after 
discontinuation
(months)
Reported 
side effects
Ref
Rosbe 30 F Subglottic 5 weeks Corticosteroids, 
laser, vincristine, 
tracheotomy
6 1.8 7 16 Good NA None 18
31 F Pre-postauricular, neck, 
subglottic
7 weeks Corticosteroids 8 1 10 Ongoing (18, 
weaning )
Good None
32 M Chest, ears, mandibular 
areas, subglottic
3 weeks Corticosteroids, 
dual therapy with 
propranolol
3 weeks 2 4 Ongoing Good None
Sans 33 M Nose with dyspnoe NA Corticosteroids 4 3 10 14 Good NAd 19
34 F Face, parotidal areas, 
subglottic
NA Corticosteroids 6 2 8 14 Good
35 M Hemiface, neck, nose, 
pharynx and glottis.
NA Corticosteroids 2 3 8 10 Good
36 M Face (nasal tip),
mediastinal area
NA Corticosteroids 9 2 1st 19
2nd 
ongoing
1st  10
2nd ongoing
Relapse, 
effect restart 
unknown
Theletsane 37 F Lip, ear, neck, laryngeal, 
oropharyngeal, subglottic
2 weeks Corticosteroids 6 weeks 2 6 Ongoing Good None 20
Truong 38 F Subglottic 5 Corticosteroids 15 weeks 2 5 5 Good NA None 21
Truong 39 F Pharynx, subglottic 1 Corticosteroids, 
tracheotomy
18 2 10 28 Good 14 None 22
40 F Supraglottic, subglottic, 2 Corticosteroids 6 2 6 12 Good 13 None
41 F Subglottic 1 Corticosteroids 2 2 6 8 Good 10 None
42 F Subglottic 3 Corticosteroids, laser 5 2 6 11 Good 8 None
43 F Supraglottic 3 Corticosteroids 22 2 6 28 Good 6 None
44 F Subglottic 1 Corticosteroids, open 
resection
4 2 5 9 Good 10 None
Raol 45 F Subglottic 1 Corticosteroids 1 3 > 12 Ongoing Good none 23
46 F Subglottic and left leg 1 Corticosteroids 1 3 11 12 Good NA None
47 F Face, neck, chest
beard and subglottic
1 Propranolol, later 
tracheotomy and 
oral and intralesional 
steroids
1 3 > 12 Ongoing Failure None
Goswamy 48 F Subglottic 2.5 Corticosteroids, 
propranolol
3 2 15 Ongoing Good None 24
49 F Nose tip 3 Corticosteroids, 
propranolol
3 2 5 Ongoing Good None
50 M Parotid, submandibular, 
subglottic
4 Propranolol, later 
tracheostomy and 
corticosteroids
4 2 1 5 Failure None
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Author Pt. no Gender Location of IH Age at 
presentation
(months)
Alternative 
treatment
Age at  
start of 
propr.
(months)
Propranolol 
dosage  
(mg/kg/day)
Duration 
therapy
(months)
Age at end
propranolol
(months)
Response: 
good, relapse 
or failure
Follow up after 
discontinuation
(months)
Reported 
side effects
Ref
Rosbe 30 F Subglottic 5 weeks Corticosteroids, 
laser, vincristine, 
tracheotomy
6 1.8 7 16 Good NA None 18
31 F Pre-postauricular, neck, 
subglottic
7 weeks Corticosteroids 8 1 10 Ongoing (18, 
weaning )
Good None
32 M Chest, ears, mandibular 
areas, subglottic
3 weeks Corticosteroids, 
dual therapy with 
propranolol
3 weeks 2 4 Ongoing Good None
Sans 33 M Nose with dyspnoe NA Corticosteroids 4 3 10 14 Good NAd 19
34 F Face, parotidal areas, 
subglottic
NA Corticosteroids 6 2 8 14 Good
35 M Hemiface, neck, nose, 
pharynx and glottis.
NA Corticosteroids 2 3 8 10 Good
36 M Face (nasal tip),
mediastinal area
NA Corticosteroids 9 2 1st 19
2nd 
ongoing
1st  10
2nd ongoing
Relapse, 
effect restart 
unknown
Theletsane 37 F Lip, ear, neck, laryngeal, 
oropharyngeal, subglottic
2 weeks Corticosteroids 6 weeks 2 6 Ongoing Good None 20
Truong 38 F Subglottic 5 Corticosteroids 15 weeks 2 5 5 Good NA None 21
Truong 39 F Pharynx, subglottic 1 Corticosteroids, 
tracheotomy
18 2 10 28 Good 14 None 22
40 F Supraglottic, subglottic, 2 Corticosteroids 6 2 6 12 Good 13 None
41 F Subglottic 1 Corticosteroids 2 2 6 8 Good 10 None
42 F Subglottic 3 Corticosteroids, laser 5 2 6 11 Good 8 None
43 F Supraglottic 3 Corticosteroids 22 2 6 28 Good 6 None
44 F Subglottic 1 Corticosteroids, open 
resection
4 2 5 9 Good 10 None
Raol 45 F Subglottic 1 Corticosteroids 1 3 > 12 Ongoing Good none 23
46 F Subglottic and left leg 1 Corticosteroids 1 3 11 12 Good NA None
47 F Face, neck, chest
beard and subglottic
1 Propranolol, later 
tracheotomy and 
oral and intralesional 
steroids
1 3 > 12 Ongoing Failure None
Goswamy 48 F Subglottic 2.5 Corticosteroids, 
propranolol
3 2 15 Ongoing Good None 24
49 F Nose tip 3 Corticosteroids, 
propranolol
3 2 5 Ongoing Good None
50 M Parotid, submandibular, 
subglottic
4 Propranolol, later 
tracheostomy and 
corticosteroids
4 2 1 5 Failure None
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Author Pt. no Gender Location of IH Age at 
presentation
(months)
Alternative 
treatment
Age at  
start of 
propr.
(months)
Propranolol 
dosage  
(mg/kg/day)
Duration 
therapy
(months)
Age at end
propranolol
(months)
Response: 
good, relapse 
or failure
Follow up after 
discontinuation
(months)
Reported 
side effects
Ref
Sierpina 51 M Left bronchus 3 weeks Corticosteroids, 
antibiotics 
bronchodilators, laser
1 2 1 2 Failure None 25
Javia 52 F Laryngotracheal 2 Corticosteroids, 
surgical
4 2 10 14 Good 15 None 26
53 F Laryngotracheal 5 Corticosteroids, 5 2 4.5 9.5 Good 18 None
54 M Laryngotracheal 2 Corticosteroids 2 2 1st 10.5
2nd NA
Total 12.5, 1st, 
2nd NA
Relapse, restart 
good effect
29 Constipation
55 F Laryngotracheal 1 Corticosteroids, open 
surgery, tracheotomy
2 2 10.5 12.5 Initial failure, 
after surgery 
recurrence, 
propranolol 
restarted with 
success.
20
None
56 F Laryngotracheal 3 None 3 2 11 14 Good 11 Diarrhea
57 F Laryngotracheal 3 Corticosteroids, 
tracheostomy
7 2 13 20 Failure 27 None
58 F Laryngotracheal 5 1 day corticosteroids 5 2 8 13 Good 8 None
59 F Laryngotracheal 2 1 day corticosteroids 2 2 10 12 Good 10 None
60 F Laryngotracheal 2 3 day corticosteroids 2 2 6 8 Good 6 None
61 M Laryngotracheal 2 Corticosteroids 2 2 increased  
to 3 at 6 m.
11 Ongoing Good None
62 F Laryngotracheal 6 Corticosteroids, 
planning resection 
and tracheostomy
6 2 11 17 Failure 12 None
63 M Laryngotracheal 1 None 1 2 10 Ongoing Good None
Mahadevan c 64 F Subglottic 3 Corticosteroids 3 2 9 12 Good NA Hypoglycemia 27
65 F Subglottic, parotid, neck 2 Corticosteroids 2 2 11 13 Good NA None
66 M Subglottic 3 None 3 2 10 13 Good NA None
67 F Subglottic 2 Corticosteroids 2 2 10 12 Good NA None
68 M Subglottic 3.5 Corticosteroids 3.5 2 8 11.5 Good NA None
69 F Subglottic, parotid, neck 2 Corticosteroids 2 2 7 9 Good NA None
70 F Subglottic 2.5 None 2.5 2 6 Ongoing Good None
71 M Subglottic 4 None 4 2 6 Ongoing Good None
72 F Subglottic 3 Corticosteroids 3 2 4 Ongoing Good None
73 F Subglottic, parotid 2 Corticosteroids 2 2 6 Ongoing Good None
Solomon 74 F PHACES; face and neck 25 days Corticosteroids, 
vincristine
About 2.5 2 6 Ongoing Good None 28
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Author Pt. no Gender Location of IH Age at 
presentation
(months)
Alternative 
treatment
Age at  
start of 
propr.
(months)
Propranolol 
dosage  
(mg/kg/day)
Duration 
therapy
(months)
Age at end
propranolol
(months)
Response: 
good, relapse 
or failure
Follow up after 
discontinuation
(months)
Reported 
side effects
Ref
Sierpina 51 M Left bronchus 3 weeks Corticosteroids, 
antibiotics 
bronchodilators, laser
1 2 1 2 Failure None 25
Javia 52 F Laryngotracheal 2 Corticosteroids, 
surgical
4 2 10 14 Good 15 None 26
53 F Laryngotracheal 5 Corticosteroids, 5 2 4.5 9.5 Good 18 None
54 M Laryngotracheal 2 Corticosteroids 2 2 1st 10.5
2nd NA
Total 12.5, 1st, 
2nd NA
Relapse, restart 
good effect
29 Constipation
55 F Laryngotracheal 1 Corticosteroids, open 
surgery, tracheotomy
2 2 10.5 12.5 Initial failure, 
after surgery 
recurrence, 
propranolol 
restarted with 
success.
20
None
56 F Laryngotracheal 3 None 3 2 11 14 Good 11 Diarrhea
57 F Laryngotracheal 3 Corticosteroids, 
tracheostomy
7 2 13 20 Failure 27 None
58 F Laryngotracheal 5 1 day corticosteroids 5 2 8 13 Good 8 None
59 F Laryngotracheal 2 1 day corticosteroids 2 2 10 12 Good 10 None
60 F Laryngotracheal 2 3 day corticosteroids 2 2 6 8 Good 6 None
61 M Laryngotracheal 2 Corticosteroids 2 2 increased  
to 3 at 6 m.
11 Ongoing Good None
62 F Laryngotracheal 6 Corticosteroids, 
planning resection 
and tracheostomy
6 2 11 17 Failure 12 None
63 M Laryngotracheal 1 None 1 2 10 Ongoing Good None
Mahadevan c 64 F Subglottic 3 Corticosteroids 3 2 9 12 Good NA Hypoglycemia 27
65 F Subglottic, parotid, neck 2 Corticosteroids 2 2 11 13 Good NA None
66 M Subglottic 3 None 3 2 10 13 Good NA None
67 F Subglottic 2 Corticosteroids 2 2 10 12 Good NA None
68 M Subglottic 3.5 Corticosteroids 3.5 2 8 11.5 Good NA None
69 F Subglottic, parotid, neck 2 Corticosteroids 2 2 7 9 Good NA None
70 F Subglottic 2.5 None 2.5 2 6 Ongoing Good None
71 M Subglottic 4 None 4 2 6 Ongoing Good None
72 F Subglottic 3 Corticosteroids 3 2 4 Ongoing Good None
73 F Subglottic, parotid 2 Corticosteroids 2 2 6 Ongoing Good None
Solomon 74 F PHACES; face and neck 25 days Corticosteroids, 
vincristine
About 2.5 2 6 Ongoing Good None 28
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Discussion
IHs are usually benign self-limiting tumors of infancy but may become life-threatening in 
case of airway involvement, causing respiratory insufficiency with a difficult interventional 
approach due to localization. The lack of an effective and uniform treatment plan for 
airway IHs makes new treatments necessary. We described five children with threatening 
Table 1  Continued
Author Pt. no Gender Location of IH Age at 
presentation
(months)
Alternative 
treatment
Age at  
start of 
propr.
(months)
Propranolol 
dosage  
(mg/kg/day)
Duration 
therapy
(months)
Age at end
propranolol
(months)
Response: 
good, relapse 
or failure
Follow up after 
discontinuation
(months)
Reported 
side effects
Ref
Katona 75 F Subglottic, face, arm 1.5 NA 1,5 2 NA > 12 Good 15 None 29
76 F Subglottic 3 NA 3 2 NA > 12 Good 15 None
Loizzi 77 F Subglottic 2 None 2 2 6 Ongoing Good None 30
Durr 78=32 b M PHACES; subglottic 16 days Corticosteroids, 3 weeks 2 Average 
18
NA Good Average follow up 
35(range, 13-76)
None 31
79 F PHACES; subglottic 83 days None 83 days 2 Average 
18
NA Good None
80 F PHACES; subglottic, 
epiglottis, extended to 
trachea
19 days Corticosteroids, 19 days 2, increased 
to 3
1st 17 
2nd NA
1st 16
2nd ongoing
Relapse, on 
lower dose. 
Increasing dose 
effective
None
81=30 b F PHACES; subglottic 47 days Corticosteroids, 
vincristine, laser, 
tracheotomy
6 2 10 16 Good None
82 F PHACES; subglottic, 
extended to pharynx, 
esophagus
NA Corticosteroids NA 2 14 Ongoing Good None
Graaf 83
F
Subglottic NA Intralesional 
corticosteroids
2.5 1.8 NA Ongoing Good Hypotension,
vomiting
32
84 F Subglottic NA Intralesional 
corticosteroids
6 2 NA Ongoing Good None
85 F Subglottic NA Intralesional 
corticosteroids
2 2 NA On going Good Cold 
extremities
F, Female; M, Male; NA, not available. Prop, propranolol, Ref, reference
a Blanchet et al. treated two patients with acebutolol [4]
b  If patients were doubly reported, they were analyzed one time only, unless longer follow-up revealed new 
information (#14)
c  Mahadevan et al. described in two of ten patients, which one were not specified, recurrence of airway 
symptoms after 9 months of therapy, which improved after dose adjustment to body weight [27]
d  A few adverse effects were noted during  propranolol  treatment in a cohort of 32 patients  with severe infantile 
hemangiomas, including 4 cases with airway involvement.
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airway IH that caused severe respiratory distress. They were all treated successfully with 
oral propranolol, which confirms the efficacy of propranolol for this indication. Several 
lessons can be drawn from the current experience with our cases in combination with the 
case series described in literature. 
Diagnosis
The correct diagnosis has to be made early. In case #5 prolonged treatments with OCS 
could have been avoided if the correct diagnosis was made and re-evaluation with 
laryngoscopy was performed earlier while the stridor persisted. In case of uncertainty, a 
biopsy can be considered with GLUT1 staining; this confirmed the diagnosis in case #3. If 
the correct diagnosis is made, delay of treatment with propranolol has to be avoided. 
Other imaging modalities, such as duplex ultrasonography, MRI, computed tomography 
(CT) with contrast and laryngoscopy may be useful in confirming the diagnosis.2 But in a 
Table 1  Continued
Author Pt. no Gender Location of IH Age at 
presentation
(months)
Alternative 
treatment
Age at  
start of 
propr.
(months)
Propranolol 
dosage  
(mg/kg/day)
Duration 
therapy
(months)
Age at end
propranolol
(months)
Response: 
good, relapse 
or failure
Follow up after 
discontinuation
(months)
Reported 
side effects
Ref
Katona 75 F Subglottic, face, arm 1.5 NA 1,5 2 NA > 12 Good 15 None 29
76 F Subglottic 3 NA 3 2 NA > 12 Good 15 None
Loizzi 77 F Subglottic 2 None 2 2 6 Ongoing Good None 30
Durr 78=32 b M PHACES; subglottic 16 days Corticosteroids, 3 weeks 2 Average 
18
NA Good Average follow up 
35(range, 13-76)
None 31
79 F PHACES; subglottic 83 days None 83 days 2 Average 
18
NA Good None
80 F PHACES; subglottic, 
epiglottis, extended to 
trachea
19 days Corticosteroids, 19 days 2, increased 
to 3
1st 17 
2nd NA
1st 16
2nd ongoing
Relapse, on 
lower dose. 
Increasing dose 
effective
None
81=30 b F PHACES; subglottic 47 days Corticosteroids, 
vincristine, laser, 
tracheotomy
6 2 10 16 Good None
82 F PHACES; subglottic, 
extended to pharynx, 
esophagus
NA Corticosteroids NA 2 14 Ongoing Good None
Graaf 83
F
Subglottic NA Intralesional 
corticosteroids
2.5 1.8 NA Ongoing Good Hypotension,
vomiting
32
84 F Subglottic NA Intralesional 
corticosteroids
6 2 NA Ongoing Good None
85 F Subglottic NA Intralesional 
corticosteroids
2 2 NA On going Good Cold 
extremities
F, Female; M, Male; NA, not available. Prop, propranolol, Ref, reference
a Blanchet et al. treated two patients with acebutolol [4]
b  If patients were doubly reported, they were analyzed one time only, unless longer follow-up revealed new 
information (#14)
c  Mahadevan et al. described in two of ten patients, which one were not specified, recurrence of airway 
symptoms after 9 months of therapy, which improved after dose adjustment to body weight [27]
d  A few adverse effects were noted during  propranolol  treatment in a cohort of 32 patients  with severe infantile 
hemangiomas, including 4 cases with airway involvement.
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compromised airway due to IH, any delay before starting propranolol should be avoided. 
From this it is worth considering starting propranolol right away, in case of unexplained 
respiratory distress, if IH is a serious part of the differential diagnosis before any further 
investigation. Progressive and unexplained signs of higher airway obstruction, e.g. 
inspiratory stridor and dyspnea may point towards an airway IH.
Efficacy
In our opinion, propranolol is the first choice treatment for airway IHs considering its 
efficacy and relatively mild side effects. In cases #1, #3 and #4 propranolol was the initial 
and only treatment for the IH. Inspiratory stridor disappeared within 24 hours and 
discoloration and softening of the skin localization of the IH was visible within a few days. 
These effects have never been equaled by any other treatment in the past.
 Review of literature revealed another 76 cases with propranolol treated airway 
obstructing IHs. Despite the efficacy of propranolol in the majority of this patients, 
treatment modalities other than propranolol were still initially started, predominantly OCS 
(77%). These treatments with OCS were however less successful and only after starting 
propranolol significant clinical improvement was observed. Besides, propranolol has less 
significant side effects than OCS.33 
 Peridis et al. performed a meta-analysis, on the effectiveness of propranolol for the 
treatment of airway IHs, compromising 36 patients.34 In a retrospective manner, they 
analyzed the effectiveness of propranolol versus steroids, CO2 laser or vincristine in 
predominantly case reports with relatively small sample sizes in each treatment group. It 
could be demonstrated that propranolol is the most effective treatment as compared to 
former treatments. An important issue is that the patients treated with vincristine and CO2 
laser concomitantly received corticosteroids, which confounded the efficacy assessment 
of one single treatment. In the present overview of 81 cases the overall efficacy of 
propranolol appeared to be 90%, including the cases that responded well to a second 
course of propranolol after unsuccessful tapering of the first propranolol course. Such an 
effective and safe treatment makes randomized controlled trials hardly justifiable for this 
specific, relatively rare and severe, acute treatment indication. 
Dosage 
The most effective propranolol dosage for airway IH treatment has not yet been 
illuminated. A dosage of 2.0-3.0 mg/kg/day is regularly adequate to reduce the IH mass 
and to relief respiratory distress. A multi-institutional and multidisciplinary consensus 
group recommends, for any type of IH, a target dose of 1.0 to 3.0 mg/kg per day with most 
members advocating 2.0 mg/kg per day, the median dose reported in literature.35 
 Case #3 showed that a lower dosage appeared to be effective as well. Case #4, 
however, illustrated that a dosage lower than 3.0 mg/kg/day was inadequate in controlling 
the evolution of the segmental IH in the first months of treatment. Therefore, if well 
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tolerated, a higher dosage should be tried in case of persistence of symptoms in life-
threatening airway IH, considering potential dramatic complications of airway obstruction 
and unattractive therapeutic options. Propranolol has been used in pediatric patients for 
the treatment of hypertrophic cardiomyopathy in much higher doses.36
Relapse and treatment failure
Most case series provide the short-term effect of propranolol treatment. Many cases 
(n=38) were already published while still on propranolol treatment lacking long-term 
data. At least, in eight cases (10%), after good initial response the IH relapsed once the 
propranolol was tapered or stopped.
 Early discontinuation of propranolol, during the proliferative phase, increased the 
chance of recurrence, illustrated by case #25. Cases #1 and # 80 however showed that 
relapse of swelling of the segmental IH with a deep component and/or subglottic 
localization could also occur beyond that phase (after treatment for 15 months). In airway 
IH we advise to adjust the dose to the bodyweight during the proliferative phase and to 
continue the propranolol treatment at least until the age of 15-18 months or even longer. 
Consideration should be given to gradual tapering of propranolol over 2-3 weeks because 
of the risk of cardiac hyperactivity.
 Despite this highly effective treatment, close monitoring of the patient with airway 
IHs is required considering the risk of relapse of symptoms during or after treatment and 
the unresponsiveness to propranolol in 9% of the cases. This percentage may be higher 
due to negative publication bias, so the exact number of non-responders to propranolol 
needs to be illuminated. However, this percentage of 9% is evidently higher than the 
reported failure rate of 1.6% for propranolol treatment for any type of IH, in the recent 
multidisciplinary and multi-institutional consensus paper.35 There are a number of possible 
explanations for this difference. Firstly, for some failure-cases it is unknown whether the 
suggested diagnosis of IH was right. Secondly the failure-rate in the consensus paper may 
be underestimated because treatment failures may not always be reported.35 In the last 
place, one could speculate that the efficacy of propranolol might differ for different types 
of IH; making further research necessary. 
Safety and side effects
After more than 40 years of clinical use of propranolol in infants for cardiac reasons 
(hypertension, dysrhythmias and hypertrophic cardiomyopathy), there are anecdotal 
reports of life-threatening complications in the setting of intravenous administration and 
propranolol overdose.37,38 
 The most commonly encountered side effects of this non-selective beta-blocker are 
relatively mild; gastrointestinal discomforts, lethargy, sleep disturbances, restlessness, 
diarrhea and decreased appetite. The potentially more serious complications are 
(symptomatic) hypotension, bradycardia and bronchoconstriction. The overall frequency 
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of any complication recorded is about 15% of total 1175 published cases with IH treated 
with propranolol. In our review of airway IH, in only four patients (4.8%) a noticeable side 
effect of propranolol was reported. Two cases had mild gastrointestinal symptoms and 
two had pulmonary symptoms.
 In case #3, the patient was started on a regular dose 2.2 mg/kg/day and developed 
wheezing during viral upper airway tract infection. This bronchospasm may be caused 
either by propranolol or may be related to the viral infection and disappeared completely 
after weaning the propranolol. In case #15, severe asthma occurred during the first week 
of treatment. Propranolol could be successfully substituted by another, selective beta-
blocker.15 These observations emphasize the importance of cardiovascular and respiratory 
evaluation prior to initiation and during therapy. Considering the potential life-threaten-
ing complication of airway IH, initiation of therapy in an inpatient setting for children at 
risk is essential. 
PHACES
In cases #1 and #4 there was a segmental IH in the neck region with suspicion of PHACES 
syndrome. Although the majority of IHs occurs in otherwise healthy infants, large, 
segmental facial IHs are possibly associated with PHACES syndrome.39,40 When PHACES 
syndrome is suspected, a full workup including complete physical exam and careful 
cardiac, ophthalmologic, neurologic assessment and imaging is indicated. 
 Propranolol can be given to the majority of the patients with a congenital heart 
defect. In case #1, the LV dimensions were increased, secondary to the relatively large 
shunt of the extended IH. The LV dimension normalized after regression of the IH after 
propranolol treatment. Whether it is fully safe to treat PHACES patients with beta-blockers 
is unknown, because of vasculature abnormalities of the brain vessels. Brain perfusion 
SPECT (Single Photon Emission Computed Tomography) in seven patients however 
showed significant improvement of symptoms in patients with PHACES treated with 
propranolol, without signs of a reduction of brain blood perfusion.41 Additional research is 
needed to further elucidate this.
Conclusion
Propranolol seems to be a rapidly effective and safe treatment strategy for most IHs 
obstructing the airway. The exact number of non-responders due to publication bias and 
the mechanism of resistance to propranolol are however largely unknown and need to be 
illuminated. Propranolol has many advantages in (airway) IH over other established 
treatments, such as being non-invasive, having a rapid effect and avoiding prolonged 
OCS therapy, tracheotomy or prolonged periods of intensive care admission with 
intubation. Moreover it has a low complication rate and is inexpensive. 
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 Most case series provide the short-term effect of propranolol treatment. This report 
however has a more prolonged follow-up and focuses on the fact that propranolol should 
not be discontinued too early, in order to avoid rebound of symptoms due to swelling. 
 Ideally randomized controlled trials have to be performed to evaluate this new 
therapy; however given the fast and important effect of propranolol, randomized 
controlled trials (RCTs) are hardly justifiable for this specific subgroup of IH with an acute 
treatment indication due to airway obstruction. Therefore case series, preferably in one 
single large institution, are still very useful to establish the role of new therapeutic agents 
with respect to historical management of life-threatening IH. 
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Summary
Kaposiform hemangioendothelioma is a rare vascular tumor in children. Especially, in 
association with the Kasabach-Merritt phenomenon it can be life threatening. The 
management of these patients is very difficult and an aggressive treatment regime is 
required. Several multimodality and chemotherapeutic regimens have been described 
but with variable success and many side effects. We present a 6-week-old boy with 
Kaposiform hemangioendothelioma and Kasabach-Merritt phenomenon. Ongoing 
propranolol treatment with only 4 initial courses of vincristine resulted in a remission that 
lasted at least 1 year.
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Kaposiform hemangioendothelioma (KHE) is a rare, locally aggressive vascular tumor that 
mainly occurs during childhood. Clinically, it develops as a violaceous indurated lesion 
and shows only little tendency to involute spontaneously.1 KHE has a high mortality rate 
of 30%, nearly always related to locally invasive effects, visceral inoperable location, or as 
a result of the Kasabach-Merritt phenomenon (KMP).2 KMP, first described in 1940, 
comprises the combination of a KHE or tufted angioma with consumptive coagulopathy3,4 
The primary process behind KMP is platelet trapping within the tumor, with a significant 
decrease in platelet count (<100 x 103/µL). A proposed mechanism for this process is the 
adhesion of platelets to the endothelium, with the aggregation and activation of platelets.5
In symptomatic KHE, associated with KMP, aggressive treatment is indicated. However, 
controlled trials are almost impossible because of the relative rarity of the syndrome. 
Several treatment combinations have been described with variable success. Vincristine is 
a therapeutic option but usually an average of 22 weekly courses is needed to induce 
regression.6 Propranolol is a new promising treatment option for vascular tumors such as 
infantile hemangiomas.7 Other vascular tumors are queuing up for a trial with propranolol. 
We report a case with KHE and KMP in which propranolol was combined with only 4 initial 
courses of vincristine, resulting in a strong and lasting response. Possibly, this is the start of 
a hopeful new approach in this severe, life-threatening condition.
Case report
A 6-week-old boy was admitted to our hospital because of a progressive violaceous, 
indurated large cutaneous lesion on his abdomen, first noticed at birth and progressed 
toward his back, breast, and scrotum (Figure 1). General physical examination showed no 
other abnormalities.
Figure 1
Age 7 weeks, just before treatment with propranolol and vincristine.
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 Laboratory evaluations showed a hemoglobin level of 6.6 g/dL and severe thrombo-
cytopenia (<10 x 103/µL). Furthermore, a coagulopathy was seen with a fibrinogen level of 
1.33 g/L (reference range, 2.70 ± 2.44 g/L) and a D-dimer plasma level of 32.3 mg/L (normal 
<2 mg/L). Echographic imaging of the lesion showed a variable echogenic aspect, 
presumably in the abdominal wall. Magnetic resonance imaging showed vascular 
malformation of the entire abdominal wall, especially of the lower abdomen and inguinal 
region. Histopathologic investigation of the lesion showed areas of endothelial 
proliferation nodules and some slit-like lumina containing erythrocytes reaching from the 
dermis to the subcutis. Skin and tumor biopsies were taken after the treatment had already 
been initiated in a phase of improving platelet counts, because of the otherwise high risk 
of bleeding. Histopathology of this vascular tumor combined with coagulopathy resulted 
in the clinical diagnosis of KMP.
 Before the start of propranolol, a cardiologic screening (echocardiography and elec-
trocardiogram) showed no abnormalities. The dose was increased to 2 mg/kg/day in 3 
doses with monitoring of blood pressure, heart rate, and fasting glucose levels. On the first 
day of monotherapy with propranolol, the lesion became softer. On account of the low 
platelet count, our multidisciplinary group could not justify monotherapy with 
experimental propranolol anymore. Therefore, after mature consideration, vincristine was 
started in addition to propranolol on the second day. A total of 4 doses of vincristine were 
administered (67% of 1.5 mg/m2/wk, once a week) and propranolol was continued. In 10 
days, a normalization of the platelet count (239 x 103/µL) and an ongoing dramatically 
clinical decrease of the lesion were seen.
 After 4 weeks (Figure 2), vincristine courses were discontinued and propranolol was 
continued at a dose of 2 mg/kg/day in 3 doses until today. At the age of 15 months, the 
propranolol dosage was reduced over 2 weeks and then stopped. Neither regrowth of 
Figure 2
Age 11 weeks, 4 weeks after starting treatment with propranolol and vincristine.
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the tumor nor hematologic abnormalities has been observed until now, at the age of 17 
months. The hematologic parameters are being monitored at regular intervals to detect 
any late relapses of KHE (Figure 3). 
Discussion
KHE with KMP is a potentially life-threatening vascular abnormality that requires aggressive 
treatment. Complete surgical removal with a large margin has the best reported outcome 
but is frequently impossible because of the risk of bleeding, extensiveness, and the 
anatomic site of the lesion.8 Therefore, other different treatments (or combinations) have 
been described. Ticlopidine in combination with aspirin, heparin, low molecular weight 
heparin, embolization, and radiation therapy has been described with variable outcome 
and limited success.8–12 Systemic steroids and interferon-α are suggested but with marginal 
success rates of respectively, 10% and 50% to 60%, with a significant risk of neurotoxicity 
because of interferon.2 Currently, vincristine is mainly used for patients with KHE often 
combined with corticosteroids.13 Finally, several case reports have been described with 
positive results of other chemotherapeutic regimens with serious possible side effects.5,6,14–19
 The nonselective β-blocker propranolol was first described in 2008 by Léauté-Labrèze 
et al.20 as a promising and unequaled new therapeutic approach for infantile hemangiomas. 
The exact mechanism of action is unclear, but vasoconstriction, downregulation of 
angiogenic factors such as vascular endothelial growth factor and basic fibroblast growth 
factor, and upregulation of apoptosis of capillary endothelial cells may be responsible for 
the outstanding therapeutic effect. In the literature, there are no reports of propranolol in 
KHE and/or KMP thus far. This may be because of the relatively short experience with 
propranolol in the treatment of hemangiomas and the rarity of the KMP. But the mode of 
action that is hypothesized in infantile hemangiomas may be comparable in other vascular 
Figure 3
Age 10 months, during propranolol monotherapy.
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tumors such as KHE. In this case, monotherapy with propranolol could not be justified 
because of the life-threatening hematologic parameters. Therefore, vincristine was added. 
Although in the literature, the average treatment duration of vincristine is 22 weekly 
courses,6 in our patient a treatment period of only 4 weeks was necessary.
 The potential side effects of vincristine are tough: irritability, peripheral neuropathy, 
and abdominal pain with loss of appetite. Propranolol has long been used for other pediatric 
indications and has a well-documented safety and side effect profile. Potential side effects 
include bradycardia, hypotension, hypoglycemia, rash, fatigue, and bronchospasm.20 No 
side effects were observed in our patient.
 This preliminary report is important as propranolol is safe and seems to have a 
non-negligible potential effect in KMP. Propranolol seems to be an important addition to 
the suboptimal therapeutic arsenal for the life-threatening condition of KHE with KMP. The 
question remains whether the effect of propranolol was solely on the underlying KHE 
(with a secondary beneficial effect on KMP) or probably on both aspects of the condition.
 Obviously, more experience with propranolol in the treatment of KHE is necessary; 
however, the extraordinary effects in this case need to be communicated in this phase 
and propranolol should be considered in the treatment for future patients with KHE.
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7.1 General discussion
In this chapter, firstly the main conclusions of the current thesis will be outlined and 
discussed in line with the aims formulated in chapter 1. Secondly, the implications of these 
findings for general clinical practice are described. Finally, new developments and 
directions for future research will be outlined in the paragraph ‘future perspectives’.
7.1.1 Aims of the thesis
Aim 1:  To explore the indication area and treatment regimen of propranolol in infantile 
hemangioma. 
After the serendipitously observed, favorable effect of propranolol on IH1, the Hecovan-
working group of RUNMC also started to administer this new treatment option. From 
September 2008 till now, over 200 patients with complicated IHs were treated with 
propranolol. Our experiences with the first treated 174 patients from September 2008 till 
January 2012 were outlined in a prospective way in Chapter 2. 
 For 173 of the 174 patients (99.4%) treatment could be classified as successful within 3 
weeks, defined by fading and softening of the tumor. The patient who did not respond 
well was a premature newborn (30 weeks of gestation), started at the age of 6.5 months, 
whose propranolol dose had to be tapered and eventually discontinued due to side 
effects. This case was however one of the first children treated in our centre. With our 
increasing experience, we might currently have chosen to further reduce the dosage and 
continue treatment with intensive monitoring of vital functions. In the other patients with 
serious side effects, (temporary) dosage reduction made successful continuation of 
treatment possible. In contrast, in a few other patients, it was decided to adjust the dose 
upwards to generate an extra therapeutic effect. It can therefore be concluded that some 
flexibility with respect to the dosages may be necessary in order to achieve the optimal 
therapeutic result with minimal side effects.
 Also, with regard to treatment duration, some degree of flexibility is obligatory in order 
to accomplish the required treatment result. Dependent on the IH subtype and treatment 
indication, the treatment duration has to be adapted. In general, treatment has to be 
continued until the end of the proliferation phase, for deep or mixed IHs this implies till the 
age of 12-16 months. In case of ulceration the treatment duration could be shortened (up to 
9-12 months of age), because of the marginal risk of recurrence of ulceration afterwards. For 
deep periorbital IHs and airway IHs on the other hand, treatment is required till the age of 
15-18 months, given the seriousness of complications in case of rebound swelling.
 With respect to safety; for 108 of the 174 patients (62.1%) side effects were recorded 
during treatment. Despite this relative large number, the adverse effects were in general 
mild, reversible and dose-dependent. Nocturnal restlessness, cold acra, daytime 
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somnolence and wheezing during upper respiratory tract infections were most commonly 
reported. In literature, hypoglycemia is the side effect of most concern, impact of this side 
effect may be aggravated by the fact that propranolol can mask the early clinical 
symptoms. Therefore, in patients with a high-risk profile for hypoglycemia (patients 
younger than 3 months, ex-prematures, periods of decreased food-intake or concomitant 
treatment with OCS), intensive and frequent monitoring was performed, as well as good 
instructions for their parents. In our patient group, the measured fasting glucose levels 
were normal and no hypoglycemic side events were observed.
 For the majority of the patients, treatment was started in a clinical setting. With our 
growing experience, treatment was initiated in an outpatient setting for a selected 
uncomplicated patient group: patients born at term, with normal birth weight, no 
abnormalities in physical examination, normal blood pressure and electrocardiography 
and without threatening symptoms. We started the lowest dosage at home and 
subsequently, the dose was increased to the target dosage during a daycare admission, 
monitoring heart rate and blood pressure. Important advantages of this treatment 
schedule were the quick and easy application of the treatment without any time delay 
due to limited clinical capacity, and the fact that it is more cost-effectively and patient 
friendly. The potential disadvantage is the absence of monitoring of blood pressure and 
heart rate after the first low propranolol doses. Due to the pharmacological characteristics 
of oral propranolol the peak effect on blood pressure and heart rate is one to three hours 
after administration, also after the first lowest dose. Limited reports are available on 
accurate data of cardiovascular parameters after initiation of propranolol. Asymptomatic 
blood pressure drops (diastolic blood pressure below 50th percentile) have been reported 
in low-risk children.2,3 Except for one patient, these blood pressures were however for 
children with normal cardiac function still in the normal range. Standardization of blood 
pressure measurement and criteria to define hypotension (blood pressure below 5th 
percentile and/or symptoms) are necessary to assess the relevance of this potential side 
effect. In a recent report based on a multidisciplinary and multi-institutional consensus 
conference, cardiovascular monitoring is advised during daycare admissions, 1 and 2 
hours after the initial dose and after significant dose increase (>0.5 mg/kg/day), for 
uncomplicated patients. In addition, at least 1 measurement of blood pressure and heart 
rate after the target dosage has been suggested.4 These recommendations are also in line 
with the Dutch guidelines for the pediatric use of propranolol described in the Dutch 
Pediatric Formulary (www.kinderformularium.nl). For high risk children the initiation is still 
necessary in a clinical setting. This approach is actually preferred by the Hecovan-working 
group, however at this moment treatment is started clinically for logistic reasons. 
Nevertheless, although propranolol appears relatively safe, considering the potential side 
effects, a careful assessment should take place before initiating therapy. 
 In general, from our extensive clinical experience it can be concluded at this moment 
that propranolol is an effective and safe treatment modality in almost all patients with a 
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complicated IH. With growing experience, treatment protocols will become clearer 
although tailor-made adjustments will remain necessary for the individual patient. In 
addition, with longer follow-up, data about long term safety will become apparent.
Aim 2:  To get more insight in the role of propranolol in the treatment of ulceration, the 
most common complication of infantile hemangioma.
Ulceration is one of the most common and distressing complications in IH. Although 
relatively common, little is known about the underlying mechanism(s). In Chapter 3, two 
studies are presented that provide more insight into this problem area, respectively by 
describing the difference between ulcerated and non-ulcerated IHs and exploring the 
role of propranolol for this indication.
 In the first study, a retrospective analysis was performed of the 465 IH patients visiting 
the RUNMC from 1997 till 2007. Ulceration was registered in 23% of the patients and the 
average ulceration time was 8 weeks. 
 Characteristics of ulcerated and non-ulcerated IHs and the differences between both 
groups were described. In general larger IHs with a superficial component in areas more 
predisposed for contamination are particularly at risk for ulceration. A higher incidence of 
ulceration was found in the IHs localized in the head and neck region but also a significantly 
high percentage in the diaper area. Taken together, epidermal involvement and susceptibility 
to trauma and maceration seem to play a role in pathogenesis. The phase in which 
ulceration most frequently occurred was during the proliferation phase of the IH. The 
possible explanation for this observation is that the fast growing IH outreaches its own 
blood supply, resulting in central skin necrosis.5 
 In addition, patients with ulcerated IHs were significantly more often prematurely 
born infants. 
 In summary, studying this specific patient group enlarges our insight in the complex 
multifactorial pathogenesis of ulceration in IH, with a key role for: epidermal involvement, 
susceptibility to trauma and maceration and finally, necrosis due to outgrowth of blood 
supply in fast-growing, bulky IHs. This knowledge can be utilized to estimate the potential 
risk of ulceration, providing arguments for whether or not to start treatment early in order 
to stop growth of the IH and prevent ulceration.
 With regard to the treatment of ulcerated IHs, in literature there is no actual, uniformly 
accepted therapeutic approach. This is partly the result of the unclear pathogenesis of 
ulceration, but also due to the highly variable course of the IH and associated ulceration. 
A generally accepted treatment-triad for ulcerated IHs is: (1) adequate pain management, 
(2) topical and oral antibiotics and (3) wound care; this in addition to a formerly applied 
treatment to accelerate the involution of IH (e.g. corticosteroids). This approach regularly 
had unsatisfactory results. Therefore, the role of propranolol for this complex patient 
group was explored, in the second part of chapter 3. 
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 Twenty patients with an ulcerated IH treated with propranolol, were matched and 
compared with twenty comparable patients with a similarly severe ulcerated IH treated 
before the propranolol era, in a retrospective way. It could be concluded that patients 
treated with propranolol had a significantly shorter ulceration time than the patients in the 
historical matched control group (8.7 vs. 22.4 weeks). The moment of treatment-start 
turned out to be relevant as well: initiation of propranolol earlier in the proliferation phase 
nearly always resulted in a shorter ulceration time. In the view of the risk profile for 
ulceration outlined in the first part of chapter 3, it is probably the best choice to start 
propranolol early in IH patients with these specific characteristics. Additionally, in case of 
doubt concerning propranolol start, control visits should be planned regularly during the 
growth phase of the IH. Although belated initiation of propranolol, particularly after the 
growth phase of the IH, seems less effective, it is still worth starting in most cases, merely 
to accelerate involution of the IH.
 The observed value of propranolol in case of ulceration should be discussed in light 
of the limitations of this study. The retrospective, observational character of the study, 
implicates the risk of confounding. Only randomized placebo-controlled trials would 
provide the strongest evidence for the effectiveness of propranolol for ulceration in IH. 
But the generally undoubted clinical efficacy of propranolol in treating IH, makes this type 
of study almost unethical. Clinically useful conclusions can however be drawn despite the 
limitations of this study design. We propose that propranolol should be the first choice 
treatment for seriously ulcerating IHs. It is however preferred to start early in the 
proliferation phase to increase the effectiveness and prevent these potentially serious 
consequences, wherever possible. 
Aim 3:  To enlarge knowledge about quality of life aspects in patients with infantile hemangioma 
and their families, especially with respect to different treatment modalities.
In recent years there have been several studies comparing the effect of propranolol and 
OCS in the treatment of IH. The impact of treatment and contentment with treatment 
outcome however had never been studied and are therefore described in Chapter 4. In 
this study, the impact of both treatments on daily family life of IH patients and the QoL 
during and after this period were compared, as well as the parents’ contentment with 
treatment-outcome. The study-design was comparable to the approach used in the 
second part of chapter 3; the best possible match between 16 patients with a cervicofacial 
IH treated with propranolol and 16 patients treated with OCS was sought. The data about 
impact and contentment were obtained using telephone questionnaires. Comparison of 
the answers of the parents of both patient groups, revealed that during their child’s 
treatment, parents from the OCS group seemed to feel significantly more worried and 
insecure, compared to the parents of the children treated with propranolol. Additionally, 
parents from the propranolol group perceived less negative influence on normal life issues, 
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including parents’ work, day care admission and the vaccination of their child, and gave a 
higher Qol-mark for both the period during and after treatment.
 Despite the inevitable limitations of this retrospective study design, it is the first study 
to address important differences in impact of treatment and contentment with treatment 
outcome between children with cervicofacial IHs treated with propranolol versus OCS. 
The results of this study show that propranolol seems to change the impact of IH as a 
condition, its treatment, as well as the quality of life of the parents. Propranolol treatment 
reduces concern in parents during the therapy, which also results in greater satisfaction 
compared to the former approach with OCS. When efficacy and safety will eventually be 
further established in controlled trials including long term follow-up, the data from the 
present study may contribute in expanding the indications for propranolol from function-
threatening IHs to cosmetically disturbing and quality-of-life-changing IHs. 
Aim 4:  To explore the future role of quantitative imaging analysis, in particular 3D stereo-
photogrammetry in the follow-up of infantile hemangioma growth and regression.
After the discovery of propranolol for the treatment of IH in 2008, several new therapeutic 
agents emerged that operate in the same pathway that is derived from the concept of 
beta-blockade as therapeutic target for IH. With these developments, it is important to be 
able to quantify and compare the therapeutic effects of these novel treatments. Further, 
there is an increasing need to monitor the natural history of IH (proliferation or involution), 
which is important in deciding whether or not to intervene. A rapid, non-invasive and 
accurate technique in volume measurement of IH is however missing. In literature, two-
dimensional photography has usually been used to illustrate and monitor the natural 
evolution of IH as well as treatment effects. This technique can however only be used for 
overall follow-up and is not suitable for accurate volume measurement. In addition, several 
bedside techniques for estimating IH-volume have been described.6-8 These methods 
entail an inter-observer variation and are not applicable to irregular shaped IHs. Imaging 
techniques like duplex ultrasonography have been used but with a significant 
inter-observer variation; CT and MRI are generally not practical because of costs, required 
sedation and the involvement of invasive radiation in serial measurements for CT-scans.
 In recent years, 3D stereophotogrammetry has become an increasingly important 
technique in evaluating facial surface geometry. In a pilot study, compromising 11 patients, 
the applicability of this technique for the measurement of volume changes in facial IHs is 
explored and described in Chapter 5. 
 To obtain the data from the facial IHs, surface-based registration was used, a registration 
procedure characterized by volume subtraction of digitalized photographs at different 
times. Two methods of 3D stereophotogrammetry were applied and compared. 
 Method 1 (superimposing images) is the most basic method and calculates the volume 
difference of the region of interest of two photographs taken in time. This method is 
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applicable for every IH with volume. The major drawback of this technique is, that the 
effect of growth of the face cannot be excluded. This is however inevitable in any other 
technique of volume measurements of tumors occurring in infancy and childhood.
 Method 2 (mirroring images) uses mirroring of the face to calculate the volumetric 
difference at two different times. The disadvantages of this method are that it is slightly 
more laborious compared to method 1, only applicable for IHs not crossing the midline 
and based on facial symmetry as baseline. The major advantage is that the effect of 
growth can be minimized, making this method very accurate in follow-up volume 
measurement. 
 In general, it can be concluded that 3D stereophotogrammetry is a new promising, 
non-invasive and accurate method in volume measurement of IH. It is expected that if the 
measuring points are closer together in time, both methods may be suitable and accurate, 
but method 1 is more basic and generally applicable. In case of long time-intervals 
between the different measuring points, the second method is more suitable. More 
extensive studies are needed to specify the usability of both methods for IH. 
Aim 5:  To investigate and describe the broader applicability of propranolol in vascular 
tumors.
Since the serendipitous discovery of the beneficial effect of propranolol on the natural 
history of IH, the indication area of this beta-blocker is increasing. The favorable experience 
in our centre with propranolol in the treatment of airway IHs and Kaposiform hemangioen-
dothelioma is outlined in the first and second part of Chapter 6 respectively. 
 Infantile hemangioma is the most common benign tumor of the head and neck in 
the pediatric population but if located in the airway, it may evolve into a potentially life-
threatening entity. A clinical sign for airway involvement may be a cutaneous IH in the 
submandibulair region (‘beard IH’), but airway IHs can also occur without cutaneous signs. 
The primary presenting symptom is usually a biphasic stridor, which gets worse when the 
tumor increases in size, but also respiratory distress and feeding difficulties can be 
recognized. The mortality rate of untreated symptomatic subglottic IHs is nearly 50%, 
making early and adequate intervention of vital importance.9 Until recently, the 
management of airway IHs could be divided in medical and surgical therapies, often a 
combination of both therapies was required. Established surgical techniques were 
endoscopic laser excision, transcervical open excision and tracheotomy for relief of 
obstruction. Medical options were OCS as first choice treatment, intralesional corticosteroid 
injection and chemotherapeutic agents like vincristine and interferon as second-line 
considerations in severe, corticosteroid resistant cases.10 
 Our experience with propranolol treatment of five patients with a life-threatening 
airway IH is described, together with an overview of the experiences in literature. Derived 
from this knowledge a number of lessons could be formulated. 
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From our beneficial experience with propranolol for IH and the positive results described 
in literature, it can be concluded that propranolol is currently the first choice treatment 
option for airway IHs. The rapid effect, non-invasive character and superfluity of prolonged 
corticosteroid treatment, tracheotomy and prolonged periods of intubation, make 
propranolol superior and less expensive compared to other established treatments.
 Of great importance for this patient group is making the proper diagnosis expeditiously, 
so no time is lost before treatment is started. Further investigations can be considered in 
case of diagnostic doubts like for instance, a biopsy with GLUT1 staining or imaging 
studies like laryngoscopy, duplex ultrasonography, MRI or CT with contrast. But in case the 
diagnosis IH is considered, it is worth starting propranolol right away before diagnostic 
procedures have been performed or completed, not wasting time. Associated symptoms, 
like stridor, diminish within hours, thereby confirming the probability of the diagnosis IH. 
Regarding the propranolol-dosage, 2 mg/kg/day is generally considered adequate in 
literature. But in airway IHs doses up to 3 mg/kg/day or even higher are recommended. In 
part of the patients, reduction of the dosage due to growth of the infant, undeniably 
resulted in rebound of the symptoms. For many patients, however, usual dosages were 
also successful. 
 In conclusion, for this treatment indication, relatively higher propranolol doses seem 
required, although certain flexibility considering the treatment dosage may be obligatory, 
tailored to the specific patient. Furthermore, because of the risk of rebound swelling, it is 
important that the treatment is not discontinued too early, given the life-threatening 
symptoms. Therefore, in airway IHs we advise to continue propranolol treatment at least 
until the age of 15-18 months or even longer. 
In the second part of Chapter 6, our anecdotal but promising experience with propranolol 
for Kaposiform hemangioendothelioma (KHE) has been described.
 Kaposiform hemangioendothelioma and tufted angioma (TA) are rare vascular 
tumors of infancy and early childhood. These are thought to be related entities in the 
same spectrum of disease.11,12 Both are associated with Kasabach-Merritt phenomenon 
(KMP), a consumptive coagulopathy, caused by platelet trapping within the tumor, 
resulting in a significant decrease in platelet count, characterized by severe thrombocyto-
penia.13 In symptomatic KHE, associated with KMP, aggressive treatment is indicated 
because of the mortality rate from hemorrhagic complications may be as high as 30%.14,15 
Controlled trials on treatment are lacking because of the rare nature of KHE and TA and the 
variable natural history, sometimes even characterized by spontaneous involution. 
Complete surgical removal seems the treatment with the best therapeutic outcome, 
although many tumors are unresectable due to location, extensiveness or tissue 
infiltration. Several other therapeutic options have been described in literature, often with 
marginal effect and significant side effects. Vincristine is suggested as first line option, 
with response rates of 86-100%, but with rare complete resolution, residual lesions, 
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significant relapse rates and limited use because of side effects like neurotoxicity. In 
complicated cases often multimodal treatment is applied.16,17 
 The case reported in Chapter 6 describes a 6-week-old male with KHE and KMP 
treated with propranolol 2 mg/kg/day for 13 months and a total of 4 doses vincristine 
spread over 4 weeks (67%, 1.5 mg/m2/wk, once a week). A dramatic response was seen 
and persisted, also after discontinuation of vincristine after 4 weeks. Moreover, the skin 
and subcutis recovered remarkably well, with only limited residual lesions despite the 
previously existing extensive tumor. In literature the average treatment duration of 
vincristine is 22 weekly courses, in this case reduced to 4 weekly courses. This case 
therefore illustrates the non-negligible effect of propranolol in KMP. Propranolol is 
therefore a promising new therapeutic option for KHE and KMP but needs to be defined 
in further detail in more extensive studies. 
7.1.2 Implications for current clinical practice
Before the propranolol-era, treatment of IH was only initiated in case of life-threatening or 
severe function-threatening cases. Now that the effectiveness of propranolol is becoming 
increasingly clear, together with increasing experience, the indication area continues to 
expand. With regard to this development, for every treatment indication, the balance 
between effectiveness and possible side effects has to be evaluated critically. For the 
majority of the IH patients, treatment is unnecessary and an ‘active non-intervention’ 
policy is justified. For some patients treatment is strongly indicated because of a severe 
function-threatening or even life-threatening IH. For the significant remaining patient 
group, the consideration about whether or not to treat is much more difficult. For these 
patients, there is no standardized advice and the decision has to be taken by considering 
many different determinants e.g.: age, general health, expected growth of the IH and the 
expected short-term and long-term result from an active approach. But also factors like, 
expected functional or psychosocial implications of the IH now and for the future, social 
support, impact of the IH on the parents and the rest of the family and how the parents 
are facing the IH and the possible treatment, need to be considered. In this phase, but also 
afterwards, multidisciplinary cooperation and adequately providing information to the 
parents is essential, in making an adequate decision. 
When, after these elaborate considerations, the decision for an active approach with 
propranolol is taken, it is important that this treatment is tailored to the individual patient, 
aiming at personalized medicine. Regarding the moment of starting treatment, there is a 
group of patients in which the decision about whether or not to treat can be postponed 
1 to 2 weeks, without additional risks, allowing monitoring of growth in this period. On 
the other hand, in case of an airway IH, it is prudent to start right away, sometimes even 
without additional investigations to prove the diagnosis.
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 Regarding the dosage of propranolol, it is important to consider dosage escalation to 
3 mg/kg/day in patients with insufficient effect on the conventional dosage of 2 mg/kg/
day.4 In contrast, if side effects occur, it appears that a reduction of the dosage makes 
successful continuation of treatment possible. Also the duration of treatment is flexible 
and should be adjusted to the specific patient and treatment indication. In ulcerated IHs, 
the treatment duration can be shortened (up to 9-12 months of age) but for deep 
periorbital IHs and airway IHs on the other hand, treatment is advised till the age of 15-18 
months. 
For the relative large number of IHs with (impending) ulceration, propranolol seems an 
important contribution to the therapeutic arsenal. For this indication it is of great importance 
that propranolol is started as soon as possible, preferable before the onset of ulceration to 
prevent it. Characteristics of IH, increasing the risk of ulceration should be recognized and 
anticipated upon: large, segmental IHs, especially localized in the head and neck region, in 
skin folds but also in the perineum and buttock area. It is however important that in case 
ulceration occurs, the other components of the treatment triad for ulcerated IH should 
never be forgotten. Despite the start of propranolol, adequate pain medication and 
wound care remain crucial in many cases.
 With regard to the initiation of therapy, for a high-risk patient group initiation of 
treatment should take place in a clinical setting. High-risk patients are defined as patients 
younger than 3 months, ex-prematures and patients with comorbid conditions or 
complications affecting the cardiovascular system, the respiratory system or blood 
glucose maintenance. For the remaining uncomplicated patient group there is growing 
evidence that propranolol can be started safely in an outpatient setting, as recently 
described in a report based on a multidisciplinary and multi-institutional consensus 
conference.4 This approach characterized by initiation of treatment and increasing the 
dosage during day care admissions is currently preferred by the Hecovan-working group.
 The parents of all children starting with propranolol, should be counseled about the 
impact of treatment and the possible side effects. Parents should particularly be aware of 
the risk of hypoglycemia during fasting, diminished food-intake, gastrointestinal infection 
and concomitant use of OCS. In this way parents are enabled to recognize and, in some 
instances, avoid side effects. 
 Adequate information for all physicians that take care of infants with IH, especially 
doctors at the infant welfare centre, is important to achieve a paradigm shift in the timing 
of referral and initiation of treatment of high-risk IHs. In case of timely referral, therapy can 
be initiated before or early in the proliferation phase, rather than after growth of the IH is 
completed and complications and/or residual lesions will occur anyway. Low threshold 
(digital) consultation of specialists on this topic prevents unnecessary visits and more 
importantly avoids late referrals.
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Regarding the extension of indications, the beneficial effect of propranolol for KHE is 
described in this thesis. After our publication, a case series appeared, reporting 11 patients 
with a wide variety in clinical presentation and therapeutic history, showing that 
propranolol was not effective in 2/3 of these cases.18 In case propranolol turned out to be 
effective, a dosage of 3 mg/kg/day was given. These cases could potentially indicate that 
propranolol is only effective in a selection of the KHE and TA patients, and a relatively high 
dose is needed to achieve the desired effect. Future research will probably further explore. 
In conclusion, propranolol is a promising new therapeutic modality for a growing patient 
group with complex IH or other vascular anomalies. The risks and benefits should however 
be weighed on a case-by-case basis.
7.1.3 Future perspectives
Despite the relative frequency of IH and the potential risk of complications, evidence 
based international treatment guidelines are missing in literature. An update of the Dutch 
treatment guideline for IHs, supported by the Dutch support group for patients with 
hemangioma and vascular anomalies patients and their parents (HEVAS), will however 
appear in the near future. In general, prospective studies are rare and the available data 
are clouded by a lack of consensus on treatment criteria and objective outcome measures. 
 Research on the topic of IH however, flourished in recent years, particularly after the 
discovery of the efficacy of propranolol, which has brought a revolutionary shift in IH 
treatment with major implications for clinical practice. This shift to beta-blockade in the 
treatment of IH is also mainly based on observational studies and expert opinions. 
Nevertheless, the studies outlined in this thesis and the accumulating experience and 
evidence in literature comprise a large number of propranolol-treated patients, showing a 
relative uniformity in results, supporting the undisputed beneficial effect of beta-blocker 
treatment for this complex patient group. In literature, two randomized controlled trials 
have been described (propranolol versus placebo), confirming the effectiveness of 
propranolol.19,20 The excellent efficacy of propranolol in combination with a favorable side 
effect profile, compared to earlier treatments like OCS, made randomized controlled trials 
to support these findings however almost unwarrantable. ‘Real clinical practice data’, as 
described in this thesis are therefore obligatory to define the indication area and other 
characteristics of the treatment regimen, which are necessary, to ensure optimal effective 
and safe clinical practice. 
Detailed prospective studies with longer follow-up are an important future goal, in the first 
place to identify the long-term safety profile of propranolol for these indications. In May 
2013, during a scientific meeting on ‘Controversies in Vascular Anomalies’ in New York, 
there was concern about the long term effect of propranolol on the developing brain. 
Based on animal studies, it was hypothesized that the emotional memory can be affected 
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by the diminished formation of beta-adrenergic regulated connection between amygdala 
and hippocampus.21 This can be only tested once the child is 5 year of age or older. The 
possible future implications of this potential side effect have to be investigated and this 
illustrates yet again the importance of prospective follow-up studies on long-term safety. 
Moreover, it emphasizes that initiation of propranolol should be limited to complicated 
IHs and that the indication area should not be extended by now.
 With upcoming information on long-term results, optimalisation of treatment 
protocols will facilitate to establish the optimal duration of treatment and the most 
favorable reduction schedules tailored to the specific IH patient, in order to minimize the 
risk of relapse. 
 Furthermore the dosage schedule may be even better matched to the specific IH 
patient, with some patients starting dosages higher or lower than the standard dosage of 
2 mg/kg/day. Several studies suggesting a reduction of the initial dose for a specific 
patient population have already been described, particularly in order to reduce side 
effects.22-25 More extensive studies are needed to refine these results.
 Besides oral propranolol, the position of the topical beta-blocker timolol (timolol 
maleate ophthalmic solution 0.5% or gel forming solution (GFS) 0.1%, 0.25% or 0.5%) has 
been explored in recent years and seems especially effective for small, superficial IHs.26-34 
The role of this topical application for deep or mixed type IHs seems limited, according to 
limited permeability. The systemic absorption seems also limited, but the pharmacokinetics 
for this therapeutic mode are poorly defined.35,36 It is important to be cautious when using 
topical timolol in large, ulcerated, mucosal or perimucosal IHs, where the skin barrier is 
compromised and when occlusion is likely (e.g. diaper area), because the percutaneous 
absorption may be larger in these cases. For these patient groups however, treatment 
with oral propranolol is generally a better choice. In order to prevent delay in starting 
systemic propranolol, the indication for topical treatment must be considered carefully and 
therapeutic effect of topical timolol application has to be monitored accurately during the 
growth phase of the IH. Future trials will provide more clarity in the characteristics and 
indication profile of this topical variant of beta-blocker therapy.
The discovery of beta-blockade as an effective mechanism in the treatment of IH has also 
given an impulse to the research in cell biology of IH and recently resulted in the finding 
of expression of components of the RAS by the endothelium of this proliferating vascular 
tumor. The additional assumption that beta-blockers mediate their effect in IH by 
modulation of the RAS through inhibition of the renin activity, probably creates possibilities 
in the use of alternative and perhaps more targeted treatments for this indication.37 A few 
reports recently described casuistic experiences with ACE-inhibitors (captopril) and other, 
beta-blockers like atenolol, acebutolol and nadolol38-42 These other therapeutic 
approaches, modulating RAS, need to prove their added value in future research. Further 
investigations may also elucidate novel pathways for the RAS in the developmental 
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biology of microvasculature in general, with potentially useful implications for regenerative 
medicine and tumor biology.  
 In daily clinical practice and clinical research concerning the role of propranolol and 
upcoming related therapies in the treatment of IH, there is a growing need for accurate 
and objective outcome measurement. In the past years several scoring systems have 
been developed for the measurement of severity, complications and proliferative activity 
of IH.43,44 Accurate volume measurement is however missing and is of utmost importance 
in the assessment of the IH with respect to the risk of complications and/or residual 
lesions. The existing bedside techniques and imaging studies were in general inappropriate 
for volume measurement in IH.5-8,45,46 A new technique for this purpose is 3D stereophoto-
grammetry. This technique is adequate and promising, but the applicability needs to be 
further explored in future more extensive research.
After the identification of the endothelial expression of beta-2 adrenergic receptors in IH, 
the expression of these receptors on several other vascular anomalies is being explored 
and the investigation of the possible expansion of the indications has started.47,48 After the 
treatment of KHE and KMP described in this thesis and subsequent case series, the efficacy 
of propranolol was explored in case reports and small case series for lymphatic 
malformations, with varying results.18,49,50 In order to specify the possible expansion of the 
indication area of propranolol, further and more extensive research is required. 
In addition to the effect of beta-blockade on IH and other vascular anomalies, the role of 
the carcineurin inhibitor sirolimus (Rapamycin) has been investigated. The target of this 
treatment is a kinase of the phosphoinositide 3-kinase signaling pathway; one of the most 
important intracellular mediators of the activity of growth factor receptors like VEGF.51,52 
The potential toxicity appears to be greater than that of propranolol and well designed 
studies assessing the effect of treatment for IH are lacking.53
7.1.4 Conclusion
The discovery of the role of beta-blockade in the treatment of IH has not only changed 
the routine management of this vascular tumor, but also gives clues to new treatments 
related to the insight into this mode of action. In current clinical practice, propranolol is 
the first choice treatment for patients with a complicated IH.
 Development of treatments particularly targeting the RAS may provide innovative 
treatment-opportunities with a favorable efficacy-safety ratio for the patients of tomorrow. 
Further research on the pathomechanism behind IH may provide important new 
treatment options for diseases caused by dysregulation of angiogenesis
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8.1 Summary 
Infantile hemangiomas (IHs) are the most common soft-tissue tumors of infancy. Because 
they involute spontaneously after a period of disproportionate growth, most have little 
consequences. A significant portion however has the potential to result in complications 
of concern. For the past decades, high-dose oral corticosteroids (OCS) were the first-choice 
therapy for this patient category despite significant treatment failure and serious side 
effects. After the serendipitous discovery of the beneficial effect of beta-blockade on IH in 
2008, the treatment of this complicated patient group changed revolutionary. 
This thesis aims to obtain more insight into complicated IH. Moreover, the implications of 
the changing landscape of treatment options after the discovery of propranolol are 
further explored. The five major aims of this thesis are:
Aim 1:  To explore the indication area and treatment regimen of propranolol in infantile 
hemangioma. 
Aim 2:  To get more insight in the role of propranolol in the treatment of ulceration, the 
most common complication of infantile hemangioma.
Aim 3:  To enlarge knowledge about quality of life aspects in patients with infantile heman- 
gioma and their families, especially with respect to different treatment modalities.
Aim 4:  To explore the future role of quantitative imaging analysis, in particular 3D-stereo-
photogrammetry in the follow-up of infantile hemangioma growth and regression.
Aim 5:  To investigate and describe the broader applicability of propranolol in vascular 
tumors.
In Chapter 1, a general introduction is given on IH, followed by an overview of the different 
complications of IH and indications for their treatment. Finally, the management and 
treatment options are outlined with special attention to beta-blockade and propranolol. 
Subsequently the aims of this thesis are formulated.
In Chapter 2, the experiences of the Hecovan-working group with the first 174 patients 
treated with propranolol for complicated IHs are described in a prospective way. For 99.4% 
of the patients, propranolol treatment could be classified as successful within 3 weeks, 
defined by fading and softening of the tumor with reduction of swelling, improvement of 
ulceration or disappearance of symptoms in case of airway IH. With regard to the treatment 
regimen, it could be concluded that a certain degree of flexibility according to the dosages 
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and treatment duration is obligatory in order to achieve the optimal therapeutic result 
with minimal adverse events. The reported adverse events in this cohort were in general 
mild, reversible and dose-dependent.
 Concerning the treatment-start, initiation of treatment and increase to the target 
dosage should be carried out in a clinical setting for high-risk patients. For the remaining 
uncomplicated patient group, the Hecovan-working group prefers cardiovascular 
monitoring during daycare admissions, after the initial dose and after significant dose 
increase (>0.5 mg/kg/day), in this phase of research. 
In the first part of Chapter 3, a retrospective analysis is performed, investigating the 
differences between ulcerated and non-ulcerated IHs. Larger IHs with a superficial 
component, predominantly localized in the head-neck region and diaper area are more at 
risk for ulceration. Ulceration most frequently occurred during the proliferation phase of 
the IH. In addition, patients with ulcerated IHs were significantly more often born 
prematurely. These characteristics of the IH and prematurity are important factors in the 
consideration of whether or not to start treatment. 
 In the second part of chapter 3 a retrospective study is described, in which the role of 
propranolol for patients with ulcerated IH is explored. Twenty patients with an ulcerated 
IH treated with propranolol were compared with a historical control group. The propran-
olol-treated patients had a significantly shorter ulceration time and moreover initiation of 
propranolol earlier in the proliferation phase nearly always resulted in a tendency to faster 
healing. In view of the risk profile for ulceration outlined in the first part of chapter 3, it is 
therefore probably the best choice to start propranolol early in an IH with characteristics 
prone for future ulceration.
Chapter 4 presents a retrospective study exploring the impact and contentment with 
treatment for propranolol-treated IH patients and their parents compared with a matched 
patient group treated with OCS. During treatment, parents from the OCS group felt 
significantly more worried and insecure in general. Additionally, parents from the 
propranolol group perceived less negative influence on normal life issues and gave a 
higher quality of life (QoL)-score for both the periods during and after treatment. In 
general, it seems that propranolol diminishes the impact of IH as a condition and, for the 
parents, improves the impact of treatment and the quality of life.
In Chapter 5, a pilot study is described, in which the role of 3D stereophotogrammetry for 
the measurement of volume changes in facial IH is explored. To obtain data, a registration 
procedure was used, characterized by volume subtraction of digitalized photographs at 
two times. This technique could be used in two different ways. Images were either 
superimposed (method 1) or mirrored with the unaffected side of the face (method 2). 
With both methods the volumetric difference at two different times was calculated. In 
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general, 3D stereophotogrammetry is a new, promising, non-invasive and accurate 
method in volume measurement of IHs. It is expected that if the measuring points are 
closer together in time, both methods may be suitable and accurate, but method 1 is 
more basic and generally applicable. In case of long time intervals between the different 
measuring points, the second method seems more suitable, because it corrects for the 
growth of the child. 
In the first part of Chapter 6, the role of propranolol for airway IHs is described based on 
a case series and an overview of the experiences in literature. Propranolol turned out to be 
a rapidly effective and safe treatment strategy for most airway-comprising IHs and should 
be the first-choice treatment for airway IHs at this time. Despite the efficacy of propranolol 
in the majority of the patients, OCS or intralesional steroids were often started primarily, 
unfortunately with insufficient effect. Of great importance for this patient group is making 
the proper diagnosis expeditiously, so no time is lost before treatment is started. In case IH 
is in the differential diagnosis, it is worth considering initiation of propranolol right away, 
before (invasive) diagnostic procedures have been performed. The effect on the 
symptoms can be already noticeable within one day after starting treatment. Also for this 
treatment indication, a certain flexibility regarding the treatment dosage may be 
obligatory, because in some cases a relative higher propranolol target dosage was 
required. Finally, it is important that the treatment is not discontinued too early, given the 
potential complications of relapse. 
 In the second part of chapter 6, a patient with Kaposiform hemangioendothelioma 
(KHE) and Kasabach-Merritt phenomenon (KMP) is described, treated with propranolol 
and a total of 4 weekly doses vincristine. A dramatic response was seen and persisted, also 
after discontinuation of vincristine. In literature, the average treatment duration of 
vincristine is 22 weekly courses, in this case reduced to 4 weekly courses. This case 
illustrates the non-negligible effect of propranolol in KMP. Propranolol is therefore a 
promising new therapeutic option for KHE and KMP but needs to be defined in further 
detail in more extensive studies.
In Chapter 7, the aims of this thesis are discussed in the light of the findings described in 
the studies in chapter 2-6. Moreover, recommendations for further clinical research are 
outlined and viewpoints for future developments are revealed.
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8.2 Samenvatting
Infantiele hemangiomen (IH) zijn de meest voorkomende weke-delen tumoren op de 
kinderleeftijd. Omdat het natuurlijke beloop, na een periode van disproportionele groei, 
gekenmerkt wordt door spontane involutie, worden er bij de meeste patiënten geen 
grote problemen gezien. Een deel gaat echter wel gepaard met zorgelijke complicaties. 
De behandeling van eerste keuze voor deze groep patiënten was de afgelopen decennia 
het toedienen van hoge doses orale corticosteroïden (OCS), ondanks het beperkte 
resultaat en serieuze bijwerkingen. 
 Na de serendipiteuze ontdekking van het gunstige effect van beta-adrenerge blokkade 
op IH in 2008, is de behandeling van deze gecompliceerde patiëntengroep revolutionair 
veranderd.
Dit proefschrift beoogt meer inzicht te verschaffen in gecompliceerde IH. Daarnaast 
worden de implicaties van het veranderende landschap van behandelingsmogelijkheden 
na de ontdekking van propranolol verder onderzocht. De vijf belangrijkste doelstellingen 
van dit proefschrift zijn:
Doelstelling 1: Het onderzoeken van het indicatiegebied en het behandelprotocol van 
propranolol voor infantiele hemangiomen.
Doelstelling 2: Meer inzicht verwerven in de rol van propranolol bij de behandeling van 
ulceratie, de meest voorkomende complicatie van infantiele hemangiomen. 
Doelstelling 3: Het inzicht vergroten in de kwaliteit van leven aspecten van patiënten met 
een infantiel hemangioom en hun families, in het bijzonder rondom de verschillende be-
handelingsmodaliteiten.
Doelstelling 4: De toekomstige rol van kwantitatieve beeldanalyse verkennen, in het 
bijzonder 3D fotografie, in de follow-up van groei en regressie van infantiele hemangiomen.
Doelstelling 5: Het onderzoeken en beschrijven van de bredere toepasbaarheid van 
propranolol voor vasculaire tumoren. 
In Hoofdstuk 1 wordt een algemene inleiding gegeven over IH, gevolgd door een 
overzicht van de verschillende complicaties en behandelindicaties. Vervolgens worden de 
verschillende behandelmogelijkheden voor IH uiteengezet, met het accent op 
beta-adrenerge blokkade en propranolol. Tot slot worden de doelstellingen van dit 
proefschrift geformuleerd.
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In Hoofdstuk 2 wordt een prospectieve analyse beschreven van de ervaringen van de 
Hecovan-werkgroep met de eerste 174 patiënten die werden behandeld met propranolol 
in verband met een gecompliceerd IH. Voor 99.4% kon deze behandeling worden 
aangemerkt als succesvol binnen 3 weken, gedefinieerd als het lichter en zachter worden 
van de tumor, met vermindering van zwelling, verbetering van ulceratie en verdwijnen 
van symptomen in geval van luchtwegbetrokkenheid. Met betrekking tot het behandel-
protocol, kon er geconcludeerd worden dat er een zekere flexibiliteit noodzakelijk is ten 
aanzien van de doseringen en behandelduur. Dit om het optimale therapeutische 
resultaat te bereiken met zo weinig mogelijk bijwerkingen. In ons cohort waren de 
gerapporteerde bijwerkingen in het algemeen mild, reversibel en dosisafhankelijk.
 Wat betreft de start van de behandeling, dient voor hoogrisico patiënten het 
opstarten en het ophogen naar de streefdosering plaats te vinden in een klinische setting. 
Voor de resterende ongecompliceerde patiëntengroep, heeft opstart van propranolol 
met cardiovasculaire monitoring tijdens dagopnames, na de eerste dosering en na 
significante ophoging van de dosering (>0.5 mg/kg/dag), de voorkeur van de Hecovan-
werkgroep, in deze fase van onderzoek.
In het eerste deel van Hoofdstuk 3 is een retrospectieve analyse beschreven, waarbij het 
verschil tussen ulcererende en niet-ulcererende IH wordt beschreven. Er kon geconcludeerd 
worden dat grote IH, met een superficiële component, met name gelokaliseerd in het 
hoofd-hals gebied en luiergebied, frequenter ulcereerden. Ulceratie trad meestal op 
tijdens de proliferatiefase van het IH. Patiënten met een ulcererend IH waren significant 
vaker prematuur geborenen. Deze eigenschappen van het IH of de IH-patiënt zijn 
belangrijk in de overweging om wel of niet over te gaan tot behandeling.
 In het tweede deel van hoofdstuk 3 wordt een retrospectieve studie beschreven 
waarin de rol van propranolol in de behandeling van ulceratie werd onderzocht. Twintig 
met propranolol behandelde patiënten met een ulcererend IH werden vergeleken met 
een historische controlegroep. Het bleek op de eerste plaats dat de propranolol-patiën-
ten een significant kortere ulceratietijd hadden en bovendien dat het opstarten van 
propranolol vroeg in de proliferatiefase bijna altijd resulteerde in een tendens tot snellere 
genezing. Met betrekking tot het risicoprofiel voor ulceratie weergegeven in het eerste 
deel van hoofdstuk 3, is het waarschijnlijk de beste keuze om propranolol vroeg in de 
proliferatiefase te starten voor IH met een hoog risico op ulceratie.
In Hoofdstuk 4 wordt een retrospectieve studie beschreven, waarin de impact van de 
behandeling en de tevredenheid met de behandeling werd onderzocht voor een groep 
met propranolol behandelde patiënten en hun ouders. Deze gegevens werden vervolgens 
vergeleken met de gegevens van een overeenkomstige historische controlegroep die 
behandeld was met OCS. Ouders van patiënten in de OCS groep maakten zich tijdens de 
behandelingsperiode significant meer zorgen en voelden zich onzekerder. De ouders in 
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de propranolol groep ondervonden significant minder negatieve invloed op algemene 
dagelijkse bezigheden en gaven een hogere kwaliteit van leven score voor zowel de 
periode tijdens als na de behandeling. In het algemeen lijkt propranolol de impact 
van het IH te verminderen en, voor de ouders, de impact van behandeling gunstig te 
beïnvloeden, alsmede de kwaliteit van leven.
In Hoofdstuk 5 wordt er een pilotstudy beschreven waarin de rol van 3D fotografie voor 
de meting van volumeveranderingen van faciale IH werd onderzocht. Om data te 
verkrijgen werd er een registratieprocedure toegepast, gekenmerkt door volume 
subtractie van digitale foto’s op verschillende meetmomenten. Deze techniek kon 
gebruikt worden op twee verschillende manieren waarin beelden respectievelijk over 
elkaar geprojecteerd werden (methode 1) of gespiegeld werden met het niet-aangedane 
deel van het gelaat (methode 2). Met beide methoden kon het verschil in volume op twee 
verschillende tijdstippen berekend worden. In het algemeen kan er geconcludeerd 
worden dat 3D fotografie en nieuwe, veelbelovende, niet invasieve en nauwkeurige 
methode is in de volumemeting van IH. Wanneer de meetpunten dicht bij elkaar liggen, 
lijken beide methoden geschikt en nauwkeurig, maar methode 1 is eenvoudiger en 
breder toepasbaar. In geval van langere intervallen tussen de verschillende meetmomenten, 
lijkt methode 2 meer geschikt omdat deze corrigeert voor de groei van het kind.
In het eerste deel van Hoofdstuk 6, wordt de rol van propranolol voor luchtweg IH 
beschreven, gebaseerd op een serie van vijf casus en een overzicht van de ervaringen 
beschreven in de literatuur. Propranolol blijkt een snelle, effectieve en veilige behandeling 
te zijn voor de meeste luchtwegbedreigende IH en zou de eerste keuze behandeling voor 
luchtweg IH op dit moment moeten zijn. Ondanks het effect van propranolol bij de 
meerderheid van de patiënten, werden orale of intralesionale steroïden vaak in eerste 
instantie gestart, echter vaak met onvoldoende resultaat. Van groot belang voor deze 
patiëntengroep is dat de diagnose snel gesteld wordt, zodat er geen tijd verloren gaat 
voordat de behandeling wordt gestart. Voor de patiënten waarbij een IH differentiaal 
diagnostisch wordt overwogen, is het de moeite waard om meteen met propranolol te 
starten zonder tijd te verliezen met (invasieve) diagnostische procedures, omdat het 
effect op de symptomen al binnen een dag merkbaar kan zijn. Ook voor deze behande-
lingsindicatie is het van belang dat er een zekere flexibiliteit ten aanzien van de behandel-
dosering in acht wordt genomen, omdat in sommige gevallen een hogere streefdosering 
noodzakelijk bleek te zijn. Tot slot is het van belang dat de behandeling niet te snel wordt 
gestaakt, gezien het potentiële risico op complicaties in geval van recidief zwelling.
 In het tweede deel van hoofdstuk 6 wordt een patiënt met Kaposiform hemangioen-
dothelioom (KHE) en het Kasabach-Merritt fenomeen (KMP) beschreven, die werd 
behandeld met propranolol in combinatie met in totaal 4 wekelijkse doseringen vincristine. 
Een indrukwekkende respons werd gezien welke persisteerde, ook nadat de vincristine 
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was afgebouwd. In de literatuur is de gemiddelde behandelduur met vincristine 22 
weken; in deze casus kon de behandelduur dus worden gereduceerd tot 4 wekelijkse 
doseringen. De casus illustreerde het niet te verwaarlozen effect van propranolol voor 
KHE/ KMP. Propranolol is daarom een veelbelovende nieuwe therapeutische optie voor 
KHE en KMP. Deze rol dient echter verder onderzocht te worden in grootschaliger 
onderzoek.
In Hoofdstuk 7 worden de antwoorden op de doelstellingen van dit proefschrift 
geformuleerd in het licht van de studies die beschreven zijn in hoofdstuk 2 tot en met 6. 
Verder worden er aanbevelingen gedaan voor verder klinisch onderzoek en worden er 
gezichtspunten voor toekomstige ontwikkelingen gesuggereerd.
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verschillend maar hebben onze liefde voor dit vak en ‘onze kindjes’ als grote overeenkomst; 
dat bleek het allerbelangrijkste. Veel heb ik van je kunnen leren, op vele vlakken. Hier zal ik 
in de toekomst nog vaak gebruik van maken. Een betere copromotor had ik me niet 
kunnen wensen. Bedankt dat je er altijd in hebt geloofd.
-Dr. IM van Beynum, beste Ingrid, vele vele mailtjes, telefoontjes en afspraken verder is het 
gelukt. Ondanks de drukte in jouw leven en de afstand tussen ons na je verhuizing, was je 
er altijd voor me als ik je belaagde met mijn vragen. Heel erg dankbaar ben ik voor jouw 
steun, hulp en altijd waardevolle inbreng.
-Prof. dr. LJ Schultze Kool, beste professor, bedankt voor de begeleiding en de adviezen 
tijdens het schrijven van dit proefschrift. 
-Prof. dr. dr. PCM van de Kerkhof, beste professor, uw relativeringsvermogen en vertrouwen 
kwamen altijd op het juiste moment. We kunnen altijd wel ergens om lachen samen en 
dat is wat ik nodig had.
-Judith Hendricksen-Roelofzen, lieve Judith, tijdens de opleiding was je mijn beste maatje. 
Jouw nuchterheid heb ik vele malen hard nodig gehad de afgelopen jaren. Man wat zijn 
wij verschillend, maar ach, wat is het toch altijd gezellig. Ontelbaar vaak heb je gezegd; ‘ik 
zou me daar niet zo druk om maken’ en dat deed ik dan ook niet meer (in ieder geval voor 
vijf minuten). Fijn dat je mijn paranimf bent. Dat voelt echt goed. Ik kan wel wat van die 
Achterhoekse rust gebruiken.
-Ella, Esther, Vera, lief en leed deelden we met elkaar tijdens onze soms bijna wekelijkse 
etentjes. Ondanks mijn bizar slechte kookkunsten kwamen jullie toch elke keer weer 
opdagen. Ik zou echt niet zonder jullie kunnen. Lieve Ella, zo fijn dat je als ‘vertegenwoor-
diging’ mijn paranimf wil zijn, je bent voor mij heel speciaal.
-Beste collega arts-assistenten, bedankt voor jullie gezelligheid, humor en interesse de 
afgelopen jaren. Mijn meest recent kamergenootjes op de Piet Dullerstraat 1.54, Marloes 
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en Rieke: fijn dat jullie nooit gek van me zijn geworden in mijn vaak neurotische periodes 
en fijn dat jullie het nooit gezegd hebben als dat wel zo was…
-Beste stafleden, verpleging, administratie, arts-onderzoekers en andere medewerkers van de 
afdeling Dermatologie, jullie zorgden ervoor dat ik met zoveel plezier kwam werken elke 
dag. We hebben veel samen meegemaakt. Het was nooit saai en er was altijd wel iets te 
lachen.
-Beste medisch fotografen, bedankt voor de prachtige foto’s die jullie hebben gemaakt.
-Rogier Donders, dank voor je hulp bij mijn statistische vragen, je laagdrempeligheid en 
enthousiasme. 
-Jeffrey Zweegers,  bedankt voor je inspanningen bij het werken aan ons ‘quality of life stuk’.
-Thomas Maal, bedankt voor het kijkje in de keuken van de 3D fotografie en de fijne 
samenwerking. 
-Lieve vrienden, bedankt voor jullie interesse, gezelligheid en steun de afgelopen jaren. De 
kwantiteit kan altijd beter, maar de kwaliteit was altijd fantastisch en dat is toch het 
belangrijkste. 
-Lieve Inge, samen zijn wij de hoofdsponsor van menig telefoon provider geweest. 
Vijfentwintig jaar geleden begonnen we met kletsen over zin en onzin en eigenlijk zijn we 
nooit meer gestopt. Mijn verhaal is bij jou altijd in goede handen. Je bent heel bijzonder 
voor mij geweest de afgelopen jaren.
-Mam, Pap, John, Laureen, bedankt voor jullie vertrouwen en steun bij alle keuzes die ik 
maakte. Mam, bedankt dat je uren naar mij hebt geluisterd als ik weer eens ging uitweiden 
over iets wat ook in een minuut had gekund. Je wist me altijd weer te stimuleren en gaf 
me een groots vertrouwen.
-Lieve opa en oma, fijn dat jullie altijd zo trots op mij zijn zoals alleen opa’s en oma’s dat 
kunnen. Minstens zo trots ben ik dat jullie erbij zijn.
-Mijn familie en schoonfamilie, erg bedankt voor jullie steun en interesse.
-Tot slot: lieve Jan, ontelbaar vaak heb je in de afgelopen jaren gezegd: ‘misschien moet je 
gewoon even normaal doen!’ Ik beloof dat ik dat vanaf nu ga doen. Zonder jouw 
nuchterheid en rust was ik nergens en waarschijnlijk nog drukker. Zonder jou had ik dit 
nooit zo kunnen doen. 
-Feline, lief poppedopje, je bent mijn alles.
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